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Preface
Antisense therapy, or oligotherapy, is an emerging field of disease treatment and a 
revolution that has completely changed gene therapy. Antisense oligonucleotides 
are small synthetic fragments of DNA that have potential to target and bind to 
messenger RNA of a particular gene causing a particular disease, and modulate 
specific protein production in human genome. Antisense therapy using oligonucle-
otides has many applications in clinical medicine and has great potential to change 
the therapeutic landscape for many disease conditions, including their prevention, 
treatment, and management. This book presents oligonucleotides as an important 
therapeutic option and discusses how they may be used to treat cancer and other 
diseases. It not only covers important developments in the field of molecular 
mechanisms, but also highlights novel therapeutic approaches in several human 
disorders including cancer.  There was a need to bring this information together 
in a single volume, as much of the recent developments are dispersed throughout 
biomedical literature, largely in specialized journals.
It is my hope that readers will appreciate the complexity of oligonucleotides 
research, especially for healthcare treatment. In the era of precession medicine, 
targeted therapy plays an important role.  Identifying disease-specific molecular 
changes and targets for precision treatment is critical. In theory, oligonucleotides 
are designed to control the transfer of genetic information, but the use of antisense 
therapy is likely to benefit the patient and help manage disease. This book sum-
marizes the current state of the field of oligo-based therapy in cancer and is an ideal 
resource for clinicians and researchers interested in antisense therapy. It will also 
appeal to physicians, surgeons, residents, biomedical scientists, and students.
Shashwat Sharad, Ph.D. 
Center for Prostate Disease Research, 
Department of Surgery, 
Uniformed Services University of Health Sciences (USU) and 
Walter Reed National Military Medical Center (WRNMMC), 
Bethesda, Maryland, USA
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Chapter 1
Antisense Therapy: An Overview
Shashwat Sharad
Abstract
Nucleic acids are the backbone of antisense therapy. Antisense oligonucleotide-
based therapeutics involves downregulation of gene expression. RNA-based drugs 
that include antisense oligonucleotides bear great therapeutic potential toward 
treatment of various diseases by altering RNA and/or reducing, restoring, and mod-
ifying protein expression through multiple molecular mechanisms. Pharmacology 
of targeted antisense therapy has provided the platform to translate its utility to the 
clinic.  Over the years, chemical modifications of antisense oligonucleotides have 
not only enhanced the specificity and efficacy but also reduced the side effects.   
These have changed the whole clinical trial design and provide newer strategies 
for therapies. Improvement in antisense oligonucleotide therapy technology has 
allowed and brought research from bench to clinic. Additionally, the use of small 
interfering RNAs, micro RNAs, ribozymes, and other antisense compounds toward 
the treatment of deadly diseases like cancers have demonstrated both preclinical 
and clinical responses. Furthermore, antisense therapy has great potential to target 
specific genes of interest in the context of precision medicine. Optimization of 
enhanced delivery, specificity, affinity, and nuclease resistance with reduced toxic-
ity is underway in different disease context. This chapter gives a complete overview 
of antisense therapy and highlights its potential. Here, we focused on the advances 
of the antisense technology, pharmacology, therapeutics, and drug discovery.
Keywords: antisense oligonucleotides, antisense therapy, antisense drug, 
antisense therapeutic, gene therapy
1. Introduction: antisense technology
The advancement in the next-generation sequencing enables us to identify the 
genetic heritages of several diseases, such as cancer, Parkinson’s, rheumatoid arthri-
tis, and Alzheimer’s, which brings to attention the development of personalized 
medicine [1]. This knowledge has been well adapted and accepted for diagnosis, 
but the field still lags toward pharmaceutical interventions to address the genetic 
defects underlying diseases. At present, small molecules and proteins are the two 
major classes of US Food and Drug Administration (FDA)-approved drugs [2]. 
Small-molecule drugs inhibit target proteins through competitive binding, whereas 
protein-based drugs (such as antibodies) can bind with high specificity to several 
targets. The size and stability of proteins are the major limitations of their utility 
for majority of disease targets [2], and both protein and small-molecule drugs 
cannot target every disease-relevant protein or gene. Thus, there is a current need 
to develop the drugs for personalized genomics. The mRNA- and DNA-based drugs 
are therapeutically more promising and have the great potential to cure the genetic 
defect [1]. The RNA-based drugs have emerged as a promising candidate to treat 
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diseases at the genetic (gene and RNA) levels. The delivery of therapeutic RNA has 
been limited due to several numbers of factors such as nucleic acid design, deliv-
ery methods, and materials for transport of RNA drugs to the site of  interest [1]. 
The current advancement in RNA and RNA-protein therapy has shown the great 
potential for the development of RNA delivery, and the clinical applications of 
RNA-based drugs have been proven by modulating gene/protein expression and 
gene editing [1].
An approach to fight disease by utilizing short DNA-like molecules is known as 
antisense oligonucleotides. This is the most effective and commonly used technol-
ogy to regulate the gene expression and drugs for targeted gene therapy. These 
antisense oligonucleotides bind to messenger RNA (mRNA) and impair the protein 
production and inhibit the gene expression. The antisense molecules are synthetic 
replica of specific mRNA sequence to block the function of the specific target gene 
of interest in the human genome. Recently, antisense therapy has emerged as a 
promising tool to treat various diseases, and for treatment, several antisense drugs 
have been approved by the FDA. For antisense gene therapy, chemically engineered 
oligonucleotides complementary to specific mRNA are inserted into the cells which 
stop the translation of the specific protein. Similarly, the antisense drug contains 
the vital molecule—“the noncoding mRNA”—which blocks the translation of a 
specific protein. The antisense oligonucleotides could be very useful to treat the 
viral diseases, genetic/hereditary diseases, as well as cancers. The naturally occur-
ring oligonucleotides bear poor stability and very low specificity and have a lot 
of side effects in vivo. The therapeutic use of oligonucleotides can be achieved 
by enhancing the stability and specificity of the molecules and reducing the side 
effects by chemical modification. The most common therapeutic oligonucleotides 
are small interfering RNA, ribozyme, DNAzyme, anti-gene, CpG, decoy, and 
aptamer. The chemical modification of antisense oligonucleotides can improve their 
ability to enter the cells to bind the specific target gene sequences which further 
disrupt the targeted gene function. Several antisense RNA and antisense oligonucle-
otide delivery systems such as virus vectors (retrovirus, adenovirus, and adeno-
associated virus) and liposomes have been developed to carry the antisense RNA or 
oligonucleotides through the cell membrane into the cytoplasm and nucleus. The 
oligonucleotides mainly target the ribonucleic acid (RNA), whereas small molecules 
and antibodies primarily target proteins due to their chemical properties and 
distinct molecular mechanism of action. The mRNA codes for protein to noncoding 
RNAs (such as microRNA, transfer RNA, small interfering RNAs, ribosomal RNA, 
and long noncoding RNAs). The main function of noncoding RNAs is the transfer 
of genetic information from DNA to protein [3]. The major therapeutic approach to 
target RNA-based therapy is antisense oligonucleotides because of their high affin-
ity, selectivity, ease of chemical modifications, and less toxicity. This chapter will 
provide a comprehensive overview of antisense therapy and their major therapeutic 
approaches.
The remarkable progress in the field of gene therapy and antisense therapy is 
apparent from numerous gene therapy- and antisense therapy-based clinical trials 
that are currently underway worldwide.
Gendicine (Ad-p53), the first gene therapy-based product, was approved in 
China for the treatment of head and neck squamous cell carcinoma in conjunction 
with radiotherapy. One AON drug, Vitravene, had been also approved for the local 
treatment of cytomegalovirus-induced retinitis, and several others are in clini-
cal trials, including those siRNAs, miRNAs, and ribozymes that are targeting the 
mRNA of different oncogenes and other cancer-promoting genes.
Although the application of gene therapy and antisense therapy to mediate tumor 
regression is well demonstrated in experimental and clinical settings, impediment 
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remains when translating this into large clinical application. The main obstacles 
that remained in cancer gene therapy and antisense therapy are the lack of delivery 
systems that successfully deliver an efficacious dose of a therapeutic gene (s) or 
antisense drug(s) to the targeted tumor site. Targeted gene or antisense drug delivery 
to distant tumors for therapeutic approaches is a demanding task that urges the 
development of delivery vectors capable of overcoming many barriers. Many scien-
tists have used viral and non-viral vectors to deliver the therapeutic gene or antisense 
compound in to the targeted tumor cells or tissues. Although the results of early gene 
therapy- and antisense therapy-based clinical trials using either viral or non-viral 
vectors have been encouraging, still it is difficult to find a single method that meets 
all the conditions for an ideal gene transfer and vector expression.
Limitations of the present vector technologies have slowed the progress of gene 
therapy and antisense therapy for cancer to the clinic. Thus, the development of 
appropriate delivery systems for targeting therapeutic genes and antisense agents 
into targeted tumor cells and tissues is one of the potential approaches that have to 
be further explored in the future in order to augment gene therapy and antisense 
therapy against a wide range of cancers. It is hoped that the next generation of carri-
ers could be a promising technology for systemic cancer gene therapy and antisense 
therapy.
2. Pharmacology of antisense drugs
The antisense oligonucleotides have the potential to manipulate the gene 
expression which prompted the field toward the therapeutic application and value 
of oligonucleotides as potential drugs and their targets [4]. The direct route to 
target RNA in a selective way is a well-established platform for drug discovery. 
The well-defined mechanisms, uncomplicated and easy to design, bring antisense 
oligonucleotides as a promising candidate for therapeutic development. The thera-
peutic potential of antisense drugs for the treatment of several diseases is already 
translated from bench to bedside, and many antisense drugs have entered into 
clinical trials for the treatment. The first patent on antisense therapy was granted 
to Molecular Biosystems company in 1991 for developing the antisense compounds. 
The first FDA-approved antisense product drug was afovirsen developed by Ionis 
Pharmaceuticals in 1992 which was a phosphorothioate oligonucleotide that 
targeted mRNA sequence of the E2 gene, which is associated with human papil-
lomavirus transcription and replication. Later oblimersen, a phosphorothioate 
oligonucleotide, was designed to target the Bcl-2 protein for the treatment of 
melanoma and certain leukemias. Unfortunately, both the drugs failed in the clini-
cal trial programs due to lack of efficacy and failure to demonstrate overall survival 
benefits and dose-limiting toxicity. Currently, several gene therapy- and antisense 
therapy-based clinical trials are ongoing. The major challenge of antisense drugs is 
effective and safe delivery to the target. The advancement toward antisense-based 
drug delivery is in progress. Several chemical modifications, novel chemistries, bet-
ter formulation, and design of oligonucleotide not only have improved the potency 
and tolerability of antisense drug but also have enhanced the drug distribution to 
the targeted RNA inside the cells [5, 6]. The clinical application of antisense drugs 
requires safe and efficient carrier system, and currently, the viral and non-viral vec-
tors are the most common methods used to deliver the antisense drugs specifically 
to the target tissues and cells. The viral vector-based delivery is most advantageous 
due to their high transfection efficiency [7]. Also, the new chemistries and better 
antisense oligonucleotide designs further improve the unwanted side effects, safety, 
and tolerability. From the last three decades, several antisense drugs have entered 
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into clinical trials and market for the treatment of a broad variety of diseases, and 
numerous oligonucleotides are under clinical development [6, 8–10]. The first-
generation antisense drug, fomivirsen, targeting cytomegalovirus, was approved 
for the treatment of cytomegalovirus retinitis [11]. Many second-generation drugs 
are under development and are showing encouraging activity in the clinic. Now 
oligonucleotide therapy has come a long way and has been established as promising 
therapeutic tool. During this period, several clinical trials have been performed on 
thousands of participants for several diseases and only six molecules provided the 
clear clinical benefit in rigorously controlled trials [10]. As of now, there are six 
FDA-approved drugs based on oligonucleotide therapy: (1) fomivirsen for treat-
ment of CMV retinitis in AIDS patients, (2) mipomersen for treatment of familial 
hypercholesterolemia, (3) defibrotide for treatment of veno-occlusive disease in 
the liver, (4) eteplirsen for the treatment of Duchenne muscular dystrophy, (5) 
pegaptanib for the treatment of neovascular age-related macular degeneration, and 
(6) nusinersen for the management of spinal muscular atrophy [10, 12]. In conclu-
sion oligonucleotide-based antisense therapy has provided solutions to untreatable 
diseases. Future inventions in this technology will help in establishing the better 
and affordable cure to many more diseases.
3. Antisense therapeutic interventions in various diseases
The antisense technology is well placed to influence the developments in human 
genetics and genomics to generate drugs for the treatment of monogenic and 
polygenic diseases. The “antisense” are the oligodeoxyribonucleotide molecules 
complementary to the DNA or RNA sequence of the target gene designed to hybrid-
ize specific mRNA. By capitalizing “antisense” DNA approach, the overexpressed 
proteins can be blocked in several diseases such as cancer, neurological diseases, 
cardiovascular diseases, inflammation and autoimmune diseases, infectious 
diseases, etc. [6].
3.1 Antisense therapy for cancer
The beauty of antisense technology is that it can precisely recognize the DNA 
location in a gene, a single mRNA class, and can distinguish between the normal 
and mutated oncogenes in cancer cells. Several studies have confirmed that in can-
cer patients, this can be used as an inhibitor of gene expression, which will decrease 
the tumor growth by manipulating the important cellular functions and protein 
production. By decreasing the specific gene expression, inducing the degradation 
of target mRNA, and initiating the premature termination of transcription, the 
antisense therapy can correct the abnormal expression of cellular genes and muta-
tions in tumor cells. One of the major limitations of this approach is nuclease deg-
radation. For this, several strategies are under development. Delivery of antisense 
oligo or drug to distant as well target tumors is a major hurdle. The development of 
suitable delivery systems for targeting therapeutic genes and antisense agents into 
targeted tumor cells and tissues is one of the potential approaches that needs to be 
further developed and explored. In order to enhance the gene therapy and antisense 
therapy against a wide variety of cancers and cancer types in future, the develop-
ment of next generation of carriers will a remarkable progress in the field of gene 
therapy and could serve as a promising technology for systemic cancer gene therapy 
and antisense therapy. As we know, cancer has been a major area of therapeutic 
investigation for antisense technology. Currently, custirsen, a chimeric 2′MOE-
modified antisense drug targeting clusterin, is being evaluated in phase III clinical 
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trials for the treatment of prostate and lung cancers [13]. Also, the antisense drug, 
AZD9150, which targets signal transducer and activates the transcription 3 (STAT3) 
in several types of cancers [14] has shown encouraging activity as a single agent in 
several cancer types. The modified oligonucleotide targeting androgen receptor is in 
the clinical trial as a possible treatment for prostate cancer [15]. Several additional 
antisense drugs, including microRNAs and siRNAs, are in early-stage clinical trials.
3.2 Antisense therapy for cardiovascular diseases
The first antisense drug, mipomersen, is approved by the FDA as an adjunct 
therapy for homozygous familial hypercholesterolemia, which reduces apolipopro-
tein B mRNA levels [16]. Apolipoprotein C III (apoCIII) plays a critical role in the 
metabolism of triglyceride-rich lipoproteins, and decreased expression is associated 
with a lower risk of cardiovascular disease [16, 17]. The clinical trial of volane-
sorsen, an antisense drug, is designed to reduce apoCIII mRNA levels, and the drug 
is currently being investigated in placebo-controlled phase III clinical trials for the 
treatment of familial chylomicronemia syndrome and familial partial lipodystro-
phy. It has been shown that severe factor XI deficiency provides protection against 
deep vein thrombosis and therefore cardiovascular morbidity and mortality [6]. 
The antisense drug IONIS-FXIRx can lower the factor XI levels and has the poten-
tial to be more effective than conventional anti-thrombotics. A phase II study with 
IONIS-FXIRx/BAY 2306001 is ongoing to investigate the drug’s effects in patients 
with end-stage renal disease on hemodialysis [6, 18, 19].
3.3 Antisense therapy for inflammation and autoimmune diseases
The antisense drugs have been and are currently being evaluated for multiple 
inflammatory diseases, such as inflammatory bowel disease. The oral drug, mon-
gersen targeting the SMAD7 mRNA, showed the promising effects on patients with 
ulcerative colitis. Also, alicaforsen drug, targeting intercellular adhesion molecule 1 
(CD54), has been tested for its effects by systemic delivery in patients with Crohn’s 
disease [20] as well as in the rectal enema patients with ulcerative colitis (or active 
unremitting pouchitis) [21–23]. This drug is currently being developed for the 
treatment of chronic refractory pouchitis [21, 24].
3.4 Antisense therapy in neurological disorders
Antisense drugs are being evaluated for multiple neurological diseases and are 
administered systemically into the cerebrospinal fluid (CSF) that surrounds the 
brain. Antisense oligonucleotides cannot cross the intact blood–brain barrier effi-
ciently; therefore, they are directly introduced into the CSF or parenchyma to treat 
brain or spinal cord diseases. Thus, neurological diseases can be approached using 
different antisense mechanisms and oligonucleotide designs, with single-stranded 
antisense oligonucleotides and siRNAs used for local therapy [6]. Duchenne 
muscular dystrophy is a progressive, severely disabling, and ultimately lethal 
neuromuscular disease caused by point mutations, insertions, or chromosomal 
rearrangements in the dystrophin gene resulting in truncated protein or loss of 
transcript through nonsense-mediated decay [25]. Because of multiple genomic 
alterations in Duchenne muscular dystrophy, no single oligonucleotide will address 
all forms of the disease [6, 25]. Antisense oligonucleotides designed to promote 
skipping of exon 51 are the most advanced in clinical trials, and the modified 
phosphorothioate oligonucleotide drug, eteplirsen, is under regulatory review for 
marketing approval. Additional antisense drugs are currently under development 
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into clinical trials and market for the treatment of a broad variety of diseases, and 
numerous oligonucleotides are under clinical development [6, 8–10]. The first-
generation antisense drug, fomivirsen, targeting cytomegalovirus, was approved 
for the treatment of cytomegalovirus retinitis [11]. Many second-generation drugs 
are under development and are showing encouraging activity in the clinic. Now 
oligonucleotide therapy has come a long way and has been established as promising 
therapeutic tool. During this period, several clinical trials have been performed on 
thousands of participants for several diseases and only six molecules provided the 
clear clinical benefit in rigorously controlled trials [10]. As of now, there are six 
FDA-approved drugs based on oligonucleotide therapy: (1) fomivirsen for treat-
ment of CMV retinitis in AIDS patients, (2) mipomersen for treatment of familial 
hypercholesterolemia, (3) defibrotide for treatment of veno-occlusive disease in 
the liver, (4) eteplirsen for the treatment of Duchenne muscular dystrophy, (5) 
pegaptanib for the treatment of neovascular age-related macular degeneration, and 
(6) nusinersen for the management of spinal muscular atrophy [10, 12]. In conclu-
sion oligonucleotide-based antisense therapy has provided solutions to untreatable 
diseases. Future inventions in this technology will help in establishing the better 
and affordable cure to many more diseases.
3. Antisense therapeutic interventions in various diseases
The antisense technology is well placed to influence the developments in human 
genetics and genomics to generate drugs for the treatment of monogenic and 
polygenic diseases. The “antisense” are the oligodeoxyribonucleotide molecules 
complementary to the DNA or RNA sequence of the target gene designed to hybrid-
ize specific mRNA. By capitalizing “antisense” DNA approach, the overexpressed 
proteins can be blocked in several diseases such as cancer, neurological diseases, 
cardiovascular diseases, inflammation and autoimmune diseases, infectious 
diseases, etc. [6].
3.1 Antisense therapy for cancer
The beauty of antisense technology is that it can precisely recognize the DNA 
location in a gene, a single mRNA class, and can distinguish between the normal 
and mutated oncogenes in cancer cells. Several studies have confirmed that in can-
cer patients, this can be used as an inhibitor of gene expression, which will decrease 
the tumor growth by manipulating the important cellular functions and protein 
production. By decreasing the specific gene expression, inducing the degradation 
of target mRNA, and initiating the premature termination of transcription, the 
antisense therapy can correct the abnormal expression of cellular genes and muta-
tions in tumor cells. One of the major limitations of this approach is nuclease deg-
radation. For this, several strategies are under development. Delivery of antisense 
oligo or drug to distant as well target tumors is a major hurdle. The development of 
suitable delivery systems for targeting therapeutic genes and antisense agents into 
targeted tumor cells and tissues is one of the potential approaches that needs to be 
further developed and explored. In order to enhance the gene therapy and antisense 
therapy against a wide variety of cancers and cancer types in future, the develop-
ment of next generation of carriers will a remarkable progress in the field of gene 
therapy and could serve as a promising technology for systemic cancer gene therapy 
and antisense therapy. As we know, cancer has been a major area of therapeutic 
investigation for antisense technology. Currently, custirsen, a chimeric 2′MOE-
modified antisense drug targeting clusterin, is being evaluated in phase III clinical 
5
Antisense Therapy: An Overview
DOI: http://dx.doi.org/10.5772/intechopen.86867
trials for the treatment of prostate and lung cancers [13]. Also, the antisense drug, 
AZD9150, which targets signal transducer and activates the transcription 3 (STAT3) 
in several types of cancers [14] has shown encouraging activity as a single agent in 
several cancer types. The modified oligonucleotide targeting androgen receptor is in 
the clinical trial as a possible treatment for prostate cancer [15]. Several additional 
antisense drugs, including microRNAs and siRNAs, are in early-stage clinical trials.
3.2 Antisense therapy for cardiovascular diseases
The first antisense drug, mipomersen, is approved by the FDA as an adjunct 
therapy for homozygous familial hypercholesterolemia, which reduces apolipopro-
tein B mRNA levels [16]. Apolipoprotein C III (apoCIII) plays a critical role in the 
metabolism of triglyceride-rich lipoproteins, and decreased expression is associated 
with a lower risk of cardiovascular disease [16, 17]. The clinical trial of volane-
sorsen, an antisense drug, is designed to reduce apoCIII mRNA levels, and the drug 
is currently being investigated in placebo-controlled phase III clinical trials for the 
treatment of familial chylomicronemia syndrome and familial partial lipodystro-
phy. It has been shown that severe factor XI deficiency provides protection against 
deep vein thrombosis and therefore cardiovascular morbidity and mortality [6]. 
The antisense drug IONIS-FXIRx can lower the factor XI levels and has the poten-
tial to be more effective than conventional anti-thrombotics. A phase II study with 
IONIS-FXIRx/BAY 2306001 is ongoing to investigate the drug’s effects in patients 
with end-stage renal disease on hemodialysis [6, 18, 19].
3.3 Antisense therapy for inflammation and autoimmune diseases
The antisense drugs have been and are currently being evaluated for multiple 
inflammatory diseases, such as inflammatory bowel disease. The oral drug, mon-
gersen targeting the SMAD7 mRNA, showed the promising effects on patients with 
ulcerative colitis. Also, alicaforsen drug, targeting intercellular adhesion molecule 1 
(CD54), has been tested for its effects by systemic delivery in patients with Crohn’s 
disease [20] as well as in the rectal enema patients with ulcerative colitis (or active 
unremitting pouchitis) [21–23]. This drug is currently being developed for the 
treatment of chronic refractory pouchitis [21, 24].
3.4 Antisense therapy in neurological disorders
Antisense drugs are being evaluated for multiple neurological diseases and are 
administered systemically into the cerebrospinal fluid (CSF) that surrounds the 
brain. Antisense oligonucleotides cannot cross the intact blood–brain barrier effi-
ciently; therefore, they are directly introduced into the CSF or parenchyma to treat 
brain or spinal cord diseases. Thus, neurological diseases can be approached using 
different antisense mechanisms and oligonucleotide designs, with single-stranded 
antisense oligonucleotides and siRNAs used for local therapy [6]. Duchenne 
muscular dystrophy is a progressive, severely disabling, and ultimately lethal 
neuromuscular disease caused by point mutations, insertions, or chromosomal 
rearrangements in the dystrophin gene resulting in truncated protein or loss of 
transcript through nonsense-mediated decay [25]. Because of multiple genomic 
alterations in Duchenne muscular dystrophy, no single oligonucleotide will address 
all forms of the disease [6, 25]. Antisense oligonucleotides designed to promote 
skipping of exon 51 are the most advanced in clinical trials, and the modified 
phosphorothioate oligonucleotide drug, eteplirsen, is under regulatory review for 
marketing approval. Additional antisense drugs are currently under development 
Antisense Therapy
6
for targeting other exons, which will broaden the treatment of the patient popula-
tion. Myotonic dystrophy type 1 (DM1) is a multisystemic disease caused by a 
triplet repeat expansion (CTG) in the 3′ untranslated region of myotonic dystrophy 
protein kinase (DMPK) gene [26]. IONIS-DMPK-2.5Rx is a chimeric antisense 
oligonucleotide and is currently under a randomized controlled study trail in DM1 
patients. Transthyretin amyloidosis is a form of systemic amyloidosis caused by 
misfolded transthyretin protein (TTR), in multiple tissues, including peripheral 
nerves, the gastrointestinal tract, and the heart [27]. Three different antisense 
drugs, IONIS-TTRRx, RNase H–dependent, and patisiran, are currently in develop-
ment for the treatment of TTR amyloidosis, as well as for both familial amyloid 
polyneuropathy and cardiomyopathy [28]. Spinal muscular atrophy (SMA), a 
progressive motor neuron disease, usually occurs in infancy or childhood caused 
by deletions or mutations in the survival of motor neuron 1 (SMN1) gene [29]. 
Nusinersen drug is a fully modified oligonucleotide designed to bind to a specific 
sequence in intron 7 of the SMN1 and 2 pre-mRNAs, enhancing exon 7 inclusion 
and increasing the production of SMN protein [30, 31] which is under review 
for market authorization. Huntington’s disease (HD) is an autosomal dominant 
neurodegenerative disorder resulting from an expanded CAG repeat in the hunting-
tin (HTT) gene, which causes a toxic gain of function due to an expanded polyglu-
tamine tract in the resulting protein. Antisense oligonucleotide designed to lower 
total HTT has been shown to provide a prolonged improvement in HD, and the drug 
is in clinical trial phase [30, 31].
3.5 Antisense therapy for infectious diseases
Various antisense mechanisms can be utilized to inhibit viral replication—for 
example, by binding to viral mRNA to block the translation of the protein or to 
degrade the viral RNA through an RNase mechanism or by blocking host microR-
NAs that support viral replication [6]. Several antisense therapies are currently 
undergoing clinical trials for various infectious diseases. MicroRNA-122 (miR-122) 
is highly abundant in the liver and is essential to the stability and propagation of 
hepatitis C virus (HCV) [32]. This mRNA binds to a highly conserved 5′ untrans-
lated region of the HCV genome, protecting it from degradation and host innate 
immune responses [32]. Additionally, miR-122 is also believed to play a major 
role in inflammatory activity in the liver [33], and RG-101, a GalNAc-conjugated 
oligonucleotide drug, is designed to inhibit miR-122 and HCV replication. The 
results from this clinical trial were very encouraging and support continued study 
of the drug.
4. The past, present, and future
The discovery of DNA as hereditary material and the helical structure base par-
ing of DNA have opened the new avenue toward the current understanding and use 
of nucleic acids for the development of oligonucleotide-based therapies [6, 34]. The 
antisense oligonucleotides bind to RNA through Watson-Crick base pairing theory 
and modulate the function of the targeted RNA. This leads to the key discovery and 
direct importance of development of oligonucleotide-based drugs and medicine [6, 
34]. The initial discovery of antisense technology is to enhance or improve the pro-
tein and small molecule-based technology by targeting RNA instead of protein. As 
a therapeutic strategy, it effects the RNA processing and modulates protein expres-
sion by binding to RNAs encoding difficult-to-target proteins. However, translating 
this technology into the clinic had some disadvantage such as inadequate target 
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arrangement, insufficient biological activity, and off-target toxic effects over two 
decades, but this strategy significantly develops the numbers and types of targets 
that can be approached for therapy. Further, this technology has a great advantage to 
develop drugs for the treatment of both monogenic and polygenic diseases as well as 
influence the human genetics and genomics [12, 34]. The novel chemical modifica-
tions of antisense oligonucleotides have been engaged to address these limitations 
over the years. Both antisense alterations and their mechanism of their action have 
not only improved the clinical trial design but also provide the breakthrough toward 
the translation of antisense oligonucleotide-based strategies into therapies [6, 34]. 
Additionally, multiple clinical trials have clearly confirmed the clinical uses of 
antisense pharmacology in humans and demonstrated their safety by using various 
mechanisms. The current antisense drugs, which are under clinical development 
phase, target different tissues both systemically and locally. The advanced oligo-
nucleotide chemistry further enhances the antisense drug properties by increasing 
potency, safety, and broader tissue distribution [6]. The advancement of oligonucle-
otide designs had improved the antisense mechanism of binding to RNA to inhibit 
their function with and without out RNA degradation. Recently, several researchers 
demonstrated that antisense oligonucleotides can also be utilized to overexpress 
or suppress the protein production [34, 35]. Many nonpathogenic disease condi-
tions lack an effective treatment; the rapid development of new improved next-
generation antisense oligonucleotide-based drugs bear the potential of intense 
clinical application and therapeutic impact on the treatment soon, demonstrating 
that this new class of molecular medicines/drugs has several potential and advan-
tageous applications in the clinic. There was always a lag period from the early 
discoveries till the therapy enters into the clinical trials and further in the market 
[34]. RNA-based precision medicine and gene therapy still need the improvement 
because of their off-target effects. The future applications of antisense technology 
will solely depend on the performance of novel molecules in the clinical trials. Till 
date tremendous progress has been made toward the antisense technology, despite 
the fact this has yet to deliver its full potential [36]. There are still more unanswered 
questions which need further improvement of the technology. The establishment 
of first-generation phosphorothioate oligodeoxynucleotides is a great asset and 
valuable pharmacological tool, which has shown the promise of new therapies to 
the patient. Further development of new improved second- and third-generation 
antisense oligonucleotides with novel formulation will result in better therapies 
for patients. Even though the tremendous progress has been made in antisense 
technology, there are still more questions that remain unanswered for the technol-
ogy and opportunities to further improve upon the platform [36]. This technology 
has provided solutions and confidence to diseases which were earlier considered 
untreatable. The high-cost factor has prevented this treatment mode inacces-
sible for the general masses. To fulfill the clinical need, future innovations to this 
technology might help in finding better and affordable cure to many more diseases 
which is available to all. Furthermore, the development of CRISPR, an RNA-guided 
gene-editing technology, and the delivery of mRNA transcribed in vitro are a major 
development of the RNA therapeutics. The clinical applications and validations of 
RNA-based antisense drugs for modulation of gene/protein expression and genome 
editing are currently being investigated both in the laboratory and in the clinic [1]. 
The CRISPR-Cas genome editing has transformed the field and impacted the bio-
medical science field which has stimulated the development of RNA-based antisense 
delivery approaches to facilitate clinical translation of CRISPR-Cas technology [1]. 
For cancer therapy, the first US-based human trial using CRISPR-Cas9 ex vivo is 
isolated from the T cells of cancer patients by knocking out the genes encoding 
PD1 and T-cell receptor alpha/beta [1]. Unquestionably, the field of antisense RNA 
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therapeutics is presently undertaking foremost development, and the potential for 
using RNA antisense drugs for personalized medicine and immunotherapy as well 
as to address genetic, infectious, and chronic diseases will ensure the continued 
development of antisense RNA therapeutics for years to come [1].
5. Summary and conclusion
In summary the antisense oligonucleotides are short, synthetic, single-stranded 
oligodeoxynucleotides that can alter RNA and reduce, restore, or modify protein 
expression through several distinct mechanisms by targeting the source of the 
pathogenesis; antisense-mediated therapies have a higher chance of success than 
therapies targeting downstream pathways. The advancement in the understanding 
of antisense pharmacology has provided new energy to translate these therapeutics 
into the clinic. Further advancement of antisense technology in the clinical settings 
requires more optimization of antisense delivery, target engagement, and safety 
profile. This technology holds the potential to change the therapeutic landscape for 
many disease conditions in near future. Most recently, the first gene therapy-based 
product, Gendicine (Ad-p53), got approved to treat head and neck squamous cell 
carcinoma in combination with radiotherapy. Also, the drug, Vitravene (known as 
fomivirsen), was approved for cytomegalovirus retinitis, Macugen (known as pegap-
tanib) for age-related macular degeneration, Kynamro (known as mipomersen) for 
homozygous familial hypercholesterolemia, Exondys 51 (known as eteplirsen) for 
Duchenne muscular dystrophy, Defitelio (known as defibrotide) for severe hepatic 
veno-occlusive disease, and Spinraza (known as nusinersen) for spinal muscular 
atrophy by the FDA. The development of antisense therapeutics has now become a 
clinical reality. The true advancement in the antisense design, chemistries, synthesis, 
and delivery technologies has been made for adequate stability, efficacy, specificity, 
and immune evasion. Finally, antisense technology is beginning to bear fruit.
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Antisense Oligonucleotides,  
A Novel Developing Targeting 
Therapy
Sara Karaki, Clément Paris and Palma Rocchi
Abstract
Antisense oligonucleotides (ASOs) have been validated as therapeutic agents 
and an important tool in molecular biology. Indeed, ASOs are used either in vitro or 
in vivo to generate mRNA selective knockouts. They can be used for human therapy 
since ASOs can inhibit specifically target genes especially whose are difficult to 
target with small molecules inhibitors or neutralizing antibodies. However, despite 
their specificity and broadness of use, some practical obstacles remain unsolved in 
antisense pharmacology, such as insufficient stability due to nucleases degradation 
activity, and poor cellular delivery as a result of low cellular uptake difficult biologi-
cal membrane crossing. Moreover, in many cases, potential off-target effects and 
immunostimulation are also part of the problems derived from their use. In this 
review, we will discuss ASOs, their chemistry, limitation of use, some solutions to 
increase stability, and finally some of their therapeutical application.
Keywords: antisense oligonucleotide, ASO chemistry, ASO delivery,  
therapeutic target, cancer
1. Introduction
The usage of nucleic acids in therapeutics is founded on the inhibition of RNA 
expression and on their capacity to modulate the expression of a target protein asso-
ciate to a disease [1]. ASOs are typically modified synthetic nucleic acids. They are 
single stand oligonucleotide with 16-mer to 21-mer sequence with high affinity for 
a specific RNA target sequence, through base pairing [2]. The two general chemical 
classes of nucleic acids commonly used today are antisense oligonucleotides (ASOs) 
and siRNA. The first is single-stranded, and modulates RNA function either by 
degrading the RNA sequence in question due to enzyme RNase H activity, or by 
modifying splicing function thus affecting RNA metabolism; and the second is 
double-stranded synthetic oligonucleotides that degrade target RNA through an 
RNA-induced silencing complex (RISC). Importantly, both must reach the nucleus 
and/or cytoplasm to exert their activity, and thus must cross a biological membrane.
Although ASOs and siRNA share similarities, they are divergent on some points, 
and so, choosing ASO or siRNA strategy for gene targeting depends on the target 
gene. However, since ASOs are single stranded, as opposed to siRNA, they have 
lower cost of production. Moreover, it is easier to deliver ASOs in vivo, since they 
do not a vector and a simple chemical modification can increase their resistance 
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to nucleases, as opposed to siRNA that need a carrier. Finally, for in vitro studies, 
siRNA is considered a better technology, since it’s relatively easier to obtain a potent 
siRNA since unmodified RNA works with high potency as opposed to ASOs.
In this review we will mainly focus on ASOs chemistry and mechanism of action.
Indeed, since Zamecnik in 1978 used an ASO-like unmodified DNA sequence in 
cell culture, notable progress has been made in ASO pharmacology [3]. Currently, 
the efficacy of different ASOs is being studied in many neurodegenerative diseases 
such as Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, and amyo-
trophic lateral sclerosis but also in several cancer states. Numerous ASO-based 
therapeutics are being tested in clinical trials. In Table 1 figures some of the ASO in 
clinical trial for cancer treatments. However, until now, only two ASOs have been 
approved by the US FDA to be used on humans, namely, fomivirsen (Vitravene), 
Table 1. 
Registered clinical studies with ASO in cancer treatments in clinical trials.gov.
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a first-generation ASO for cytomegalovirus (CMV) retinitis, and mipomersen 
(Kynamro), a second-generation ASO for homozygous familial hypercholesterol-
emia (HoFH) [4, 5], both developed by Isis Pharmaceuticals. They work via RNase 
H-mediated cleavage of the targeted RNA.
2. ASO’s design, chemistry and mechanism of action
2.1 ASO’s mechanism of action
Two major mechanisms contribute to the antisense activity. The first is that 
most ASOs are designed to activate RNase H, which cleaves the RNA moiety of a 
DNA–RNA heteroduplex and therefore leads to degradation of the target mRNA in 
the nucleus and cytoplasm. In addition, ASOs that do not induce RNase H cleavage 
can be used to inhibit translation by steric blockade of the ribosome in the cyto-
plasm [6]. When the ASOs are targeted to the 5′-terminus, binding and assembly of 
the translation machinery can be prevented [7]. Most mammalian RNAs undergo 
multiple post-transcriptional processing steps in the cell nucleus including addition 
of a 5′-cap structure, splicing and polyadenylation.
Regulation of RNA processing is another efficient mechanism in which ASOs 
can be utilized to regulate gene expression. Studies have been published document-
ing that ASOs can be used to destabilize pre-mRNA [8] and to regulate RNA splic-
ing [9]. Another viable approach to reversibly ‘switch’ protein function is alternative 
splicing that generates RNA encoding antagonistic proteins (Figure 1). Whether 
RNaseH activity takes place favorably in the cytoplasm or in the nucleus is not well 
documented. However, most studies suggest that the most part of the inhibition 
takes place in the cytoplasm. Controversially, ASOs that targets pre-mRNA and are 
splice modulators are active in the nucleus.
Figure 1. 
ASOs mechanism of action. (1) In the absence of ASO, normal gene and protein expression is maintained. 
(2) Formation of ASO-mRNA heteroduplex in cytoplasm induces activation of RNase H, leading to mRNA 
degradation or (3) steric interference of ribosomal assembly. Alternatively, ASO can enter the nucleus and 
regulate mRNA maturation by (4) inhibition of 5′ cap formation, (5) inhibition of mRNA splicing and  
(6) activation of RNase H.
Antisense Therapy
14
to nucleases, as opposed to siRNA that need a carrier. Finally, for in vitro studies, 
siRNA is considered a better technology, since it’s relatively easier to obtain a potent 
siRNA since unmodified RNA works with high potency as opposed to ASOs.
In this review we will mainly focus on ASOs chemistry and mechanism of action.
Indeed, since Zamecnik in 1978 used an ASO-like unmodified DNA sequence in 
cell culture, notable progress has been made in ASO pharmacology [3]. Currently, 
the efficacy of different ASOs is being studied in many neurodegenerative diseases 
such as Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, and amyo-
trophic lateral sclerosis but also in several cancer states. Numerous ASO-based 
therapeutics are being tested in clinical trials. In Table 1 figures some of the ASO in 
clinical trial for cancer treatments. However, until now, only two ASOs have been 
approved by the US FDA to be used on humans, namely, fomivirsen (Vitravene), 
Table 1. 
Registered clinical studies with ASO in cancer treatments in clinical trials.gov.
15
Antisense Oligonucleotides, A Novel Developing Targeting Therapy
DOI: http://dx.doi.org/10.5772/intechopen.82105
a first-generation ASO for cytomegalovirus (CMV) retinitis, and mipomersen 
(Kynamro), a second-generation ASO for homozygous familial hypercholesterol-
emia (HoFH) [4, 5], both developed by Isis Pharmaceuticals. They work via RNase 
H-mediated cleavage of the targeted RNA.
2. ASO’s design, chemistry and mechanism of action
2.1 ASO’s mechanism of action
Two major mechanisms contribute to the antisense activity. The first is that 
most ASOs are designed to activate RNase H, which cleaves the RNA moiety of a 
DNA–RNA heteroduplex and therefore leads to degradation of the target mRNA in 
the nucleus and cytoplasm. In addition, ASOs that do not induce RNase H cleavage 
can be used to inhibit translation by steric blockade of the ribosome in the cyto-
plasm [6]. When the ASOs are targeted to the 5′-terminus, binding and assembly of 
the translation machinery can be prevented [7]. Most mammalian RNAs undergo 
multiple post-transcriptional processing steps in the cell nucleus including addition 
of a 5′-cap structure, splicing and polyadenylation.
Regulation of RNA processing is another efficient mechanism in which ASOs 
can be utilized to regulate gene expression. Studies have been published document-
ing that ASOs can be used to destabilize pre-mRNA [8] and to regulate RNA splic-
ing [9]. Another viable approach to reversibly ‘switch’ protein function is alternative 
splicing that generates RNA encoding antagonistic proteins (Figure 1). Whether 
RNaseH activity takes place favorably in the cytoplasm or in the nucleus is not well 
documented. However, most studies suggest that the most part of the inhibition 
takes place in the cytoplasm. Controversially, ASOs that targets pre-mRNA and are 
splice modulators are active in the nucleus.
Figure 1. 
ASOs mechanism of action. (1) In the absence of ASO, normal gene and protein expression is maintained. 
(2) Formation of ASO-mRNA heteroduplex in cytoplasm induces activation of RNase H, leading to mRNA 
degradation or (3) steric interference of ribosomal assembly. Alternatively, ASO can enter the nucleus and 
regulate mRNA maturation by (4) inhibition of 5′ cap formation, (5) inhibition of mRNA splicing and  




There are several screening strategies to obtain potent ASO, such as using a compu-
tational algorithm in ASO design [10], mRNA walking [11], OD array [12] and RNase 
H mapping [13]. However, some of these approaches are labor intensive and require 
expensive automation equipment. Many factors can affect the strength and stability of 
the ASO-mRNA interaction, such as the mRNA secondary structure, thermodynamic 
stability and also the position of the hybridization site relative to functional motifs on 
the target RNA, such as the 5’ CAP region or translational start site.
To find a highly potent ASO, the “hit rate” can be increased by considering four 
parameters during ASO design:
2.2.1 Prediction of the secondary structure of the RNA
It is recognized that a secondary structure of the RNA accurately predicted, 
leads to effective ASO design [14, 15]. Some algorithm able to predict any single 
mRNA secondary structure and folding pattern are currently available, such as the 
mfold and the sfold program.
2.2.2 Identification of preferable RNA secondary local structures
In order for the ASO to be effective, it should target mRNA regions accessible 
to hybridization [16], such as joint sequences, internal loops, and hairpins of 10 or 
more consecutive nucleotides, usually located at the terminal end of the sequence 
[17]. It has been shown that highly conserved motifs are a good target of a potent 
ASO, whereas ASO targeting variable local motifs may induce non-sequence 
specific effects [18]. Therefore, the best approach to increase the ‘hit rate’ of potent 
ASO design is to target these conserved motifs among several optimal mRNA 
predicted secondary structures.
2.2.3 Motifs searching and GC content calculation
Although RNase activity is stimulated by the formation of the ASO-mRNA het-
eroduplex, leading to the mRNA degradation, it has been shown that this activity 
occurs independently of the ASO sequence, but is rather strongly correlated to the 
GC content which is also known to affect thermodynamic stability.
The perfect content of GC is still controversial; it is described that a strong ASO 
effect is observed with a percentage of 45–65% of G or C residues [10]; however, 
many of the ASOs used in therapy today do not have a GC content in this range.
2.2.4 Binding energy prediction
Thermodynamic energy is also important to a successful ASO design. Some 
available software can calculate thermodynamic properties between the target 
mRNA sequence and the ASO. To design a potent ASO, the binding energy between 
the ASO and mRNA should be DG37 ≥ −8 kcal/mol, whereas the energy for binding 
between ASOs should be DG37 ≥ −1.1 kcal/mol [19].
2.3 ASO’s chemical modification
The use of unmodified ASOs is limited as they have an overall charged property 
that prevents them from getting through the cell membrane and are rapidly attacked 
by all types of intracellular endonucleases and exonucleases, usually via 3′-5′ activity 
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in biological fluid. In addition, the degradation products of phosphodiester ODs 
may be cytotoxic and also exert anti-proliferative effects. Moreover, some unspecific 
hybridization has been observed and finally for most applications immunostimula-
tion has also been a matter of concern [20, 21]. This part will be further detailed in 
the toxicity chapter.
Numerous chemical modifications have been developed to improve nuclease 
resistance, extend tissue half-life, reduce non-sequence-specific toxicity, as well as 
to increase affinity and potency (Figure 2).
2.3.1 First-generation ASO
First-generation ASOs are the ones having a phosphorothioate (PTO) modi-
fied backbone. These ASOs have a sulfur atom that substitutes the non-bridging 
oxygen atoms in the phosphodiester bond [22] (Figure 2a). PTO modification 
confers higher resistance to the ASO against nuclease degradation, leading to higher 
bioavailability. Additionally, they are highly soluble and have excellent antisense 
activity [23]. Finally, PTO-modified ASOs promote degradation of target mRNA by 
RNase H enzyme. Nevertheless, this modification may slightly reduce the affin-
ity of the ASO for its mRNA target because the melting temperature (Tm) of the 
ASO-mRNA heteroduplex is decreased [20]. PTO modification is the most widely 
Figure 2. 
Chemical modifications of ASO. (a) First-generation PTO, (b) second generation, RNase H cleavage induced 
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in biological fluid. In addition, the degradation products of phosphodiester ODs 
may be cytotoxic and also exert anti-proliferative effects. Moreover, some unspecific 
hybridization has been observed and finally for most applications immunostimula-
tion has also been a matter of concern [20, 21]. This part will be further detailed in 
the toxicity chapter.
Numerous chemical modifications have been developed to improve nuclease 
resistance, extend tissue half-life, reduce non-sequence-specific toxicity, as well as 
to increase affinity and potency (Figure 2).
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fied backbone. These ASOs have a sulfur atom that substitutes the non-bridging 
oxygen atoms in the phosphodiester bond [22] (Figure 2a). PTO modification 
confers higher resistance to the ASO against nuclease degradation, leading to higher 
bioavailability. Additionally, they are highly soluble and have excellent antisense 
activity [23]. Finally, PTO-modified ASOs promote degradation of target mRNA by 
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ity of the ASO for its mRNA target because the melting temperature (Tm) of the 
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Figure 2. 
Chemical modifications of ASO. (a) First-generation PTO, (b) second generation, RNase H cleavage induced 
by chimeric ASO, and (c–e) third-generation ASO.
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performed chemical modification of ASOs for loss-of-function studies in vitro 
and in vivo for gene target identification and validation. These data have led to the 
introduction of PTO ASOs into clinical therapeutic trials. Indeed, Fomivirsen, a cur-
rently FDA approved drug for clinical use, is a first-generation PTO-modified ASO 
[24]. Despite the fact the PTO modifications are the most widely used ODs, they 
have many properties which render them suboptimal antisense effector molecules. 
The PTO backbone is known to induce sequence-independent effects attributable to 
its length dependent high affinity for various cellular proteins. However, this seem-
ingly negative property of PTO ASOs to interact with certain proteins proved to 
be advantageous for the pharmacokinetic profile. Their binding to plasma proteins 
protects them from filtration and is responsible for an increased serum half-life [25]. 
Finally, these oligonucleotides can interact with components of the innate immune 
system such as Toll-like receptors (TLRs), inducing an immune response and 
triggering cytokines expression and other genes coding for the nonspecific defense 
mechanisms [26].
Nevertheless, to try to solve the several non-specific problems [27], new 
chemical modifications have been developed. Modifications to the base, sugar and 
backbone have been identified that increase binding affinity for the target RNA.
2.3.2 Second-generation ASO
The second generation represents oligonucleotides in which the structural 
modification is not limited to the backbone linkage but additionally includes 
structural modifications of the ribose: ASO with 2’-O-alkyl modifications of 
the ribose were developed (Figure 2b). These modifications intend to improve 
binding affinity, to increase efficacy, to modulate the protein binding of oli-
gonucleotides and to enhance nuclease resistance. 2’-O-Methyl (2’-OMe) and 
2’-O-Methoxyethyl (2’-MOE) modifications of ASO-PTO are the most widely 
studied [28]. These second-generation ASOs are less toxic than PTO- modified 
ASOs and have a slightly enhanced affinity towards their complementary RNAs 
[29]. Moreover, an important aspect for these ASOs is that 2’modifications can 
reduce immunostimulatory effect [30]. However, 2’-OMe and 2’-MOE substitu-
tions do not activate the RNase H to cleave the target mRNA, which decreases 
the efficacy of the ASO [31]. Indeed, mechanistic studies have been conducted to 
elucidate RNase H activity. They have shown that the flexibility of the ASO, the 
accessibility of the 2′-OH group of the RNA and the correct width of the minor 
groove of the ASO-RNA duplex are necessary for effective RNase H mediated 
mRNA degradation [32]. Since 2′-O-alkyl RNA ODs do not activate the RNase 
H, they inhibit mRNA expression only by a steric interference with translation. 
However, to increase its potency, an ASO should be able to induce cleavage by 
RNase H. Therefore, a chimeric ASO was developed (Figure 2b). It consists of a 
central ‘gap’ region containing 10 DNA or PTO DNA monomers and flanked on 
both sides (5’and 3’extremities) by approximatively 5 modified nucleotides such as 
2′-OM or 2’-MOE (indicated by red and yellow regions of the OD in Figure 2b). 
This chimeric ‘gapmer’ ASO allows RNase H to sit in the central gap and to execute 
target-specific mRNA degradation; meanwhile, the flanking 2′-alkyl modified 
ends prevent nuclease cleavage of ASO. The 2′-O-MOE-PTO gapmers OGX-427 
(Apatorsen) developed by Rocchi et al., directed against HSP27 and OGX-011 
(Curtisen) against clusterin are currently undergoing clinical trials (Table 1). The 
ODs being tested clinically mainly incorporate relatively simple chemical modifi-
cations such as the PTO modifications and the 2′-alkyl modifications (first- and 
second-generation ODs).
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2.3.3 Third-generation ASO
Third-generation ASOs have been developed to further improve nuclease resis-
tance, increase binding affinity, and to enhance pharmacokinetics and biostability. 
They are characterized by chemical modifications of the nucleotide, and more 
precisely to its furanose ring [33]. Many modifications have been described, such as 
N3′-P5′ phosphoramidates, 2′-deoxy-2′-fluoro-β-D-arabino nucleic acid analogue 
(FANA), cyclohexene nucleic acids (CeNAs) and tricyclo-DNA (tcDNA), however, 
peptide nucleic acid (PNA), phosphoramidate morpholino oligomer (PMO) and 
locked nucleic acid (LNA) are the three most studied third-generation ASOs [34, 35].
It should be noted that there is no single modification that covers all the desired 
properties for a modified ASO. As described before, chemical modifications can 
improve ASO-RNA hybridization affinity, enhance nuclease resistance, decrease toxic-
ity and modulate pharmacokinetics. An optimal antisense can be designed depending 
on its use by mixing and matching the numerous chemical modifications accordingly.
2.3.3.1 Peptide nucleic acid
PNA is a synthetic DNA mimic in which the deoxyribose phosphate backbone is 
replaced by polyamide linkages [36] (Figure 2c). PNAs are biologically very stable 
and have good hybridization properties. However, they do not activate mRNA cleav-
age via RNase activity, but rather block translation and thus protein expression, by 
forming sequence-specific duplex with mRNA, hence generating steric hindrance. 
Due to their neutral backbone, PNAs have low solubility and their cellular uptake 
remains a challenge for exploiting them as therapeutics antisense. PNAs delivery 
can be enhanced annealing a PNA strand with a negatively charged complementary 
oligonucleotide, and then enclosed the obtained duplex with a cationic lipid. To this 
end, PNAs are also conjugated to peptides for improving their cellular uptake [37, 38]. 
Furthermore, PNA can elicit antigen effects by hybridizing with double-stranded 
DNA [36, 39] resulting in transcriptional arrest. Substantial data have revealed the 
effectiveness of PNA in gene silencing in various in vitro models [39, 40].
2.3.3.2 Phosphoramidate morpholino oligomer
PMOs are non-charged ASOs whose pentose sugar is substituted by a morpho-
lino ring and the inter-nucleotide linkages are phosphoramidate bonds in place of 
phosphodiester bonds [41] (Figure 2d). PMOs avoid the RNase H recruitment; their 
effect is primarily mediated by steric interference of ribosomal assembly resulting in 
translational arrest. Synthetic PMOs are resistant to nucleases degradation in biologi-
cal fluid. Because their backbone is uncharged, PMOs are unlikely to form unwanted 
interactions with nucleic acid-binding proteins [42]. PMOs do not enter mammalian 
cells easily in culture, but it has been shown that conjugating it with peptides such  
as arginine-rich peptide (ARP) can enhance its cellular uptake and antisense potency 
[43]. Antisense PMO oligonucleotide, have shown efficacy in animal models in vivo 
and in human clinical trials [44, 45]. Indeed, a PMO antisense agent is currently in 
phase II clinical trials for restenosis, cancer and polycystic kidney disease.
2.3.3.3 Locked nucleic acid
Locked nucleic acids oligonucleotides figure among the most promising candi-
dates developed the last few years. LNAs are chemically modified nucleotides with 
a ribose containing a methylene bridge between the 2′-oxygen and the 4′-carbon 
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of the ribose [46]. LNA modifications improve significantly the ASO hybridization 
affinity towards mRNA target, due to the important increase in the thermal stability 
of the DNA/RNA heteroduplexes [47]. In addition, LNAs avoid nuclease degrada-
tion. As their ribose 2’-O position are modified, LNAs are not recruiting RNase H 
[48]. Nevertheless LNA nucleotides can be freely incorporated at the ends of RNA 
and DNA sequences to form chimeric oligonucleotides resulting in restoration of 
RNase H-mediated cleavage of mRNA. It has been shown that the chimeric LNA/
DNA/LNA gapmer with seven to 10 phosphorothioate-modified DNA central gaps 
flanked by three to four LNA nucleotides on both 5′-end and 3’ends induces efficient 
mRNA cleavage, because of their high target affinity and nuclease resistance [29]. 
In the first in vivo study reported, the LNA ASOs appeared to be nontoxic in the 
optimal dosage. Therefore, full LNA and gapmers LNA·DNA·LNA ASOs seem to 
offer an attractive set of properties, such as potent biological activity and appar-
ent lack of acute toxicity, making it a promising antisense agents [49–51]. Table 2 
recapitulates the chemical modifications characteristics.
Despite the large number of molecules being evaluated in the clinical trials, 
the clinical progress of ASOs had to face many challenges; indeed, poor pharma-
cokinetics [52], poor cell membrane permeation [53], and off-target effects [27]. 
Last decade, the development of oligonucleotide delivery through lipid or polymer 
systems has improved the cellular uptake and the pharmacokinetic behavior [54].
3. ASO’s pharmacokinetics, toxicity and delivery
3.1 ASO’s pharmacokinetics and toxicity
The pharmacokinetics of ASOs has been extensively studied; they rapidly 
distribute to all tissues in vivo [55]. First and second-generation PTO ODs are 
broadly distributed to all peripheral tissues. The highest concentrations of ODs are 
found in the liver, kidney, spleen, lymph nodes and bone marrow with no measur-
able distribution to the brain [52]. Moreover, they not only distribute to tissues 
but also accumulate within cells in tissues [56]. The mechanism(s) by which ODs 
accumulate within cells following parenteral administration is currently unknown 
[57]. However, ODs that do not contain a PTO linkage appear to be rapidly excreted 
in the urine [58]. This difference in tissue distribution appears to be due largely to 
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In summary, pharmacokinetic studies of PTO ASO demonstrate that they are 
well absorbed from parenteral sites, distribute broadly to all peripheral tissues, 
do not cross the blood-brain barrier (BBB), and are eliminated primarily by slow 
metabolism. Altogether, their pharmacokinetic properties depend on chemistry 
rather than sequence.
Concerning ASO’s toxicity, there are two broad categories of potential toxicities 
for ASOs; toxicities due to exaggerated pharmacology and toxicities due to non-
antisense effects of the ASO. The former category of side effects results from the 
ASO binding to off-target RNA, producing an undesirable effect. The potential for 
such toxicities can be further minimized by vigilant selection of the drug target and 
homology searches against human genomic databases. The second category of poten-
tial toxicities (non-antisense effects) has been documented at higher doses of ASOs. 
In clinical trials PTO ASOs have proven to be safer than originally anticipated [31, 34, 
35]. ASOs drugs principally induce mild-to-moderate toxicities related to the admin-
istered dose. In vivo, the two mains mechanism that induce acute toxicity through 
ASOs administration are for the first one the activation of the transient complement 
cascade and for the second one the inhibition of the clotting cascade. The increase 
in the clotting times is defined by a transient concentration-dependent escalation of 
activated partial thromboplastin times (aPTT) [59]. Another frequently occurring 
sub chronic toxicity is immune stimulation, manifested as splenomegaly, lymphoid 
hyperplasia and diffused multi-organ mixed mononuclear cell infiltrates [60]. This 
is due to an unmethylated cytosine-phosphorous-guanine (CpG) motif in the ASO 
sequence that can be recognized by Toll-like receptor (TLR)-9 in immune cells. This 
results in the release of cytokines, interleukin (IL)-6, IL-12, interferon (INF)-γ), B 
cell proliferation, antibody production and activation of T lymphocyte and natural 
killer (NK) cells [61]. In order to avoid the immune response, the cytosine of the 
sequences including CpG motif are substituted by methylated cytosine. Also, for 
preventing this side-effect, the sequences of ASOs drug can be designed without 
CpG motif. These both stimulatory immune responses are related to the sequence 
and the chemical modification of the ASOs [6]. Indeed, second-generation ASOs 
have been shown to have smaller immune stimulation that ASOs PTO. In addition, 
introduction of LNA into the PTO-ASO has been shown to reduce, and even elimi-
nate, CpG dinucleotide-mediated immunostimulation [62, 63]. When ASO’s plasma 
concentration is high, some toxicities have been observed, such as elevated liver 
enzyme such as aspartate aminotransferase (AST) and alanine amino-transferase 
(ALT), thrombocytopenia, and hyperglycemia [52].
3.2 ASO’s delivery
Although the clinical relevance of ASOs has been demonstrated, inefficient 
cellular uptake, both in vitro and in vivo, limit the efficacy of ASOs and has been a 
barrier to therapeutic development. Cellular uptake can be <2% of the dose result-
ing in too low ASO concentration at the active site for an effective and sustained 
outcome [22]. Indeed, many researches are conducted on the improvement of ASO 
delivery via the use of delivery vehicles.
3.2.1 Mechanism of cellular uptake
Cellular uptake refers to the combination of both OD membrane-binding and 
internalization. It is challenged by numerous barriers, most importantly, the lipo-
philic nature of the cell membrane, which makes the passage of these large anionic 
molecules complicated. Several barriers to cellular uptake exist such as the lipophilic 
cell membrane, through which these large, anionic molecules must pass to reach the 
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accumulate within cells following parenteral administration is currently unknown 
[57]. However, ODs that do not contain a PTO linkage appear to be rapidly excreted 
in the urine [58]. This difference in tissue distribution appears to be due largely to 
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nate, CpG dinucleotide-mediated immunostimulation [62, 63]. When ASO’s plasma 
concentration is high, some toxicities have been observed, such as elevated liver 
enzyme such as aspartate aminotransferase (AST) and alanine amino-transferase 
(ALT), thrombocytopenia, and hyperglycemia [52].
3.2 ASO’s delivery
Although the clinical relevance of ASOs has been demonstrated, inefficient 
cellular uptake, both in vitro and in vivo, limit the efficacy of ASOs and has been a 
barrier to therapeutic development. Cellular uptake can be <2% of the dose result-
ing in too low ASO concentration at the active site for an effective and sustained 
outcome [22]. Indeed, many researches are conducted on the improvement of ASO 
delivery via the use of delivery vehicles.
3.2.1 Mechanism of cellular uptake
Cellular uptake refers to the combination of both OD membrane-binding and 
internalization. It is challenged by numerous barriers, most importantly, the lipo-
philic nature of the cell membrane, which makes the passage of these large anionic 
molecules complicated. Several barriers to cellular uptake exist such as the lipophilic 
cell membrane, through which these large, anionic molecules must pass to reach the 
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site of action. In cultured cells, the internalization of naked ASOs is generally ineffi-
cient, with only a few ASO molecules actually penetrating the cell [21]. Exogenously 
administered ASOs enter cells in vitro by a combination of fluid-phase (pinocytosis), 
caveolae potocytosis, adsorptive and receptor-mediated endocytosis (Figure 3),  
cellular uptake mechanisms being different depending on the ASO chemical struc-
ture. However, this results in a trafficking problem because not all of the internalized 
ASO will be able to reach their target and interact with it. This is because the majority 
of internalized ASO is sequestered into endosome or lysosomal compartments [21]. 
A significant amount of the OD is also compartmentalized within other cellular 
organelles, such as the Golgi complex and the endoplasmic reticulum [64].
To improve cellular uptake and OD’s activity, a range of techniques and trans-
porters have been developed [65, 66]. Simultaneously, the use of these vectors 
increases the stability of ODs against nuclease digestion and allows the use of lower 
concentrations of ODs.
3.2.2 General delivery methods
OD delivery can occur through carrier molecules. Receptor-mediated endocytosis-
directed uptake utilizes import mechanisms already present in the cell membrane 
for the uptake of biomolecules necessary for cell function [67]. ODs can be linked 
directly to a carrier protein via a covalent bond or non-covalently via poly-L-lysine 
(PLL)-carrier conjugates. The choice of the carrier is dependent on its known ability 
to bind to specific cell membrane receptors and accumulate in the cell via endocytosis. 
Not only OD’s internalization can be potentially improved, but cell-specific delivery 
can also be achieved by targeting receptors exclusively expressed or over-expressed 
on certain target cells. However, the OD is generally sequestrated in endosomal 
compartments, thereby limiting the utility of this method for delivery [22]. The use of 
peptides can help overcome this issue. Indeed, as peptides have membrane transloca-
tion properties, they can increase ODs passage through the plasma membrane. For 
example, fusogenic peptides have been used to promote peptide fusion of OD-peptide 
conjugates with either cell or lysosomal membranes [68]. To facilitate OD transport 
to the nucleus, nuclear localization signals (NLS) can be used for ODs that inhibit 
pre mRNA splicing [69]. Another peptide used is CPP, a short peptide sequence 
Figure 3. 
Cellular uptake and intracellular trafficking of oligonucleotides. Oligonucleotides enter cells via several 
endocytotic pathways. Most of ODs are recycled in early recycling endosomes. ODs accumulate in endosomes, 
multivesicular bodies (MVB) and lysosomes. A significant amount is compartmentalized in cellular organelles 
like the trans Golgi network (TGN).
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(<30 amino acids) with net positive charge that uses an energy dependent pathway 
to allow internalization of large molecules like ASOs. Commonly used CPP include 
penetratin, HIV TAT peptide and transportan. Through disulfide bond, ASOs and 
CPP can be conjugated. To evaluate ASO-CPP effect on mRNA degradation in vitro 
and in vivo, PNA is the most used [43, 70, 71]. An interesting variation is to couple 
two different ASOs to a single CPP thus addressing two targets simultaneously [72]. 
The most dramatic advance in OD targeting has involved delivery via the asialogly-
coprotein receptors (ASGR). ASGPR, also known as the Ashwell receptor, is a lectin 
that is abundantly expressed on hepatocytes [73] and clears serum glycoproteins by 
receptor-mediated endocytosis [74]. The functional receptor is a trimer comprised 
of two proteins and exhibits high affinity for N-acetyl galactosamine (GalNAc) 
terminated oligosaccharides [75]. A major breakthrough came from researchers who 
developed multivalent GalNac conjugated siRNAs that bind to the ASGR [76]. The 
conjugates were effectively taken up into primary mouse hepatocytes by a receptor-
specific mechanism, leading to silencing of targeted genes. GalNac based conjugates 
have similarly been used to transport ASOs to the liver in mice with good effects on 
reduction of target gene expression [77]. Indeed, GalNac-ASOs showed high affin-
ity for mouse ASGPR, which resulted in enhanced ASO delivery to hepatocytes. 
Furthermore, once inside the cell, GalNac-ASO’s metabolism leads to ASO release 
in the liver, thus acting like a prodrug targeting hepatocytes. Moreover it improved 
potency and extent the effect of both antisense targeting human transthyretin (TTR) 
and human apolipoprotein C-III in transgenic mice. This study highlighted several 
of the virtues of conjugates including use of a molecularly defined entity, high tissue 
and cell selectivity and lack of substantial toxicity. The successes with glycoconjugates 
in the laboratory have facilitated their rapid translation to clinical evaluation, with 
several hepatic genes being addressed. Finally, an additional approach to OD internal-
ization is to generate transient permeabilization of the plasma membrane and allow 
naked ODs to penetrate into the cells by diffusion. It consists of inducing transitory 
pores in the membrane, either chemically by streptolysin-O-permeabilization, 
mechanically by microinjection, or by electroporation [78] or ultrasound.
All of these methods, under defined circumstances, can permit charged or 
uncharged ODs to enter cells rapidly and localize in the nucleus, where they pro-
duce antisense inhibition of gene function.
Nevertheless, one of the most promising strategies used to overcome cellular 
barriers is the use of nanotechnology. Indeed, nanocarriers offer the possibility to 
encapsulate drugs but also nucleic acid, to protect it from degradation, enhance its 
distribution to the tissues and the cells, but also reduce toxicity and thus second-
ary effects by targeting specific organs. It is a very promising tool for combination 
therapy and theranostics applications. To bypass the limitations of ASO-based 
therapy, like insufficient stability and low intracellular delivery and distribution, 
Dr. Rocchi’s lab recently developed a modified first-generation ASO by using 
a lipid-conjugated oligonucleotide modification (LASO) able to overcome the 
problems to ASO administration. The idea is to improve ASO’s stability, efficiency 
and biodisponibility by adding a hydrophobic lipid chain at the 5’end of the hydro-
philic DNA sequence. As amphiphiles, LASOs self-assemble in aqueous media with 
an encapsulation rate of 100%, which yields in small spherical objects of ~11 nm 
in diameter [79]. Due to their small size, these nanomicelles, can accumulate 
inside the tumor via EPR effect (enhanced permeability and retention effect), 
which permits passive targeting and reduced systemic toxicity. Interestingly, 
transfection with these lipid-modified ASO leads to rapid and prolonged internal-
ization via micropinocytosis with no transfecting agent. Interestingly, the addition 
of the lipid, does not affect LASO’s efficacy in vitro and in vivo with little or no 
toxicity in animal models.
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that is abundantly expressed on hepatocytes [73] and clears serum glycoproteins by 
receptor-mediated endocytosis [74]. The functional receptor is a trimer comprised 
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specific mechanism, leading to silencing of targeted genes. GalNac based conjugates 
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barriers is the use of nanotechnology. Indeed, nanocarriers offer the possibility to 
encapsulate drugs but also nucleic acid, to protect it from degradation, enhance its 
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ary effects by targeting specific organs. It is a very promising tool for combination 
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4. Discussion/conclusion
Antisense oligonucleotide based therapies are promising. They can be used for 
human therapy and can specifically inhibit target genes. Despite the promising 
progress since their discovery, only a few have been approved for clinical use. This 
low success rate can be explained by their anionic charge which prevents them 
from getting through the cell membrane and are rapidly destroyed by nuclease. To 
address these problems many chemical modifications have been developed. Finally, 
improvement of their delivery to the tissues, and thus their efficacy is an important 
issue that has to be addressed. To solve this problem, many strategies have been 
studied; nanotechnology is one of the most promising to overcome the cellular 
barriers for the ASO delivery towards targeted therapy.
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Abstract
As master modulators of the human genome, miRNAs are involved in all cancer 
hallmarks, disrupting the normal function of their targets. By gaining or losing 
the function, miRNAs lead to the validation of tumor phenotype, its progression, 
and metastasis as well as to drug resistance. Increasing the evidence suggests that 
the modulation of miRNAs in cancer cells, by suppressing the oncogenic miRNAs 
(oncomiRs) and substituting the deficient tumor suppressive miRNAs (TS-miRNAs), 
could become a reliable tool for improving the cancer therapy. In this chapter, we will 
present an up-to-date overview of the role of miRNA-based therapeutics in oncology, 
highlighting their role in cancer management, how these therapies can be used, and 
which would be the future challenges related to miRNA-based therapies.
Keywords: cancer, invasions, metastasis, miRNA, therapy
1. Introduction
With an increasing incidence each year, cancer represents a major health prob-
lem worldwide, ranked second, after cardiovascular disease. According to the last 
estimation presented by the International Agency for Research on Cancer (IARC) 
in 2012, more than 14 million new cases of cancers were encountered, while the 
cancer-related deaths reached around 8.2 million people [1]. Unfortunately, the 
estimation for 2030 shows an increase in over 21 million new cancer cases and about 
13 million cancer deaths [2]. Cancer is characterized by changing the phenotype of 
the cells in which it occurs, leading to an uncontrolled proliferation, invasion, and 
metastasis. Albeit the cancers in early stages are treatable, especially by surgery, the 
major challenge is to treat cancers in advanced stages. Currently, the therapeutic 
regimens for treating the advanced cancers depend on several factors such as local-
ization, phenotype, and tumor size and are based on a combination of at least two 
of more approaches, represented by surgery, chemotherapy, radiotherapy, hormone 
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As master modulators of the human genome, miRNAs are involved in all cancer 
hallmarks, disrupting the normal function of their targets. By gaining or losing 
the function, miRNAs lead to the validation of tumor phenotype, its progression, 
and metastasis as well as to drug resistance. Increasing the evidence suggests that 
the modulation of miRNAs in cancer cells, by suppressing the oncogenic miRNAs 
(oncomiRs) and substituting the deficient tumor suppressive miRNAs (TS-miRNAs), 
could become a reliable tool for improving the cancer therapy. In this chapter, we will 
present an up-to-date overview of the role of miRNA-based therapeutics in oncology, 
highlighting their role in cancer management, how these therapies can be used, and 
which would be the future challenges related to miRNA-based therapies.
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1. Introduction
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13 million cancer deaths [2]. Cancer is characterized by changing the phenotype of 
the cells in which it occurs, leading to an uncontrolled proliferation, invasion, and 
metastasis. Albeit the cancers in early stages are treatable, especially by surgery, the 
major challenge is to treat cancers in advanced stages. Currently, the therapeutic 
regimens for treating the advanced cancers depend on several factors such as local-
ization, phenotype, and tumor size and are based on a combination of at least two 
of more approaches, represented by surgery, chemotherapy, radiotherapy, hormone 
therapy, and target therapy. Nevertheless, this anticancer armamentarium is not 
very efficient because about 90% of advanced cancers lead to metastasis and death 
ultimately [3]. Current anticancer therapies target either antiproliferative or pro-
apoptotic pathways of tumor cells or activate immune response against tumors, but 
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none of the currently available antitumor therapies target the molecular pathways 
involved in invasion and metastasis.
Tumor invasion and metastasis, as they were pointed out by Hanahan and 
Weinberg [4], represent one of the most important hallmarks of cancer, and 
therefore, exploiting these features of tumor cells could bring new data to develop 
more powerful anticancer therapies. Tumor invasion and metastasis are very 
complex processes that involve a series of sequential and interrelated steps. In this 
line, epithelial-to-mesenchymal transition (EMT) represents the most important 
event underlying the tumor invasion [5]. During EMT, tumor cells lose their 
epithelial characteristics and adhesion and acquire increased motility by shifting 
toward a mesenchymal phenotype while also diminishing apoptosis and senescence 
and gaining stem cell properties. The EMT regulation includes a network of many 
regulators, inducers, and effector molecules, which sustains tumor cell dissemina-
tion to distant organs [6].
The “omics” revolution has brought us new data about the complexity of signal-
ing pathways in cancer, the type of molecules that are involved in them, and which 
alterations are associated with cancer. Moreover, noncoding RNAs, including miR-
NAs, have proved their crucial role in the regulation of mRNA translation in both 
physiological and pathological status. Because of their high capacity to modulate 
mRNA expression, miRNAs are defined as master modulators of the human genome. 
Therefore, miRNAs are involved in all cancer hallmarks, disrupting the normal func-
tion of their targets. By gaining or losing the function, miRNAs lead to the validation 
of tumor phenotype, its progression, and metastasis as well as to drug resistance.
Increasing the evidence suggests that the modulation of miRNA expression 
in cancer cells, through the inhibition of oncogenic miRNAs (oncomiRs) and the 
substitution of deficient tumor suppressive miRNAs (TS-miRNAs), could represent 
a reliable tool for improving the cancer therapy. In this chapter, we will present 
an up-to-date overview about the role of miRNA-based therapeutics in oncology, 
highlighting their role in cancer management, how these therapies can be used, and 
which would be the future challenges related to miRNA-based therapies.
2. Short overview about biogenesis and function of miRNAs
If deciphering the whole human genome has represented a milestone of mod-
ern biology, the identification of its precise functionality is still a great challenge. 
However, by completing the ENCODE project, many data about how the human 
genome is functioning were revealed. Such as, it is estimated that about 1.5% of 
human genome includes coding DNA exons from protein-coding genes (PCGs), 
while the rest of 98% represents noncoding DNAs including regulatory sequences 
such as the ones defining noncoding RNAs (ncRNAs), as well as introns, and other 
DNA sequences with unknown functions [7].
About 80% of human genome is activated in cell physiology, and an impor-
tant part of noncoding regulatory elements involved in the regulation of PCGs 
includes noncoding RNAs. Since their recognition as a distinct class of biological 
regulators [8], micro-RNAs (miRNAs) have become the most studied species of 
noncoding RNAs. miRNAs are coded by genes located in almost all regions of the 
genome, including both PCGs and noncoding transcripts. About a half of miRNA 
genes are located in both intronic (40%) and exonic (10%) regions of noncod-
ing genes, while the majority of the other miRNA loci are located in intragenic 
regions of PCGs [9]. The first step of miRNA biogenesis includes the transcription 
of pri-miRNA, a primary long hairpin transcript with a length of hundreds or 
thousands of nucleotides (Figure 1). Furthermore, after its processing to a shorter 
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hairpin structure of about 70 nucleotides, the pre-miRNA is exported into the 
cytoplasm, where under enzymatic processing, it is reduced to a single-stranded 
RNA (mature miRNA) of about 21–23 nucleotides in length. Afterward, by its 
incorporation into Argonaute 2 protein and then in the RNA-induced silenc-
ing complex (RISC), the mature miRNA will function as a guide molecule for 
silencing complex, targeting specific mRNA transcripts, usually by base-pairing 
specific mRNA transcripts, in the 3′ untranslated region (3′ UTR). Targeting the 
mRNA by a specific miRNA leads to the translational repression of mRNA and its 
exonucleolytic decay [9].
Because of their capacity to modulate up to 60% of PCGs, miRNAs are defined 
as “master modulators” of the human genome [10]. An important feature of 
miRNAs is that a single miRNA can target up to 200 mRNAs, while a single mRNA 
can be modulated by different miRNAs [11]. Nevertheless, to increase the accuracy 
of miRNA-mRNA binding, several combinatorial prediction tools based on ther-
modynamic modeling and machine learning techniques have been developed lately 
[12, 13], bringing new understanding about how miRNAs can exert their regulatory 
function through a combinatorial-cooperative activity.
Figure 1. 
miRNA biogenesis. The miRNA biogenesis starts in the nucleus, with a pri-miRNA transcription. Afterward, 
the pri-miRNA is processed to a shorter hairpin structure of about 70 nucleotides, by Drosha and DGCR8, and 
it is exported in the cytoplasm by Exportin 5. After enzymatic processing by DICER, double-stranded miRNAs 
are reduced to a single-stranded mature RNA (21–23 nucleotides in length). Furthermore, by incorporating into 
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At the moment, 48,885 mature miRNA products from 271 species, including 2654 
mature human miRNAs, have been reported in the latest available miRNA database 
(miRBase release 22; http://www.mirbase.org/) [14]. In normal phenotype, by their 
modulatory effects, miRNAs maintain the cell physiology, while by their aberrant 
expression, miRNAs lead to the validation of many diseases including cancer.
3. The role of miRNAs in cancer
Croce’s group established for the first time an association of mRNAs with cancer, 
indicating an alteration of miR-15a/16-1 cluster, in chronic lymphocytic leukemia 
[15]. Further functional analyses have demonstrated that miR-15 and miR-16 can 
target and suppress the expression of BCL2 oncogene, inducing the apoptosis. [16]. 
Through exploring the role of miRNAs, Croce’s group has demonstrated that miRNA 
profiling could be taken into consideration for characterizing the malignant pheno-
type [17], opening a new perspective for identifying new cancer-specific miRNAs. 
Interestingly, for poorly differentiated tumors, tissue miRNA profiling has revealed 
better diagnosis than mRNA profiling, highlighting their role as tumor biomarkers 
[18]. An important feature of miRNAs, given by their high stability in formalin-fixed 
paraffin embedded (FFPE) tissues, blood including serum and plasma, as well as 
other biological fluids such as urine, tears, breast milk, saliva, and seminal fluids, 
makes them important candidates for the discovery of new minimally invasive 
biomarkers [19, 20]
Therefore, a myriad of studies describing the role of miRNAs in cancer develop-
ment have been provided, with more than 21,565 papers that are published in PubMed 
today, when “miRNA, miR, microRNA, and cancer” are used as a string search.
Alteration of miRNA expression in cancer is due to genetic and epigenetic 
events. Genetic alterations include: chromosomal rearrangements or loss of het-
erozygosis (LOH) (e.g. miR-15a/16-1), gene amplification (e.g. miR-17-92 cluster, 
miR-155), deletions (e.g. let-7 family member), or mutations (e.g. miR-16) [15]. 
Moreover, genetic alteration may occur in the PCGs involved in the synthesis of the 
protein components of the Drosha, DGCR8, Exportin 5, Dicer, and AGO2, the main 
enzymes that process the biogenesis and activation of miRNAs. Pre- and post-
transcriptional controls of not only miRNA biogenesis but also epigenetic events, 
including methylation and acetylation, were also related to aberrant expression of 
tumor miRNAs [21, 22]. Not lastly, the presence of the single-nucleotide polymor-
phism (SNP) mutations in the miRNA-coding genes may lead to the alterations of 
mature miRNA structure, reducing its specificity to the mRNA target [23].
Functionality studies have demonstrated that the expression of oncogenes and 
tumor-suppressor genes in cancer is closely controlled by miRNAs (Figure 2). 
Such as, miRNAs that target and modulate the oncogenic expression are defined 
as tumor-suppressor miRNAs (TS-miRNAs), while the miRNAs that modulate the 
expression of tumor-suppressor genes are known as oncomiRs [24]. Genetic and 
epigenetic alterations occurring in cancer lead to “gain of function” of oncomiRs 
and inactivation or “loss of function” of TS-miR (Figure 2), which translate into 
regulating the expression of their targets through downregulation of tumor-
suppressor genes and upregulation of oncogenes, respectively [25]. miRNAs are 
involved in all hallmarks of cancer, including self-sufficiency in growth signals 
(let-7 family, miR-21), insensitivity to antigrowth signals (e.g. miR-17-92 cluster, 
miR-195), evasion from apoptosis (e.g. miR-34a, miR-185, miR-15/miR-16), 
limitless replicative potential (e.g. miR-372/373 cluster, miR221/222), angiogenesis 
(e.g. miR-210, miR-26, miR-15b, miR-155), invasion and metastases (e.g. miR-10b, 
miR-31, miR-200 family, miR-21, miR-15b), reprogramming energy metabolism 
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(e.g. miR-23a/b, miR-378, miR-143, miR-15b), evading immune destruction (e.g. 
miR-124, miR-155, miR-17-92), tumor-promoting inflammation (miR-23b, miR-
155, let-7d), and genomic instability (miR-21, miR-155, miR15b) [22, 26, 27].
4. Strategies used for miRNA-based therapies
4.1 miRNA inhibition therapies for oncomiRs
The choice to use mRNA-based therapies is based on the fact that the expression 
of mRNAs in tumor cells is altered, and tumor phenotype can be changed by the 
modulation of the miRNA expression [28].
Figure 2. 
The role of miRNAs in cancer and their use of miRNA-based therapy. (A) miRNAs that function as oncomiRs 
and TS-miRs. Tumors are characterized by aberrant upregulation of oncomiRs that lead to downregulation 
of tumor-suppressor genes and inactivation of TS-miRs reflected in overexpression of oncogenes. All of these 
contribute to tumor development, invasion, and metastasis as well as decrease cell death. (B) The use of 
anti-miRNA therapies leads to block the oncomiR activities, resulting in the upregulation of tumor-suppressor 
genes, while substituting TS-miR therapies increases the cellular level of TS-miRs, leading to the inactivation 
of oncogenes. The effects of miRNA-based therapy indicate an increase in cell death concomitantly with 
inactivation of tumor development.
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MiRNA inhibition therapy is used to suppress the expression of oncomiRs that are 
frequently overexpressed in human cancers and reestablish the normal expression 
of tumor-suppressor genes that are targeting directly (Figure 2). The therapy for 
miRNA inhibition includes the following agents: antisense anti-miR oligonucleotides 
(AMOs), locked nucleic acid (LNA) anti-miRs, antagomiRs, miRNA sponges, and 
small molecule inhibitors of miRNAs (SMIRs) [27]. The principle of this therapy 
consists of an isolation of the endogenous miRNAs in an unrecognizable configura-
tion, leading to inactivating and excluding the mature miRNAs from the RISC.
AMOs are single-stranded, chemically modified antisense oligonucleotides 
of about 17–22 nucleotides that are complementary to a miRNA of interest [28]. 
These antisense oligonucleotides anneal to the complementary mature miRNAs and 
inhibit their interaction with specific mRNA targets.
LNA anti-miRs represent an example of a modified antisense anti-miR oligo-
nucleotide [29]. LNA-modified oligonucleotides present a higher thermal stability 
and affinity for their miRNA target molecules, as well as a higher aqueous solubility 
and increased metabolic stability for in vivo delivery [30].
The antagomiRs are single-stranded RNA molecules of about 23 nucleotides in 
length complementary to miRNA targets that are chemically modified to increase the 
stability of the RNA and protect it from degradation [31]. One of the most important 
aspects of using these agents is due to their lack of inducing any immune response.
miRNA sponges represent a class of RNAs that include multiple artificial bind-
ing sites similar to those found in the endogenous miRNA targets. The expression 
vectors represent the source of miRNA sponge transcription, thus reducing the 
miRNA’s effects and increasing the expression of the miRNA’s native targets [32].
SMIRs are small molecules that suppress the miRNA biogenesis or block the 
interaction between a miRNA and the target. The inhibition therapy using SMIRs is 
an encouraging one due to the reduced time of production, approval, and cost [33].
4.1.1 Discussion
Krützfeldt et al. [31] demonstrated that intravenous administration of several 
antagomiRs toward miR-16, miR-122, miR-192, and miR-194 leads to a significant 
reduction in the corresponding endogenous miRNAs.
Moreover, an important positive effect observed in this study was that after the 
administration of antagomiR-122, the cholesterol levels in plasma have decreased. 
Due to the fact that, so far, the therapy using antagomiRs did not induce a signifi-
cant immune response, it is worth into consideration the development of a promis-
ing antisense therapy based on antagomiRs.
One of the main advantages of using locked nucleic acid (LNA) anti-miRs is that 
they present a higher thermal stability, high-affinity Watson-Crick hybridization 
with their RNA target molecules, higher aqueous solubility, and increased meta-
bolic stability for in vivo delivery. Overexpression of miR-21 is a common place in 
glioblastomas, and Griveau et al.’s [34] study was able to silence miR-21 in U87MG 
glioblastoma cell line, using a LNA conjugated to lipid nanocapsules (LNC). 
Another advantage of using LNA-LNC complexes in combination with external 
beam radiation is represented by the improvement of cell sensitivity to treatment.
4.2 miRNA replacement therapies for tumor-suppressor miRNAs
Also defined as miRNA restoration therapy, the replacement therapy with 
miRNAs includes the following agents: small molecules, synthetic miRNA mimics, 
and DNA plasmids encoding a miRNA gene that epigenetically alters endogenous 
expression of miRNAs [35].
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Small molecules in miRNA replacement therapy are represented by hypometh-
ylating agents (Decitabine or 5-azacytidine) and enoxacin, exerting a role in the 
nonspecific miRNA expression.
miRNA mimics are double-stranded synthetic RNAs, which are aimed to com-
pensate the lack of tumor-suppressor miRNAs by replacing the lost miRNAs. These 
chemically structures are loaded into RISC to provide the downstream inhibition of 
the target mRNAs [27].
4.2.1 Discussion
One of the main challenges of miRNA replacement therapy is represented by 
finding the most suitable, efficient, and specific delivery system. The efficacy of 
this therapy is significantly decreased by an unsuitable size of the vector or by gene 
expression. Since miRNAs can be introduced into cells using a similar technique to 
small interference RNAs [36], it is recommended to improve those techniques based 
on the insertion of synthetic miRNA mimics, DNA plasmids, and small molecules, 
as well as to improve the quality of molecules used for this type of therapy.
4.3 miRNA delivery systems
An important aspect that is worth considering in miRNA cancer therapy aims to 
use miRNA delivery systems. One of these delivery systems including microvesicles 
and exosomes aim to block miRNA-entrapped exosomes released by tumors. It is 
already demonstrated that miRNA-entrapped exosomes secreted by tumor cells can 
regulate gene expression in the receiving cells by binding to their target mRNAs 
[37]. The use of some agents that block specific miRNAs (such as LNA anti-miR-21 
and LNA anti-miR-29a) in tumor cells could lead to the reduction in miRNA-
entrapped exosomes, released by cancer cells [38]. However, an ideal delivery 
system meets the following criteria: protects the miRNAs from early degradation in 
the bloodstream, efficient distribution to the target cells, facilitates cellular uptake, 
does not induce an immune response, and made of biocompatible and biodegrad-
able materials [39].
The most commonly used vectors for miRNA delivery include viral and 
nonviral vectors. Previous data demonstrated that viral vectors mainly caused 
an immune response; therefore, the focus of the actual studies is on developing 
efficient nonviral vectors. Nonviral vectors are classified into three main groups, 
including polymeric vectors (polyethyleneimines, atelocollagen, polylactic-co-
glycolic acid, polyamidoamine dendrimers), lipid-based carriers (positively, 
negatively or neutral charged), and inorganic materials (gold, diamond, silica, and 
ferric oxide) [40].
The delivery system based on viral vectors transfers the pri-miRNA or mature 
miRNAs, usually a TS-miR, into a plasmid, which contains a viral promoter, an 
antibiotic resistance gene, and a restriction enzyme gene, to the tumor cells. After 
nuclear integration of the miRNA and further transcription, the mature miRNA 
represses the translation and/or induces the degradation of the target mRNA [41].
4.3.1 Discussion
One of the most studied classes of polymeric vectors was represented by polyeth-
ylenimines (PEIs) but was removed from clinical studies due to their high toxicity, 
given by an excessive positive charge, low biological degradation, and inactivation in 
serum caused by a nonspecific protein. Ibrahim et al. [42] have demonstrated that by 
using low molecular weight, PEIs as system delivery for miR-145 and miR-33a would 
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Moreover, an important positive effect observed in this study was that after the 
administration of antagomiR-122, the cholesterol levels in plasma have decreased. 
Due to the fact that, so far, the therapy using antagomiRs did not induce a signifi-
cant immune response, it is worth into consideration the development of a promis-
ing antisense therapy based on antagomiRs.
One of the main advantages of using locked nucleic acid (LNA) anti-miRs is that 
they present a higher thermal stability, high-affinity Watson-Crick hybridization 
with their RNA target molecules, higher aqueous solubility, and increased meta-
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Another advantage of using LNA-LNC complexes in combination with external 
beam radiation is represented by the improvement of cell sensitivity to treatment.
4.2 miRNA replacement therapies for tumor-suppressor miRNAs
Also defined as miRNA restoration therapy, the replacement therapy with 
miRNAs includes the following agents: small molecules, synthetic miRNA mimics, 
and DNA plasmids encoding a miRNA gene that epigenetically alters endogenous 
expression of miRNAs [35].
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Small molecules in miRNA replacement therapy are represented by hypometh-
ylating agents (Decitabine or 5-azacytidine) and enoxacin, exerting a role in the 
nonspecific miRNA expression.
miRNA mimics are double-stranded synthetic RNAs, which are aimed to com-
pensate the lack of tumor-suppressor miRNAs by replacing the lost miRNAs. These 
chemically structures are loaded into RISC to provide the downstream inhibition of 
the target mRNAs [27].
4.2.1 Discussion
One of the main challenges of miRNA replacement therapy is represented by 
finding the most suitable, efficient, and specific delivery system. The efficacy of 
this therapy is significantly decreased by an unsuitable size of the vector or by gene 
expression. Since miRNAs can be introduced into cells using a similar technique to 
small interference RNAs [36], it is recommended to improve those techniques based 
on the insertion of synthetic miRNA mimics, DNA plasmids, and small molecules, 
as well as to improve the quality of molecules used for this type of therapy.
4.3 miRNA delivery systems
An important aspect that is worth considering in miRNA cancer therapy aims to 
use miRNA delivery systems. One of these delivery systems including microvesicles 
and exosomes aim to block miRNA-entrapped exosomes released by tumors. It is 
already demonstrated that miRNA-entrapped exosomes secreted by tumor cells can 
regulate gene expression in the receiving cells by binding to their target mRNAs 
[37]. The use of some agents that block specific miRNAs (such as LNA anti-miR-21 
and LNA anti-miR-29a) in tumor cells could lead to the reduction in miRNA-
entrapped exosomes, released by cancer cells [38]. However, an ideal delivery 
system meets the following criteria: protects the miRNAs from early degradation in 
the bloodstream, efficient distribution to the target cells, facilitates cellular uptake, 
does not induce an immune response, and made of biocompatible and biodegrad-
able materials [39].
The most commonly used vectors for miRNA delivery include viral and 
nonviral vectors. Previous data demonstrated that viral vectors mainly caused 
an immune response; therefore, the focus of the actual studies is on developing 
efficient nonviral vectors. Nonviral vectors are classified into three main groups, 
including polymeric vectors (polyethyleneimines, atelocollagen, polylactic-co-
glycolic acid, polyamidoamine dendrimers), lipid-based carriers (positively, 
negatively or neutral charged), and inorganic materials (gold, diamond, silica, and 
ferric oxide) [40].
The delivery system based on viral vectors transfers the pri-miRNA or mature 
miRNAs, usually a TS-miR, into a plasmid, which contains a viral promoter, an 
antibiotic resistance gene, and a restriction enzyme gene, to the tumor cells. After 
nuclear integration of the miRNA and further transcription, the mature miRNA 
represses the translation and/or induces the degradation of the target mRNA [41].
4.3.1 Discussion
One of the most studied classes of polymeric vectors was represented by polyeth-
ylenimines (PEIs) but was removed from clinical studies due to their high toxicity, 
given by an excessive positive charge, low biological degradation, and inactivation in 
serum caused by a nonspecific protein. Ibrahim et al. [42] have demonstrated that by 
using low molecular weight, PEIs as system delivery for miR-145 and miR-33a would 
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decrease the toxicity and increase the antitumor effect, in a model of colon carci-
noma. Recent studies [43, 44] have proved that codelivery of miR-200c with chitosan, 
a cationic polymer with a high specificity for nucleic acid binding, decreased the 
angiogenesis, invasion, EMT, and metastasis and increased the apoptosis, highlight-
ing the role of miRNA concentration in treatment effectiveness. Hao et al. [45] used 
miRNA (MiR-15a, miR16-1)/ATE-APT complex formed by atelocollagen (ATE), 
a type I collagen positively charged polymer, in combination with a RNA aptamer 
(APT) used as a ligand to target PCa cells that express prostate-specific membrane 
antigen (PSMA). Their study concluded that miRNA/ATE-APT complex was more 
efficient than an ATE-miRNA complex and that by using a PSMA-targeted system, 
the chances for selective killing of prostate cancer cells significantly would increase.
Moreover, it is worth into consideration the administration methods used for 
synthetic miRNAs (miRNA mimics) delivery into cells. Previous studies of Trang 
et al. have shown that both intratumoral and intravenous administration of let-7a 
mimics lead to the diminishing of non-small-cell lung cancer (NSCLC) tumor size 
in mouse models [46, 47].
As a future improvement in miRNA delivery systems, it is recommended to 
be synthetized proteins or peptides in order to be used as vector polymeric due to 
their low cytotoxicity and immunogenicity. Finding a suitable delivery system for a 
specific miR according to tumor cell type and the development of systems to target 
specific cancer membrane antigens still represent major challenges.
5. MicroRNAs in cancer therapies
5.1 miRNA candidates used in preclinical trials
Increasing the evidence has demonstrated that miRNA expression is modified in 
cancer, and restoring the level of cellular miRNA could underpin the development 
of miRNA-based therapies. Below we briefly describe miRNAs that are currently 
used in preclinical and clinical trials and also represent examples that affect the 
emerging hallmarks of cancer such as evasion from apoptosis (miR-15/16, miR-34 
cluster) [48], enabling replicative immortality (miR-34a) [48], activating invasion 
and metastasis (miR-10b) [49], tumor-promoting inflammation (miR-155), and 
genome instability and mutation (miR-155) [50].
5.1.1 miR-10b
Guessous et al. [51] observed that miR-10b is overexpressed in human glioblas-
toma and stem cell lines when compared to healthy tissues or astrocytes. After the 
modulation of miR-10b, they found out that the inhibition of miR-10b strongly 
reduced cell proliferation, invasion, and migration of glioblastoma and stem cell 
lines, whereas its overexpression caused cell migration and invasion. Moreover, 
in a previous study, Ma’s group [52] has demonstrated that the use of miR-10b 
antagomiRs was correlated with reduced metastasis both in cell-culture lines and in 
animal model of breast tumor-bearing mice. Thus, miR-10b inhibition both in vitro 
and in vivo significantly decreased miR-10b levels and increased levels of Hoxd10 
gene, an important miR-10b target. Curiously, the administration of miR-10b 
antagomiRs in vivo did not reduce primary mammary tumor growth but signifi-
cantly suppressed the development of lung metastases, highlighting its antimeta-
static role.
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5.1.2 miR-221
Since miR-221 overexpression alters multiple cancer pathways, it becomes a 
potential target for miRNA-based therapy. In order to validate the role of miR-221 in 
tumorigenesis, Callegari et al.[53] showed that in vivo delivery of an AMO anti-
miR-221 caused a significant decrease in the size and number of tumor nodules. 
Based on the results from their study, it was highlighted the promoter role of 
miR-221 in liver carcinogenesis, being also established a valuable animal model to 
investigate the anti-miRNA-based therapy for liver cancer.
Moreover, using a colorectal cancer model, Qin et al. [54] showed that miR-221 
promotes cell migration and invasion in vitro and metastasis in vivo, identifying 
tumor-suppressor RECK gene as a direct target of miR-221.
With regard to the role of miR-221 in tumorigenesis combined with the need 
to limit its expression, Brognara’s group demonstrated that a peptide nucleic acid 
conjugate targeted against miR-221 (Rpep-PNA-a221) caused a suppression of miR-
221 expression and an upregulation of its target p27Kip1 in two breast cancer cell lines 
(MCF-7 and MDA-MB-231), respectively [55]. On the other hand, in a recent study, 
Gallo et al. [56] evaluated the pharmacokinetic and pharmacodynamic properties 
of a locked nucleic acid anti-miR-221 (LNA-i-miR-221) in the models of mice and 
monkeys. Their data highlighted that LNA-anti-miR-221 has a short half-life, optimal 
tissue bioavailability and minimal urine excretion in both species. A very important 
aspect of their study was that no toxicity was present in the pilot monkey study. This 
finding defines the potential application of LNA-anti-miRNAs in clinical studies.
5.1.3 miR-222
Sometimes developing a miRNA-based therapy is difficult because the same 
miRNA can act both as an oncogene and as a tumor-suppressor gene, due to its 
multiple targets and mechanisms of action. Such an example in this way is repre-
sented by miR-222, which has a role of oncomiR in liver cancers, by targeting and 
suppressing the PTEN tumor-suppressor gene, or TS-miRNA, whose downregula-
tion in erythroblastic leukemia leads to the overexpression of c-KIT oncogene [27].
5.1.4 miR-34
miR-34 is one of the most important TS-miRs, being positively controlled by 
TP53 [57], repressed by MYC [58], and silenced by aberrant CpG methylation [59].
Overexpression of miR-34 was related to apoptosis and cell cycle arrest [60], while 
its underexpression was linked to different tumor types, including nonsmall-cell lung 
cancer (NSCLC) [61], breast cancer [62], or ovarian cancer [63]. Several studies have 
proved that ionizing radiation upregulates the levels of expression from different 
miR-34 family members in a variety of human cell types: miR-34b in lymphocytes 
[64], miR-34c in prostate cancer cell lines [65], and miR-34a in thyroid cells [66]. 
Consequently, to increase the therapeutic efficiency, some of the future studies 
should focus on the combined use of DNA damage response related to miRNAs and 
radio- or chemotherapy. By performing a miR-34 modulation, Trang et al. [47] have 
demonstrated that synthetic miR-34 mimics incorporated in a lipid-based particle was 
able to block tumor growth in a mouse model of nonsmall cell lung. Likewise, Daige 
et al. [67] have proved that the use of encapsulating miR-34a mimics into liposomes 
(MRX34) leads to increase the level of miR34a in liver tumors, followed by signifi-
cantly reducing several of its mRNA targets, and consequently tumor regression. 
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proved that ionizing radiation upregulates the levels of expression from different 
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[64], miR-34c in prostate cancer cell lines [65], and miR-34a in thyroid cells [66]. 
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Based on these results, encapsulating miR-34a mimics into liposomes (MRX34, Mirna 
Therapeutics Inc.) was later proposed to be investigated in clinical trials [68].
5.1.5 miR-16
miR-16 represents another TS-miR whose decreased expression has been observed 
among different types of cancers, as well as in nonsmall cell lung cancer (NSCLC) 
[69], prostate cancer [70], or malignant pleural mesothelioma [71], making it a strong 
candidate for replacement therapy in future studies with potential use in clinical trials. 
The data presented by Takeshita et al. [72] revealed that systemic delivery of synthetic 
miR-16, conjugated to atelocollagen, significantly reduced bone metastases and tumor 
development in a prostate cancer animal model. Moreover, their in vitro data suggest 
that miR-16 suppresses prostate tumor growth by regulating the expression of genes 
associated with cell-cycle control and cellular proliferation such as CDK1 and CDK2. 
The Hao group has also revealed that miR-16-1/atelocollagen-aptamer complex used 
in a mice model of human prostate cancer with bone metastasis enhanced anticancer 
efficacy. They also demonstrated that the efficacy of this complex, including aptam-
ers, was higher, both in vitro and in vivo models than the other atelocollagen complexes 
that do not include aptamers. Re-expression of miR-16 mimic in malignant pleural 
mesothelioma cell lines and nude mouse models has caused the inhibition of tumor 
growth, correlated with downregulation of target genes Bcl-2 and CCND1 [71].
5.1.6 miR-155
miR-155, one of the first described oncomiRs [73], was identified as highly 
expressed in a wide range of tumors including chronic lymphocytic leukemia [74], 
lung cancer [75], breast cancer [76], acute myeloid leukemia [77], solid tumor 
including stomach, prostate, colon, pancreas [78], and melanoma [79].
OncomiR-155 was discovered to target RAD51, an important gene in the homol-
ogous recombination DNA repair pathway, and the clinical study of Gasparini 
et al. [80] for triple negative breast cancer revealed that low miR-155 expression 
level correlated with worse progression-free survival. Moreover, Pouliot et al. 
[81] reported a reduced expression of miR-155 in human epidermoid carcinoma 
cisplatin-resistant cell lines. Dysregulated expression of this miRNA sensitizes the 
cells to cisplatin-induced apoptosis by targeting WEE1 and CHK1 kinases. Based on 
these results, future studies are encouraged with the focus on the use of exogenous 
agents, such as mimics or anti-miRs to sensitize cancer cells to chemo- or radio-
therapy, thus overcoming resistance to therapy.
Alexander et al. [82] found that endogenous miR-155, an important microRNA 
that regulates inflammation, is released from dendritic cells within exosomes and 
transferred to recipient dendritic cells. Administration of miR-155 containing exo-
somes enhances inflammatory gene expression as a response to endotoxin-induced 
inflammation in mice. Their findings provide strong evidence that endogenous 
microRNAs follow a functional transfer between immune cells and represent a 
regulatory mechanism for inflammatory response.
More examples of tumor-suppressor miRNA mimics, which target multiple 
oncogenic transcripts, were recently presented by Hosseinahli et al. [41].
5.2 Clinical studies involving miRNA-based therapy
Given the results provided by in vitro and in vivo studies, several clinical trials 
including miRNA-based therapy in human cancers were subsequently initiated 
(Table 1).
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In April 2013, Mirna Therapeutics, Inc., a publicly traded company based 
in Carlsbad, California, which primarily focuses on anti-miRNAs technology, 
announced that their leading product candidate, MRX34, a mimic of miR-34 
encapsulated in a liposomal nanoparticle formulation, called NOV40, was the first 
microRNA mimic to enter clinical development. The multicenter phase I trial of 
MRX34 included patients diagnosed with primary liver cancer, nonsmall cell lung 
cancer (NSCLC), lymphoma, melanoma, multiple myeloma, or renal cell carci-
noma. The trial aimed to increase the number of intravenously doses with two times 
per week or five times per day schedule. In June 2016, a total of 99 patients suffering 
from HCC, NSCLC, or pancreatic cancer had been enrolled in the study [83]. The 
phase I clinical trial confirmed partial responses in a patient with metastasized 
hepatocellular carcinoma (HCC), a patient with advanced acral melanoma, and a 
patient with advanced renal cell carcinoma (RCC), evaluated through Response 
Evaluation Criteria in Solid Tumors (RECIST). Also, 14 patients were detected with 
stable disease (median duration 136 days; range 79–386 days). Results from white 
blood cell analysis indicated a significant reduction in two miR-34 target genes 
FOXP1 and BCL2. Nonetheless, because of the immune-related adverse responses 
involving patient deaths, the trial was finished. Since the cause of these immune 
reactions remains still unclear, preclinical trials will be need in order to better 
understand the immune-related toxicities. After passing successfully the phase I 
clinical trial, they intended to advance into two phase II clinical studies: one for 
patients diagnosed with advanced malignant melanoma and another for patients 
diagnosed with advanced renal cell carcinoma (RCC). In concordance with the 
advancements made by MRX34, their lead product candidate, through the clini-
cal development, miR-34 mimics represent a new promising class of replacement 
therapy used in cancer. Additionally, Cortez et al. [84] reported that p53 regulated 
PDL1 expression via miR-34 in nonsmall-cell lung cancer. Administration of miR-
34a mimics (MRX34), alone or in combination with radiotherapy (XRT), reduced 
PDL1 expression in the tumor and antagonized T-cell exhaustion.
In November 2014, EnGeneIC, a privately held Australian company in collabora-
tion with Asbestos Diseases Research Institute, Sydney, Australia, announced the start 
of phase I clinical trial using miR-16 mimic charged in nanocells, a bacterial-derived 
transfection system EDV™. The trial included patients suffering from malignant 
pleural mesothelioma (MPM) and advanced nonsmall cell lung cancer (NSCLC), 
refractory to standard therapy. miR-16 mimic-based therapy were delivered intrave-
nously, using EnGeneIC Delivery Vehicle (EDV)-Packaging, and were surface conju-
gated with an EGFR-targeting antibody in order to facilitate the target of tumor site 
[85]. Preliminary data presented by Van Zandwijk et al. [86] show manageable safety 
in response to infusion of 5 billion nanocells loaded with 1.5 μg miR-15/16 mimics as 
a first-dose level in the first five patients that had been enrolled. Because of the fact 
that this targomiR trial using miR-16 as a replacement therapy did not present adverse 
immune response and toxic effects, it is expected to continue to phase II study [86].
In March 2016, MiRagen Therapeutics, Inc., a privately held company based in 
Boulder, Colorado, announced the initiation of phase I clinical trial to investigate 
the anticancer product candidate: MRG-106, a synthetic microRNA antagonist 
of microRNA-155 (LNA anti-miR). The phase I clinical trial is currently tested in 
patients diagnosed with cutaneous T-cell lymphoma (CTCL) of the mycosis fungoi-
des (MF) subtype [89].
Despite some promising preclinical results, the outcome of MRX34 transla-
tional clinical trial using miR-16 as a replacement therapy, designed to restore the 
expression of miR-34 in patients diagnosed with different types of cancer, was 
discouraging due to adverse toxic effects. At present, this clinical trial is finished, 
and its suitability to further development to phase II study remains under question. 
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However, this drawback can be addressed by optimizing therapeutic doses and 
applying organ-specific administration routes [41].
6. Future challenges: new reliable miRNAs for target therapies
Epithelial-to-mesenchymal transition (EMT) allows tumor cells to enter the 
metastatic cascade by changing their morphological and molecular characteris-
tics, and it represents a wide spectrum that cancer cells keep transiting. The EMT 
program relies on an intricate network of signaling pathways that dictate a series 
of phenotypic changes in epithelial cells. One clearly visible aspect is the loss of 
apical-basal polarity and cell-to-cell interaction caused by the destabilization of 
tight junctions, decreased claudin, occludin, and E-cadherin repression by SNAIL, 
SLUG, ZEB, TWIST, and SMAD, and its interchange with N-cadherin, a process 
known as the “cadherin switch” [90, 91]. Moreover, the overexpression of vimentin, 
a cytoskeleton intermediate-filament protein of mesenchymal origin that connects 
the nucleus to the plasma membrane, enables filopodia formation and a fibroblastic 
spindle-like morphology. Vimentin was proved to be induced through Slug and Ras 
signaling, and it promotes cell movement and migration [92]. The next step is the 
degradation of extracellular matrix components under the activity of matrix metal-
loproteinases and the invasion of the surrounding stroma (Figure 3).
The EMT is coordinated by a series of signaling pathways triggered by either the 
tumor microenvironment or the intrinsic factors, and it falls under the incidence of 
regulatory noncoding RNAs, especially micro-RNAs [93].
This is the reason why finding potential microRNA targets for blocking EMT 
could support the efforts already made in blocking metastasis and improving cancer 
therapy strategies. Right below, we are succinctly reviewing the results of several 
studies that investigated the role of microRNAs in EMT and metastasis and their 
potential in becoming microRNA therapy targets (Table 2).
The influence of cancer-associated fibroblasts (CAFs) secreted exosomes over 
endometrial cancer progression was questioned in a study by Li et al. [94]. CAFs 
secreted exosomes contained significantly lower levels of miR-148b than normal 
fibroblasts, and miR-148b expression was lower in endometrial cancer specimens 
than in normal adjacent tissues. miR-148b was correlated with improved prognosis, 
in vitro and in vivo studies suggesting its role as an EMT inhibitor. Downregulation 
of DNMT1 oncogene was the mechanism proposed for miR-148b-mediated sup-
pression of endometrial cancer progression. Also, relating to the tumor micro-
environment, emerging evidence shows the prometastatic effect of a hypoxic 
Figure 3. 
The EMT-MET plasticity of tumor cells, their migration, and invasion as tumor circulating cells (CTCs).
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In April 2013, Mirna Therapeutics, Inc., a publicly traded company based 
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cancer (NSCLC), lymphoma, melanoma, multiple myeloma, or renal cell carci-
noma. The trial aimed to increase the number of intravenously doses with two times 
per week or five times per day schedule. In June 2016, a total of 99 patients suffering 
from HCC, NSCLC, or pancreatic cancer had been enrolled in the study [83]. The 
phase I clinical trial confirmed partial responses in a patient with metastasized 
hepatocellular carcinoma (HCC), a patient with advanced acral melanoma, and a 
patient with advanced renal cell carcinoma (RCC), evaluated through Response 
Evaluation Criteria in Solid Tumors (RECIST). Also, 14 patients were detected with 
stable disease (median duration 136 days; range 79–386 days). Results from white 
blood cell analysis indicated a significant reduction in two miR-34 target genes 
FOXP1 and BCL2. Nonetheless, because of the immune-related adverse responses 
involving patient deaths, the trial was finished. Since the cause of these immune 
reactions remains still unclear, preclinical trials will be need in order to better 
understand the immune-related toxicities. After passing successfully the phase I 
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patients diagnosed with advanced malignant melanoma and another for patients 
diagnosed with advanced renal cell carcinoma (RCC). In concordance with the 
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cal development, miR-34 mimics represent a new promising class of replacement 
therapy used in cancer. Additionally, Cortez et al. [84] reported that p53 regulated 
PDL1 expression via miR-34 in nonsmall-cell lung cancer. Administration of miR-
34a mimics (MRX34), alone or in combination with radiotherapy (XRT), reduced 
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In November 2014, EnGeneIC, a privately held Australian company in collabora-
tion with Asbestos Diseases Research Institute, Sydney, Australia, announced the start 
of phase I clinical trial using miR-16 mimic charged in nanocells, a bacterial-derived 
transfection system EDV™. The trial included patients suffering from malignant 
pleural mesothelioma (MPM) and advanced nonsmall cell lung cancer (NSCLC), 
refractory to standard therapy. miR-16 mimic-based therapy were delivered intrave-
nously, using EnGeneIC Delivery Vehicle (EDV)-Packaging, and were surface conju-
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that this targomiR trial using miR-16 as a replacement therapy did not present adverse 
immune response and toxic effects, it is expected to continue to phase II study [86].
In March 2016, MiRagen Therapeutics, Inc., a privately held company based in 
Boulder, Colorado, announced the initiation of phase I clinical trial to investigate 
the anticancer product candidate: MRG-106, a synthetic microRNA antagonist 
of microRNA-155 (LNA anti-miR). The phase I clinical trial is currently tested in 
patients diagnosed with cutaneous T-cell lymphoma (CTCL) of the mycosis fungoi-
des (MF) subtype [89].
Despite some promising preclinical results, the outcome of MRX34 transla-
tional clinical trial using miR-16 as a replacement therapy, designed to restore the 
expression of miR-34 in patients diagnosed with different types of cancer, was 
discouraging due to adverse toxic effects. At present, this clinical trial is finished, 
and its suitability to further development to phase II study remains under question. 
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loproteinases and the invasion of the surrounding stroma (Figure 3).
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could support the efforts already made in blocking metastasis and improving cancer 
therapy strategies. Right below, we are succinctly reviewing the results of several 
studies that investigated the role of microRNAs in EMT and metastasis and their 
potential in becoming microRNA therapy targets (Table 2).
The influence of cancer-associated fibroblasts (CAFs) secreted exosomes over 
endometrial cancer progression was questioned in a study by Li et al. [94]. CAFs 
secreted exosomes contained significantly lower levels of miR-148b than normal 
fibroblasts, and miR-148b expression was lower in endometrial cancer specimens 
than in normal adjacent tissues. miR-148b was correlated with improved prognosis, 
in vitro and in vivo studies suggesting its role as an EMT inhibitor. Downregulation 
of DNMT1 oncogene was the mechanism proposed for miR-148b-mediated sup-
pression of endometrial cancer progression. Also, relating to the tumor micro-
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microenvironment over tumor cells. Acidic conditions were shown to promote 
miR-210 overexpression by activating HIF1 [95, 96]. In prostate cancer, high levels 
of miR-210 were detected in bone metastases, and they were correlated with poor 
prognosis of prostate cancer patients. Exogenously overexpression of miR-210-3p 
in cancer cell lines enhanced cell motility and migration as well as bone metastasis 
in mouse model by inducing NF-κB signaling and EMT. Moreover, miR-210-3p 
inhibition reversed EMT and impaired the metastatic potential of cancer cells [95]. 
Another study confirmed the hypoxia-induced EMT activation and metastasis by 
HIF1-miR-210 axis in breast cancer. Tang et al. [96] identified high expression of 
miR-210 in hypoxia grown breast cancer stem cells and in isolated human breast 
cancer stem cells. The overexpression of MiR-210 in poorly metastatic MCF7 cell 
lines leads to their invasiveness and migration in vitro as well as increasing meta-
static potential in vivo. One suggested mechanism is related to the direct binding 
of miR-210 to the Open Reading Frame (ORF) of the E-cadherin mRNA and its 
post-transcriptional inhibition in breast cancer cells.
miR-652 downregulation in the acidic microenvironment of pancreatic cancer 
promoted EMT by ZEB1 activation, and it was correlated with a progressive stage, 
lymphatic invasion, vascular infiltration, and distant metastasis. In vitro experiments 
showed that miR-652 overexpression has an antimetastatic effect by inducing MET in 
PANC-1-A miR-652-mimic transfected cells, and it reduced their migration and inva-
sion. Also, in vivo studies confirmed the in vitro results with lower tumor mass, fewer 
metastases, and overexpression of E-cadherin over vimentin/N-cadherin in mouse 
xenografts PANC-1-A miR-652-mimic transfected cells vs. miR-652 inhibitor [97].
Partially due to cancer tumors heterogeneity in construction and behavior and 
the relative novelty of noncoding RNAs as potential targets for cancer therapy, there 
are still missing bricks in understanding the mechanism that triggers the regulation 
of cancer-related microRNAs. However, as shown above, tumor microenvironment 
has a great impact over cancer progression, and probably understanding its role in 
modulating microRNA expression in tumor cells might bring light to new potential 
targets for improved therapy.
From a different perspective, there are many well-known pathways underlying 
cancer development and progression. Wnt signaling pathway represents one of the 
fundamental pathways involved in cell proliferation and specialization, as well as 
cell movement during both embryonic development and tissue homeostasis. The 
canonical Wnt signaling functions by regulating the amount of the transcriptional 
coactivator β-catenin, a molecule that controls key developmental gene expression 
programs [98]. Wnt signaling aberrations have been shown to regulate various 
processes that are important for cancer progression, including tumor initiation, 
tumor growth, cell senescence, cell death, differentiation, and metastasis. Wnt 
signaling molecules and downstream effectors can promote transcriptional changes 
in order to induce EMT in cancer cells while also being further activated by EMT in 
a continuous feedback loop [99].
Several microRNAs were proven to modulate Wnt signaling in EMT and cancer 
metastasis. In endometrial cancer, Wnt signaling can be activated by miR-652, 
which targets and inhibits retinoid orphan nuclear receptor alpha (RORA) gene. 
RORA represents a tumor-suppressor gene that represses the Wnt/β-catenin path-
way through attenuating β-catenin transcriptional activity. Expression of miR-652 
is frequently increased in human endometrial cancer tissues, its high expression 
being correlated with poor tumor differentiation, shorter overall survival, and 
recurrence. Overexpression of miR-652 in endometrial cancer cell promotes their 
proliferation and migration in vitro and in vivo [100].
Another metastasis enhancer, miR-374a, acts by activating the Wnt/β-catenin 
cascade and promoting EMT. miR-374a maintains constitutively activated 
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Wnt/β-catenin signaling by suppressing multiple negative regulators including 
WIF1, PTEN, and WNT5A. miR-374a was upregulated in primary tumor samples 
from breast cancer patients with distant metastases, and it was associated with 
poor metastasis-free survival. miR-374a transfection into poorly metastatic 
MCF7 cell line promoted its motility and invasiveness in vitro and lung metastasis 
forming abilities in BALB/c mice, while miR-374a knockdown in highly invasive 
MDA-MB-231 cells decreased their motility and metastatic potential [101].
On the other hand, microRNA-590-5p was found to function as a tumor-suppres-
sor in breast cancer, inhibiting EMT, cell migration, and invasion by downregulating 
the Wnt/β-catenin pathway. Quantitative RT-PCR analysis on breast tumor tissues 
and paired adjacent normal tissues showed that miR-590-5p was downregulated in 
breast cancer together with E-cadherin, while its target PITX2, b-catenin, Wnt-1, 
N-cadherin, and vimentin were upregulated. In vitro experiments and mouse xeno-
grafts showed that miR-590-5p upregulation or PITX2 silencing inhibits the activation 
of Wnt/β-catenin signaling pathway and suppresses the EMT of breast cancer [102].
Another metastasis inhibitor, miR-625, was characterized in different patholo-
gies, and surprisingly, it maintained its function, even though it was involved in 
different pathways. miR-625 was reported as downregulated in hepatocellular car-
cinoma, gastric cancer, and colorectal cancer, and its low expression was associated 
with local invasion, lymph node, and distant metastasis. Ectopic expression of miR-
625 induces suppression of migration and invasion of hepatocellular carcinoma cells 
by post-transcriptionally inhibiting IGF2BP1. Loss of IGF2BP1 suppressed F-actin 
polymerization, inhibiting the formation of cell protrusions, required for cell migra-
tion. The same effect was observed in vivo, where miR-625 overexpression decreased 
intrahepatic and lung metastasis [103]. Moreover, when it was ectopically induced, 
miR-625 suppressed the migration and invasion of gastric cancer cells as well as 
metastasis in nude mice by inhibiting ILK protein synthesis [98]. While the exact 
signaling pathway was not fully elucidated in colorectal cancer, ectopic miR-625 
expression inhibited cell migration and invasion and suppressed colorectal cancer 
cell metastasis in nude mice [99]. The aforementioned findings highlight miR-625 
as an interesting candidate for further in vivo studies in order to test its potential for 
developing a therapeutic microRNA for blocking invasion and metastasis.
A dual and somewhat contradictory behavior can be observed in the case of 
miR-409. While low miR-409 expression in breast cancer and nonsmall cell lung 
carcinoma (NSCLC) was associated with poorer prognosis and its ectopic uptake 
decreased the invasiveness of cancer cells [104, 105], it also seems to exert the nega-
tive effect in the case of prostate cancer, where it promotes tumorigenesis and EMT 
[106, 107]. Qi Song et al. [104] showed that miR-409 inhibits NSCLC cell migra-
tion, growth, and proliferation abilities by inhibiting SPIN1 translation. miR-409 
downregulates PI3K/AKT pathway in NSCLC and inhibits its downstream targets 
such as CREB1, BCL2, and Cyclin D. Overexpression of miR-409 led to fewer lung 
metastases in nude mice, confirming its antimetastatic potential. Interestingly, miR-
409 targeted the same pathway and suppressed cell growth and invasion in breast 
cancer. miR-409-3p inhibits the proliferation, migration, and invasion of breast 
cancer by targeting and suppressing the AKT expression. miR-409-3p was down-
regulated in several human tumors compared to their corresponding nontumor 
tissues [105]. On the other hand, miR-409-entrapped exosomes secreted by cancer-
associated fibroblasts (CAFs) and promoted EMT and prostate tumorigenesis. In 
their study, Josson et al. demonstrated that miR-409-3p was highly expressed in 
CAFs derived from human patients, and it was correlated with higher Gleason score 
in prostatic tissues. Moreover, the ectopic expression of miR-409 in normal prostate 
stromal fibroblasts conferred them a CAF phenotype in vitro. Exosome-mediated 
transport of miR-409 into normal prostate stromal cells induced cell growth and 
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microenvironment over tumor cells. Acidic conditions were shown to promote 
miR-210 overexpression by activating HIF1 [95, 96]. In prostate cancer, high levels 
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lines leads to their invasiveness and migration in vitro as well as increasing meta-
static potential in vivo. One suggested mechanism is related to the direct binding 
of miR-210 to the Open Reading Frame (ORF) of the E-cadherin mRNA and its 
post-transcriptional inhibition in breast cancer cells.
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promoted EMT by ZEB1 activation, and it was correlated with a progressive stage, 
lymphatic invasion, vascular infiltration, and distant metastasis. In vitro experiments 
showed that miR-652 overexpression has an antimetastatic effect by inducing MET in 
PANC-1-A miR-652-mimic transfected cells, and it reduced their migration and inva-
sion. Also, in vivo studies confirmed the in vitro results with lower tumor mass, fewer 
metastases, and overexpression of E-cadherin over vimentin/N-cadherin in mouse 
xenografts PANC-1-A miR-652-mimic transfected cells vs. miR-652 inhibitor [97].
Partially due to cancer tumors heterogeneity in construction and behavior and 
the relative novelty of noncoding RNAs as potential targets for cancer therapy, there 
are still missing bricks in understanding the mechanism that triggers the regulation 
of cancer-related microRNAs. However, as shown above, tumor microenvironment 
has a great impact over cancer progression, and probably understanding its role in 
modulating microRNA expression in tumor cells might bring light to new potential 
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canonical Wnt signaling functions by regulating the amount of the transcriptional 
coactivator β-catenin, a molecule that controls key developmental gene expression 
programs [98]. Wnt signaling aberrations have been shown to regulate various 
processes that are important for cancer progression, including tumor initiation, 
tumor growth, cell senescence, cell death, differentiation, and metastasis. Wnt 
signaling molecules and downstream effectors can promote transcriptional changes 
in order to induce EMT in cancer cells while also being further activated by EMT in 
a continuous feedback loop [99].
Several microRNAs were proven to modulate Wnt signaling in EMT and cancer 
metastasis. In endometrial cancer, Wnt signaling can be activated by miR-652, 
which targets and inhibits retinoid orphan nuclear receptor alpha (RORA) gene. 
RORA represents a tumor-suppressor gene that represses the Wnt/β-catenin path-
way through attenuating β-catenin transcriptional activity. Expression of miR-652 
is frequently increased in human endometrial cancer tissues, its high expression 
being correlated with poor tumor differentiation, shorter overall survival, and 
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proliferation and migration in vitro and in vivo [100].
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Wnt/β-catenin signaling by suppressing multiple negative regulators including 
WIF1, PTEN, and WNT5A. miR-374a was upregulated in primary tumor samples 
from breast cancer patients with distant metastases, and it was associated with 
poor metastasis-free survival. miR-374a transfection into poorly metastatic 
MCF7 cell line promoted its motility and invasiveness in vitro and lung metastasis 
forming abilities in BALB/c mice, while miR-374a knockdown in highly invasive 
MDA-MB-231 cells decreased their motility and metastatic potential [101].
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signaling pathway was not fully elucidated in colorectal cancer, ectopic miR-625 
expression inhibited cell migration and invasion and suppressed colorectal cancer 
cell metastasis in nude mice [99]. The aforementioned findings highlight miR-625 
as an interesting candidate for further in vivo studies in order to test its potential for 
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A dual and somewhat contradictory behavior can be observed in the case of 
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decreased the invasiveness of cancer cells [104, 105], it also seems to exert the nega-
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downregulates PI3K/AKT pathway in NSCLC and inhibits its downstream targets 
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EMT in vitro and in vivo. In this case, the predicted targets of miR-409 were the 
tumor-suppressor proteins STAG2 and RSU1, which appeared downregulated 
[108]. Considering these, it would be worth exploring if miR-409 has a positive or a 
negative impact over EMT and metastasis in more human cancers, and if it could be 
taken into consideration as a future miRNA therapy target.
Table 2 comprises a set of microRNAs that were evaluated both in vitro and in 
vivo, while also being analyzed in tumor samples, in correlation with the clinical 
outcome of the patients. As it can be easily observed, the effect of microRNAs in 
modulating EMT and metastasis-related pathways varies in different cancer types. 
In certain situations, the same microRNA can induce completely opposite outcomes 
by targeting multiple signaling pathways. This would be one of the biggest chal-
lenges that need to be overcome when designing new microRNA-based therapeutic 
compounds, and it is, at the same time, an interesting research niche worth explor-
ing, especially for miR-625, that maintained its anti-EMT function in three different 
cancer types (hepatocellular carcinoma, gastric cancer, and colorectal cancer) and 
miR-409 that is able to target multiple pathways with opposing effects in NSCLC, 
breast cancer, and prostate cancer.
7. Conclusions
miRNAs represent key modulators of the human genome because of their 
capacity to affect up to 60% of protein-coding genes. In cancer, genetic and epi-
genetic events lead to the alteration of miRNA expression and consequently their 
mRNA target genes. Functional studies have demonstrated that miRNA modula-
tion in tumor cells causes changes in the phenotype, leading to increased apoptosis 
and cell death, suppression of tumor development, invasion, and metastasis by 
inhibiting the oncogenic miRNAs (oncomiRs) and/or substituting the deficient 
tumor suppressive miRNAs (TS-miRNAs). Considering the encouraging preclini-
cal and clinical data, miRNA-based therapy could become a reliable tool in cancer 
management.
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AFP and IGF-I oncoproteins were introduced as biomarkers for cancer diagno-
sis and targeted in cancer therapy on protein level, but also on transcription and 
translation levels. The protein level was targeted using an injection of antibodies or 
radiolabeled proteins. The transcription and translation levels were targeted by triple 
helix and antisense technologies, respectively. AFP was especially useful for diagno-
sis and therapy of liver cancer, IGF-I was applied in diagnosis and therapy of colon, 
prostate, liver, uterus, ovary and brain tumors. The most spectacular results were 
obtained with IGF-I anti-gene strategy. IGF-I antisense (AS)/triple helix (TH) gene 
therapy was successfully introduced in clinical trial in the USA and Europe. When 
using IGF-I anti-gene therapy, cancer cells provided from biopsies were transfected 
in vitro with IGF-I AS, IGF-I TH expression vectors. A decrease in IGF-I gene 
expression of 80 and 60% was demonstrated when using TH and AS technologies, 
respectively. These transfected cells expressing MHC-I molecules, while injected 
in vivo, induced immune antitumor response mediated by CD8 lymphocytes. The 
median survival of treated glioblastoma patients was 21–22 months. IGF-I AS/TH 
immunogene therapy constitutes one of the most promising approaches in cancer 
therapy, and more specifically when it comes to glioblastoma treatment.
Keywords: cancer, glioma, alpha-fetoprotein, IGF-I, diagnostic, antibodies, 
antisense, triple helix, immunotherapy
1. Introduction
Oncoproteins like alpha-fetoprotein (AFP), serum albumin (AS), and growth 
factors such as GH, IGF, TGF-beta, and EGF are present in embryo-fetal tissues and 
reappear in neoplastic developing tissues, including the central nervous system; this 
concerns especially AFP [1–8] and IGF-I [9–17]. AFP is present in both neural and 
glial developing and cancerous cells, whereas IGF-I is only present in glial developing 
and tumoral cells [10, 18]. This striking difference has helped us orientate a strategy 
to manage the most malignant brain tumor expressing IGF-I gene—glioblastoma.
IGF-I plays an important role in growth as a mediator of growth hormone [19–21]. 
Blocking IGF-I synthesis induces apoptotic and immunogenic phenomena [12, 22]. 
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IGF-I plays an important role in growth as a mediator of growth hormone [19–21]. 
Blocking IGF-I synthesis induces apoptotic and immunogenic phenomena [12, 22]. 
Both phenomena, apoptosis and immunogenicity, related to arrest of IGF-I expression 
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in neoplastic glial cells, were used to prepare antitumor cell vaccines for therapy of 
brain malignant tumor—glioblastoma [12, 23].
An efficient strategy targeting IGF-I was established by construction of vectors 
stopping the synthesis of this oncoprotein on translation and transcription levels: 
vectors expressing either IGF-I antisense RNA or IGF-I RNA forming RNA-DNA 
triple helix, respectively. The glioma cells transfected with these vectors, when 
injected in vivo in animals bearing tumors like glioma or teratocarcinoma or applied 
in clinical treatment of glioblastoma patients, induced an immune antitumor effect 
(CD8+) accompanied by increase of the median survival of patients (successful 
clinical results obtained in the USA, E.U., China) [22, 23].
2. Oncoproteins in diagnostic: AFP and IGF-I
2.1 AFP
AFP is present in normal and neoplastic developing tissues [1, 24–26]. The pres-
ence of AFP seems to be related to the stage of cell and tissue differentiation. AFP is 
absent from either undifferentiated or fully differentiated cells [24].
The localization of AFP was compared with that of another oncoprotein—serum 
albumin, SA. SA-mRNA gave a strong signal in differentiating structures as well 
as in undifferentiated cell clusters. AFP-mRNA was observed only in differentiat-
ing structures; this observation was especially useful in the clinical diagnostic of 
hepatocarcinoma [4, 27].
During an experiment with teratocarcinoma-bearing mice injected intraperi-
toneally with J-125 radiolabeled SA and AFP, significant accumulations of both 
SA and AFP were demonstrated in the tumors, SA being about 3-fold higher 
than that of AFP after normalization to quantity of uptake in liver. In the case of 
comparatively studied neuroblastoma presenting only neuroblastic components 
(different from teratocarcinoma containing both neuroectoblastic and neuroblastic 
elements), the accumulation of radiolabeled SA and AFP showed relationship 1:1. 
External in vivo photo scanning confirmed this relationship of accumulated 
 radiolabeled proteins in both studied tumors; the last observations were useful for 
differential diagnosis of tumors [4, 27–36].
AFP may be used to advantage in radio tracing experiments, since this isologous 
protein is not expected to induce hypersensitivity reactions. On the other hand, and 
contrary to SA, the extremely low serum levels of AFP in adult individuals should 
minimize effects due to competition with endogenous protein. This makes AFP 
a good candidate for tumor biomarker by imaging techniques. The diagnosis and 
therapies of CNS tumors including neuroblastoma are always a subject of discussion 
[36–39].
2.2 IGF-I
Another oncodevelopmental antigen, an insulin like-growth factor, IGF-I  
[20, 40–43], is present in glioma cells but absent in neuroblastoma cells [18]; neuro-
blastic cells express IGF-II [27]. These observations permitted to study separately, 
using IGF-I and IGF-II as the oncoprotein markers, glial and neural tumors [13, 15, 
20, 40–42, 44–46].
Comparative studies of AFP, IGF-I, IGF-II presence in neoplastic cells [3, 4, 18] 
have demonstrated that IGF-I constitutes an essential target for genetic testing. 
IGF-I, similarly to AFP, is involved in tissue development and differentiation, espe-
cially in the development of the nervous system [9, 15, 19, 20, 47–51]. According to 
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Baserga [43], IGF-I is one of the most important growth factors related to normal 
and neoplastic differentiation [50, 52–54].
The elements of IGF-I related transduction pathway (IRS/PI3K-PKC/PDK1/AKT-
Bcl2/GSK3/GS) [55, 56] were also considered as targets for diagnostic [9, 55, 57–66]. 
The relationship between IGF-I and IGF binding proteins are being introduced in 
clinical diagnostics as one of the indicators of precancerous development [67].
IGF-I becomes useful in molecular diagnostic of neonatal CNS malformations 
and tumors [5, 9, 13, 39, 68, 69]. Diagnosis and treatment should logically be 
related, at first using IGF-I gene testing for diagnosis [13, 21, 70], and then targeting 
IGF-I gene through special therapy, such as cancer gene therapy, especially therapy 
of gliomas [11, 22, 71–73].
3. IGF-I and anti-gene immunotherapy
3.1 Protein, translation and transcription levels
To target an oncoprotein directly on protein level, the strategy of antibodies was 
explored. Cancers treated by use of antibodies was in general not efficient.
The treatment of any cancer, especially hepatocarcinoma, demands a permanent 
perfusion, per vena porta, of anti AFP antibodies. The arrest of perfusion has pro-
duced the reappearance of cancer. Similar observation has been made when using 
antibodies against growth factors.
The only possibility was to stop the synthesis of the oncoprotein on the transla-
tion or on the transcription level of the concerned gene, and directly in the cancer 
cells. This hypothesis and our knowledge of chemistry was an epistemological 
problem, pointed out by Mosquera “how to integrate the knowledge of chemistry 
with technique” [74].
As to glioma malignant tumor, glioblastoma (the mortality remains close to 
100%), new or proposed therapies are based generally either on immune treatment 
or on immuno-gene strategies [75, 76]. In order to define new therapies, the differ-
ent techniques for inhibitors [9], and the anti-gene strategy (either antisense, AS, or 
triple helix, TH, approaches) were investigated [61] (Figure 1).
The AS technology [77, 78] has permitted us to establish new and successful 
gene therapy strategies targeting glioma’s growth factors [11, 79] and have now been 
introduced into clinical trials. Other recently introduced technologies include those 
of triple helix, TH [80–83], as well as potentially useful siRNA [84, 85] and miRNA 
(microRNA) [82, 83, 86, 87]. The role of 21–23 mer double-stranded RNA (siRNA) 
in the silencing of genes is strongly similar to that of the TH DNA mechanism, 
which also involves 23 mer RNA [81]. Whether or not siRNA technology or miRNA 
knockdown will supplant the AS and TH oligodeoxynucleotide approaches remains 
in question at this time [83, 85, 87–90]. AS methodology is currently being stan-
dardized to be largely used in clinical trials [18, 89].
As to TH strategy, the oligonucleotides are targeted to double stranded DNA 
containing polypurine-polypyrimidine sequences that readily form triple helixes. 
The studies of triple helix strategy have shown that an RNA strand containing a 
23-nucleotide (nt) oligopurine sequence [80, 86, 87] may be capable of forming 
triple helix structures with an oligopurine-oligopyrimidine sequence of the IGF-I 
gene as well in cultured rat C6 glioma as in rat CNS-1 glioma, and in mouse PCC-4 
cells [86]. Although we cannot exclude other mechanisms, triple helix formation 
remains the most plausible possibility for the inhibition of IGF-I gene expression 
[86]. The arrest of IGF-I synthesis suggests that the RNA strand, which forms the 
triple helix, has inhibited gene transcription in glioma cells.
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3.2 Antisense and triple helix experimental studies
In our experimental studies, we have shown that in IGF-I “antisense” and “triple 
helix” transfected CNS-1 rat glioma cells, PCC-4 mouse embryonal carcinoma cells, 
and in primary human glioma cells, changes in immunogenic properties and apop-
tosis occur. The induction of IGF-I triple helix forming structure, similarly to IGF-I 
antisense approach, was followed by enhanced expression of MHC-I and B-7 [5, 18, 
90–95] and loss of in vivo tumorigenicity. An extensive lymphocytic CD8 positive 
infiltration 4–5 days after injection of AS transfected glioma, teratocarcinoma and 
hepatoma cells into the respective animal bearing tumors was demonstrated [11, 27, 96]. 
These properties were used for selection of human glioma cells that were used in 
IGF-I antisense/triple helix immunogene therapy [90] (Figure 2).
In this context, antigenic peptides presented by class I MHC molecules were 
necessary but, in general, not sufficient to stimulate T cell response. In the absence 
of B-7 molecule, MHC-peptide complexes could selectively inactivate T-cells [97]. 
(Although “triple helix” cells as compared to “antisense” cells show slightly higher 
expression of MHC-I and B7 there are no qualitative immunogenic and apoptotic 
differences between IGF-I “antisense” and “triple helix” approaches).
The absence of IGF-I synthesis in AS and TH transfected cells, could lead to a 
higher level of IGF-I receptor and hence to greater tyrosine kinase content [98]. 
There is a relation between the signal transduction pathway of tyrosine kinase and 
induction of B-7 molecules: enhancement in B-7 co-stimulation through a cAMP 
mechanism linked to tyrosine kinase of the CD 28 receptor has been previously 
reported [99]. Similar signaling through the tyrosine kinase activity of the IGF-I 
receptor shows that: tyrosine kinase activates IRS-1 (Insulin receptor substrate-1), 
Figure 1. 
Schema of technologies suppressing the expression of oncoproteins, including growth factors, GF: antibodies, 
antisense and triple helix. In antibodies technology, the GF expression is directly blocked by its ligand—antibody. 
In antisense technology, the end result is the inhibition of GF mRNA (sense RNA) activity by binding to the 
antisense RNA. In triple helix technology, the oligopurine third strand (23 bp) forms RNA-DNA triple helix 
with GF gene.
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and then IRS-1 activates PI3K (phosphatidylinositol 3 kinase) [100, 101]. This 
mechanism could be considered in the cytokine induced B7–1 expression demon-
strated in fetal human microglia in culture [102].
In the AS and TH transfected cells, IGF-I-R activated by its ligand plays a very 
protective role in programmed cell death, and that this protection is even more 
striking in vivo than in vitro [103]. Apoptosis could play a specific role in our strate-
gies; the phenotypic modifications due to apoptosis may explain the recognition of 
the transfected cells by the immune system like tumor-specific immunity mediated 
by CD8+ T [11, 98]. Apoptotic cells, in the context of MHC-I are recognized by den-
dritic cells activating lymphocytes T-CD8 [104, 105]. B-7 molecules can be included 
in this mechanism, because both MHC-I and B-7 molecules are necessary for T cell 
activation [16, 27, 36, 91, 106–108].
While working on mouse hepatoma cells transfected by the IGF-I triple helix 
approach, we have observed a decrease of cytokines such as Il-10, which is a strong 
immunosuppressor [109], and TNF-alpha, which can act as a factor stimulating 
tumor growth [110, 111]. Moreover, we have found increased levels of TAP 1 and 
2 in these cells. The relationship between the immune process, related to the MHC-I 
or HLA system [112, 113], and the apoptotic process is under study.
3.3 Anti-gene clinical therapy
In the clinical trial using anti-gene IGF-I therapy after subcutaneous vaccina-
tion, the subject developed peri-tumor necrosis; the tissue section bordering the 
necrotic tumor tissue showed infiltration of lymphocytes consisting of both CD4 
and CD8 T cells [114]. Other results concerning peripheral blood lymphocytes 
(PBL) of glioblastoma patients treated by IGF-I triple helix immuno-gene therapy 
show eminent changes in CD8 T cells, especially after second injection. There was 
also an increase in the percentage of CD8 with characteristics switching from CD8+ 
Figure 2. 
Schema of cancer immunogene therapy. The cells isolated from tumor biopsy are growing in tissue culture. The 
established cell line is transfected by vector of anti-gene type (antisense and triple helix IGF-I). The transfected 
cells, and originated apoptotic cells, are injected in proportion 50–50 (“vaccine”) in the cancer patients. The 
presence of MHC-I and B7 molecules present in transfected tumor cells induce an immune response mediated by 
T lymphocytes. Moreover, APC cells also participate as shown in the immunogene mechanism. The activated T 
lymphocytes destroy as well the vaccine (transfected tumor cells) as a tumor.
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CD11b+ to CD8+ CD11b− phenotype, an alteration that may reflect the enhanced 
activation of T cytotoxic cells in blood. Additionally, as far as prognosis of glioblas-
toma patients is concerned, the patients have survived between 18 and 24 months 
after the first diagnosis. Generally, patients with diagnosed glioblastoma multi-
forme, undergoing surgeries and radiotherapy, survive up to 14 months [22, 113].
Our phase I human cancer clinical trial based on the anti-gene, antisense 
approach, is in progress in the U.S.A, Thailand, Poland and China [107, 114, 115] 
and is in parallel with previously established approaches of glioblastoma treatment 
established by either Culver [116] or by Baserga [65]. Following the same approach, 
different antisense strategies to treat glioma tumors have been recently investigated 
[26, 31, 117, 118], especially in relation to glycogen metabolism [119] in glioma 
cells. (Malignant astrocytes present a high level of glycogen [55]). The therapy of 
gliomas using strategies of growth factors inhibition is in permanent progress. The 
inhibition of the IGF-I receptor using AS technology, and its signaling pathway has 
opened a door for experimental and clinical research in various tumors [9, 14, 15, 
42, 62, 120, 121].
4. Discussion
The use of anti-gene therapy was also effective in another AS approach, 
targeted toward the molecule, TGF-beta [79]. TGF-beta2 plays a role in tumor 
progression by regulating key mechanisms including proliferation, metastasis, 
and angiogenesis. The approach of AS TGF-beta using an AS oligodeoxynucleo-
tide—compound AP 12009, has given satisfactory results [122–124]. AP-12009 
treatment was well tolerated and tumor response has been observed [123]. Two 
patients experienced long-lasting complete tumor remission [124]. In another 
clinical AS TGF-beta study, a phase I clinical trial in grade IV astrocytoma 
(GBM) was performed using autologous tumor cells modified by a AS TGF-beta2 
vector [79]. There were indications of humoral and cellular immunity induced by 
the vaccine [57, 79].
As far as AS TGF-beta therapy of GBM is concerned, the treatment of patients 
with recurrent or refractory malignant (high-grade) glioma, WHO grade III or 
IV has been shown to produce results, similar to results obtained with anti IGF-I 
treatment. The role of peripheral blood mononuclear cells in the immune antitumor 
response, and prolonged survival in both anti TGF beta and anti IGF-I approaches 
was comparatively examined. In the case of TGF-beta, it is also important to men-
tion, that although the first successful clinical results were published in 2006–2008, 
the solid experimental data, using AS technology were obtained in 1994/95 [79], 
which means, that long periods of research on the mechanism of AS TGF-beta and 
AS IGF I are required before achieving significant clinical results, confirming the 
usefulness of gene therapy in cancer treatment [90, 122, 123, 125–130].
In AS IGF-I or AS TGF-beta approaches, immune antitumor response, mediated 
by TCD8 and APC cells, was signaled as a principal mechanism of AS technology 
inhibiting growth factors and their signaling pathway [12, 79]. These cells being 
involved in HS (heat shock) protein mechanism, the inhibition of HS was intro-
duced in clinical trials as a new direction for cancer therapy [131].
More recent clinical successful strategies of gliomas treatment, generally as a 
combination therapy using different types of inhibitors (i.e., imatinib, gefitinib) 
including antibodies (i.e., avastin) targeting growth factors and their receptors 
[132–136], are now focusing on anti-gene strategy, especially on antisense or triple 
helix technologies used alone or combined also with pharmacological treatment. As 
far as antisense and triple helix strategies are compared, the triple helix blockade of 
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growth factor has given better results in vitro and in vivo. But combining both strat-
egies, the final result is most effective—stopping the expression of the oncoproteins 
on translation (AS) and transcription (TH) levels, respectively.
5. Conclusion
Among the new strategies in the efforts to successfully treat GBM, the use of AS 
approach targeting IGF-I, TGF-beta or VEGF, their receptors and their downstream 
transduction signaling elements [9, 137], appears to offer a promising solution. The 
final result of the signal transduction pathway element inhibition is an immune 
response mediated in vivo by lymphocytes T CD8 and APC cells. Using cancer 
immunogene therapy of anti-gene anti IGF-I approach, the median survival of 
treated glioblastoma patients has reached 22–24 months. But the near future in 
treating this group of disorders belongs to a combination of treatment: classical 
surgery, radiotherapy with immunotherapy, pharmacologic therapy, growth factor 
inhibitors, and the use of the antisense/triple helix gene blockade approach target-
ing signal transduction pathway elements of cancer processes [16, 22, 23, 36, 66, 90, 
125, 138–147].
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Applications of Lipidic and 




The antisense technology that emerged with the discovery of RNA interference 
nearly 20 years ago has gained a significant place in gene therapy. siRNA, one of two 
important components of RNA interference, efficiently downregulates gene expres-
sion in human cells, so it has the potential to eradicate disease. siRNA delivery 
systems, which can be applied both systemically and locally in different diseases, 
have gained significant importance. Naked small RNAs can be delivered directly to 
cells, but because of their instability, exposure to enzyme degradation, and difficul-
ties in reaching/entering the target cell or tissue in blood stream, these initiatives 
are failing. For this reason, the method of delivery or encapsulation of siRNA is 
usually required. Various nanoparticles, nanocapsules, emulsions, micelle systems, 
metal ion nanoparticles, and nanoconjugates have been used for siRNA delivery. 
In these transport systems, lipidic and polymeric systems are very attractive due to 
their advantages such as being biodegradable and biocompatible, safety, being able 
to electrostatically bind to RNA, long-term stability, well-illuminated structure and 
features, simple and easy production, etc. Issues such as particle size, zeta potential, 
and stability of siRNA-loaded system should be taken into consideration in the 
development of siRNA delivery systems.
Keywords: lipidic nanoparticles, polymeric nanoparticles, nanocarrier, transfection, 
barriers, siRNA delivery
1. Introduction
Noncoding RNAs have many functions such as gene silencing, DNA imprinting, 
and demethylation. An increased number of noncoding RNAs have been discovered 
in gene regulation and RNA processing. Of these, small interfering ribonucleic 
acid (siRNA) and microRNAs (miRNAs) that can interfere with the translation 
of the target mRNA transcript are small ncRNAs that are the cleavage products 
of the dsRNA. MicroRNAs are a class of endogenous RNA that results in mRNA 
translation inhibition or degradation, which regulates cell differentiation, prolifera-
tion, and survival, while synthetic siRNA can initiate the silencing of target genes 
without interrupting natural mRNA pathways.
siRNA is a promising therapeutic solution preventing gene overexpression in 
various pathological conditions such as infectious or ocular disease, cancer, and 
genetic or metabolic disorders. These therapeutic methods are currently being a 
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phenomenon in cancer therapy because siRNA is used to suppress oncogenes and 
to remove mutations and to illuminate key molecules in the cellular pathways of 
cancer [1, 2].
It is also effective in personalized gene therapy for several diseases, due to its 
specificity, compatibility, and targeting ability. Following this strategic discovery, 
many synthetic siRNAs are designed with the desired sequences to explicitly inhibit 
any target gene expression [3, 4]. However, naked siRNA is unstable in the blood-
stream and cannot effectively pass the cell membranes as well as being immuno-
genic [5].
There is a need for delivery systems in order to overcome the obstacles and to 
increase their potentials in the process of transporting siRNAs to the desired desti-
nation with minimal adverse effects and safe transportation to target areas. These 
carriers are usually provided with viral (retrovirus, lentivirus, adenovirus, adeno-
associated virus (AAV), cough viruses, human foamy viruses, and baculovirus) and 
non-viral vectors. Viral vectors are effective tools for transfection vectors which are 
efficient delivery systems that utilize genetically modified viruses, offering advan-
tages such as continuous gene silencing and the ease of expression of a large number 
of RNA interference (RNAi) molecules from a transcript [6, 7].
However, safety concerns such as oncogenicity, immunogenicity, viral genome 
insertion into host chromosomes, and expensive production limit the widespread 
use of viral vectors [8].
Until now, only one virus-mediated transport system has been authorized for 
marketing. Glybera® (alipogene tiparvovec using an adeno-associated virus as vec-
tor) was the first drug approved by the European Commission in late 2012 to treat 
lipoprotein lipase deficiency (LPLD). However, in early 2018, the most expensive 
drug in the world has been withdrawn from the market for financial reasons [9]. 
Therefore, it is important to design non-viral transport vectors for the in vivo 
delivery of siRNAs.
These delivery systems are mostly intended to make the siRNA more efficient 
for interaction with angiogenesis, metastasis, chemoresistance of tumors, and 
proliferation of cancer cells. Although these systems show encouraging results 
for possible therapeutic success, many obstacles still exist to implement them in 
humans, practically.
Delivery systems should not be immunogenic and should not cause undesirable 
side effects. In normal cells, siRNAs should avoid off-target silencing of genes [10].
The carrier systems should not be defined as foreign particles by the immune 
system elements, i.e., interferons and cytokines, and should not be eliminated 
before they reach the target. These difficulties have been overcome by the precise 
design of the siRNA to the target or by chemical modification of the relevant siRNA 
molecule.
For this reason, the use of lipidic/polymeric nanoparticles is the most common 
choice to overcome the above difficulties. These developed nanoparticles can pro-
tect the siRNA from plasmatic nucleases and unwanted immune responses, thereby 
facilitating endocytosis, designed to resist renal clearance; providing low cytotoxic-
ity, stable serum stability, and high structural and functional reliability; delivering 
the unstable naked siRNA to targeted tumor sites; and reducing interactions with 
nontarget cells [7].
They can also be used for on-target delivery by adding target-specific ligands 
to their surface. The most preferred among these transport systems are lipid-based 
and polymer-based systems. Several technologies and nanoparticle modifications 
developed in recent years and new nanoparticle raw materials have accelerated 
the development of siRNA-loaded nanoparticles with the desired structural and 
functional properties.
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Taking advantage of these excellent properties of nanoparticles, various delivery 
systems for siRNA have recently used the clinical trial phase, and these methods are 
followed as a very effective and promising treatment for various disease.
As the latest development in this issues, the US Food and Drug Administration 
approved the Onpattro (patisiran) infusion on 10 August 2018 for the treatment of 
peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-medi-
ated amyloidosis (hATTR) in adult patients. It is also the first FDA approval of a new 
class of drugs called small interfering ribonucleic acid (siRNA) treatment. FDA antici-
pates that this is the beginning of a new and exciting generation of therapeutics [11].
Patisiran is covered in a lipid nanoparticle (LNP) that carries the drug to the 
liver, but this carrier molecule can trigger its own immune response. Therefore, 
steroid, acetaminophen, and antihistamines should be used to reduce the likelihood 
of immune reaction in patients before taking patisiran administered by intravenous 
(IV) infusion. Further research is underway to design a drug delivery system that 
can reach the target tissue without causing an immune response. Table 1 presents 
examples of clinical trials and current status of siRNAs prepared with lipidic and 
polymeric nanoparticle.
2. Physiological barriers for siRNA
The site of action of the SiRNA therapeutics is cytosol. The obstacles to siRNA 
administration vary depending on the targeted organs, disease, and routes of 
administration. In general, siRNA therapeutics are preferred as local or systemic 
injection. The local transport of siRNA has less obstruction compared to systemic 
administration. The first of the unique features of the local administration is the 
need to an easy formulation that requires easier production and application and 
secondly provides application of lower doses that limit intracellular (time-concen-
tration-dependent) immune responses [14].
Therefore, the application is limited to easily accessible tissues such as the skin, 
eye, or mucosa, but successful results have been achieved. However, for the local 
administration of siRNA, the nervous system, lung, digestive, vagina, and inner 
coronary walls were selected as target regions [15].
For example, intranasal inhalation of the siRNA against the respiratory syncytial 
virus was carried out with TransIT-TKO commercial transfection agent and was 
found significantly effective in reducing viral infection [16].
In a recent study by Wu and colleagues, they developed novel PEGylated 
lipoplex-entrapped alginate scaffold system for vaginal epithelium-targeted siRNAs 
for the treatment of HIV virus infections. They indicated in the study the potential 
of the biodegradable PLAS system for the sustained delivery of siRNA/oligonucle-
otides to vaginal epithelium [17].
The main advantage of the systemic method is rapid action and biodistribution 
but also a wide range of applications. In addition, intravenous or intraperitoneal (IP) 
injection therapy is successfully applied for many diseases in the clinic. However, it 
causes significant difficulties for siRNA in systemic transmission. The transition steps 
of the siRNA from the application site to the target action site are shown in Figure 1.
As described above, after intravenous injection (1), siRNA is distributed to 
organs through the blood stream (3) and also undergoes elimination [7].
The siRNA molecules have unwanted physicochemical properties due to their 
negative charge, large molecular weight, size, and instability. After systemic 
administration, the naked siRNA administered without vectors is rapidly degraded 
by serum endonucleases (4), excreted by the kidney (7), or taken up by the macro-
phages (APC cells) (5) of the mononuclear phagocyte system (MPS) [7, 18].
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The result is a short plasma half-life below <10 minutes, so it cannot have enough 
time to reach the target and/or perform its functions, and therefore the gene silenc-
ing is ineffective. These problems are partially addressed by chemical modifications 
of the RNA backbone and by the use of nano-sized carriers (2) [7, 60].
Nanoparticle studies showed that the nanoparticles below 6 nm were rapidly 
excreted by renal excretion and nanoparticles in the range of 150–300 nm were 
taken by the cells of the MPS in the liver and spleen. It is stated that nanoparticles 
between 30 and 150 nm can hold in the bone marrow, kidney, etc. In addition, it has 
been reported that red blood cells (RBCs) affect the transport and distribution of 
microparticles in human microvasculature (diameter <100). In fact, due to colli-
sions with RBCs, microparticles are pushed toward the artery wall where RBCs are 
virtually absent depending on the shape and size by a radial movement called the 
“waterfall effect.” This event is also called margination, and they have stated that 
the extravasation cannot occur unless vectors are exposed to margination [14].
In a study done by D’Apolito et al. [20], they found that 3-μm particles had bet-
ter marginalization than 1 μm. For this reason, it is seen that the size of the prepared 
particles could be very effective especially in in vivo experiments.
Figure 1. 
An illustration of a nanocarrier, barriers at systemic circulatory, mechanisms of uptake of siRNA from cell 
(modified from the 26th literature). In the following text, the numbers in the figure are mentioned.
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The vectors carrying siRNA enter the tissue interstitium following extravasa-
tion. After entering the tissue interstitium, siRNA is moved to the target cells across 
the interstitial space. Transport along the vessel walls can occur via diffusion, 
convection through the capillary pores, and transcytosis. The diffusion is directed 
by the concentration gradient.
One of the unique properties of tumor microvessels is leakage (6) from endothe-
lial discontinuity. The pore size of tumor microvessels ranges from 100 to 780 nm 
in diameter. In contrast, microvessels in most normal tissues have less leakage. For 
example; the tight junctions between endothelial cells are generally <2 nm, and the 
pore size in the capillary venules is <6 nm, the endothelium of the renal glomeruli 
is 40–60 nm, and the sinusoidal endothelium in the liver and spleen has large pore 
sizes of about 150 nm [19].
Leakage in tumor vessels increases siRNA/carrier extravasation, since the naked 
siRNA cannot enter the direct cell membrane due to its high molecular weight, large 
size, and negatively charged phosphate skeleton from the anionic cell membrane; 
the carrier systems are gaining importance here, again [21, 22].
There is an evidence that endocytosis (8) plays an important role, although not all 
of the entry mechanisms are well understood. The most common endocytosis used by 
nanocarriers is clathrin-mediated endocytosis through endocytic route receptor [23].
Rejman et al. [24] showed that the size and nature of the carrier vector affect 
the internalization mechanism. Nanoparticles of about 1 μm size are taken up via 
macropinocytosis, and ~120 nm size are taken up via clathrin-mediated endocyto-
sis, whereas nanoparticles ~90 nm are taken up via clathrin/caveolae-independent 
endocytosis and caveolin-mediated endocytosis [25, 26].
Besides surface properties and size of the nanoparticles, surface modifications 
of the nanoparticles are also important in siRNA transport. The most important 
of these surface modifications is the coating of nanoparticles with PEG. The 
PEGylation is performed to keep the particles in the systemic circulation longer, 
and the positive results were obtained from until today. However, in addition to 
this positive effect, it has been reported that the increased PEGylation from 1–2 to 
5% mol reduced the transfection efficiency by neutralizing the positive surface load 
required for siRNA involvement instead of increasing the transfection [27].
After reaching the target cell, the siRNA is subjected to endocytosis internal-
ization, a process involving encapsulated siRNA in endocytic vesicles fused with 
endosomes. Endocytotic vesicles are initially associated with early endosomes and 
then mature late endosomes before fusion with lysosomes in the cell. Lysosomes are 
then formed. After internalization into the cell, the siRNA should escape from the 
fragmentation in the endosomes and be released from the carrier to the cytosol in 
order to be loaded to RNA-induced silencing complex (RISC) [28].
Sardo et al. found that endosomal escape increased with another modification 
with pH-sensitive polymers. In this study, they prepared a siRNA delivery system 
based on inulin (Inu), a plenty and natural polysaccharide. Inu was functionalized 
via the conjugation with diethylenetriamine (DETA) residues to form the complex 
Inu-DETA. The results of the study showed that while homogenous diffusion 
of siRNA was performed in JHH6 cytoplasm via micropinocytosis and clathrin-
mediated endocytosis, it was found that it did not allow caveola-mediated passage 
and no siRNA activity [29].
3. Types of nanoparticulate delivery systems for siRNA delivery
This section focuses on the biodegradable non-viral lipids and polymeric 
nanosystems used in the transport of synthetic siRNA. These nanoparticles used as 
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drug delivery vehicles are carriers having a particle size of <100 nm. They are com-
posed of different biodegradable materials, such as natural or synthetic polymers, 
lipids, or metal.
The main advantages of nanoparticles used as drug carriers are achieving appro-
priate particle size, using of physiological lipids (e.g., triglycerides) and organic 
polymers (e.g., chitosan) to reduce immunogenicity, stimulating interferon-γ pro-
duction and natural killer (NK) cells, activating antitumor immunity to increase the 
effectiveness of treatment, prolongation of blood circulation in blood, and feasibility 
of variable routes of administration; they can be viewed and monitored by marking.
However, they have some disadvantages; for example, the substances used dur-
ing the formulation and the preparation methods may cause the increase of toxicity, 
sometimes failing to carry the siRNA into the cell or insufficient accumulation at 
the target site, and problems in the stability of lipidic structures like liposomes. 
These limitations, however, can be overcome by selecting the appropriate lipid or 
polymers. The advantages thus outweigh the disadvantages [30].
3.1 Lipid-based nanoparticle delivery systems
Lipid-based siRNA delivery systems include liposomes, micelles, microemul-
sions, ionizable lipids and lipid nanoparticles, and solid lipid nanoparticles.
3.1.1 Liposomes
Liposomes are spherical vesicles consisting of an aqueous core together with a 
bilayer phospholipid structure which contain natural body components (e.g., lipids, 
sterols) and are biologically compatible and biodegradable. Furthermore, lipo-
somes are popular siRNA carriers due to their relative simplicity and well-known 
pharmaceutical properties. The amphipathic nature of liposomes allows the use of a 
wide range of hydrophilic and hydrophobic drugs. The hydrophilic molecules show 
a greater affinity between the hydrophilic head groups of the phospholipid bilayer 
and the aqueous core of the liposomes, while the hydrophobic molecules intercalate 
between the fatty acyl chains of the two lipid layers [31].
As analogues of biological membranes, liposomes are fused with the plasma 
membrane and are processed by endocytosis, and the genetic material is released 
into the cytoplasm. Cationic liposomes form complexes with negatively charged 
anionic siRNAs and polycations, and the complex is called as a “lipoplex.”
However, due to their positive charge, cationic liposomes can lead to dose-
dependent cytotoxicity and inflammatory response, and the complexes can interact 
nonspecifically with negatively charged serum proteins. In order to solve these 
problems, successful tests were taken in preclinical studies of EphA2-targeted 
siRNA therapeutic using neutral lipids such as 1,2-dioleoyl-sn-glycero-3-phosphati-
dylcholine (DOPC), which proved to effectively reduce cellular toxicity [31].
Several strategies have been implemented to overcome the disadvantages of exist-
ing lipid-based systems. Modification of the lipid structure or formulation methods 
can reduce toxicity and improve transfection. The inclusion of fusogenic lipids, such 
as dioleoylphosphatidylethanolamine (DOPE), or the use of a cationic lipid consist-
ing of biodegradable ester bonds such as DOTAP may retain toxic effects at a relatively 
short or moderate level and also may increase the endosomal release of siRNA [32].
3.1.2 Solid lipid nanoparticles
SLNs having a size range of 50–1000 nm were composed from various lipids 
which are solid form at body or room temperature and can be stabilized with 
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surfactant or surfactant mixture. SLNs consist of a lipid core surrounded by a 
surfactant layer in an aqueous dispersion [33].
While being among the most effective carriers for both hydrophilic and hydro-
phobic drugs, such as liposomes, the solid, lipophilic nucleus of SLNs may have 
difficulty carrying RNA molecules that are hydrophilic and polyanionic. Therefore, 
it can be used successfully for gene delivery by addition of cationic lipids to SLNs 
which provide a positive surface potential [34].
SLNs can be easily prepared by various methods such as hot or cold homogeniza-
tion, sonication, solvent evaporation, etc., and also they have high physical stability 
and low cytotoxicity [35].
Studies with siRNAs that have been adsorbed or encapsulated into SLNs have 
also shown positive results in the literature. For example, Şenel et al. [36] pointed 
out that Bcl-2-targeted siRNAs encapsulated into SLNs prepared by sonication 
method showed an activity to be able to compete with Lipofectamine in the liposo-
mal form commercially used.
3.1.3 Nanostructured lipid carriers (NLCs)
Nanostructured lipid carriers (NLCs) are new second-generation lipid carriers 
that combine the advantages of different nanocarriers. These are solid lipid-core-
modified SLNs in which the lipid phase may comprise solid or liquid forms at 
ambient temperature [37].
Compared to SLNs, NLCs have greater loading capacity and less water in the 
dispersion, making them more stable for storage. There was no difference in 
biotoxicity. Studies have shown that NLCs can be used as a new delivery tool for the 
genetic treatment of disease. Taratula et al. prepared a multifunctional NLC system 
containing two siRNAs against cellular resistance to doxorubicin or paclitaxel 
targeting lung cancer cells. It has been found that the system successfully increases 
the antitumor activity of the anticancer drug [38, 39].
NLCs can also be modified to achieve targeting and sustained release. For 
example, by manipulating the degradation times of NLCs, it has made possible to 
obtain long-acting siRNAs. This design raised the continuous release of siRNAs to 
9 days (with a A-tailored nanostructure carrier design delivering survivin-siRNA); 
this also facilitates clinical practice of siRNA treatment [40].
3.1.4 Ionizable lipids and lipid nanoparticles (LNPs)
Recently, new lipid types have been proposed to the delivery of RNA interfer-
ence molecules. Advanced LNP siRNA systems are lipid-based particles with 
diameters <100 nm. These may consist of a mixture of an ionizable amino lipid 
(e.g., heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate, DLin-
MC3-DMA), a phosphatidylcholine, cholesterol, and a coat lipid (polyethylene 
glycol-dimiris glycerol) in a 50:10:38.5:1.5 molar ratio [41].
These lipids developed for the encapsulation of negatively charged genetic 
materials exhibit pH-dependent charge change. These lipids are positive at acidic 
pH and are neutral at physiological pH. Thus, under acidic conditions, nucleic acids 
are encapsulated in the nanoparticle and have a minimum positive charge density in 
the bloodstream. LNP siRNA systems are produced by rapidly mixing the lipids in 
ethanol with the siRNA in aqueous buffer (pH 4.0) followed by removal of ethanol 
via dialysis against PBS buffer after the pH is raised to 7.4 [42].
The genetic material carrier formulations generated by ionizable cationic 
lipids have been shown to be of significant success in in vivo activity after the 
initial administration in hepatocytes. Other tissues used for gene silencing include 
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macrophages, osteoclasts, and osteoblasts in the “hard” bone and distal tumor 
cells [43, 44].
Other siRNA administration methods have used lipid-like molecules called 
“lipidoids” for the delivery of siRNA. Lipidoid delivery systems are similar to 
ionizable cationic LNP systems due to the use of lipid-like molecules, cholesterol, 
and PEG-lipid. The most important difference of LNPs using lipidoid is that the 
lipidoid molecules have an extra positive charge because they have a large number 
of protonizable amine bound to various acyl chains. Similar to studies with cationic 
lipids, lipidoid systems developed by screening programs have been described in the 
literature [45].
Ball et al. developed a potent and nontoxic lipidoid nanoparticle (LNP) for 
intestinal epithelial cells. In the initial studies, it was reported that GAPDH siRNA-
loaded LNPs for Caco-2 cells mediated strong, dose-dependent, and resistant gene 
silencing with a single 10-nM dose for 1 week [46].
3.2 Polymer-based delivery
Polymers of natural and synthetic origin have been used for various biomedical 
applications including drug targeting, imaging, gene therapy, prostheses, tissue 
engineering, etc. Because of their reproducible properties in terms of molecular 
weight, degradation, and mechanical properties, synthetic polymers are attractive 
for therapeutic applications. The most commonly used polymers include polyethyl-
enimine (PEI), PLGA, PEG, PLL, PLA, etc. However, the synthetic polymers have 
the disadvantage biologically, such as they can turn into undesirable side effects 
or fail to achieve the desired bioactivity and biocompatibility. On the other hand, 
natural polymers are abundant and are similar to components of those found in 
biological extracellular matrices. Thus, the natural polymers have high bioactivity 
and biocompatibility. Natural polymers include polysaccharides, proteins, and 
polyesters [47].
3.2.1 Synthetic polymers
Linear or branched cationic polymers are effective transfection agents for 
genetic material. The structural and chemical properties of these polymers are well 
known. This makes them advantageous for siRNA transport. The positively charged 
polymers form “polyplexes” with negatively charged nucleic acid phosphates 
through electrostatic interactions [48].
The polymer size, the molecular weight, the degree of polymer branching, and 
the charge density, as well as the composition of the formulation medium and the 
positive and negative charges ratio between of the polymer and the oligonucle-
otides, affect the transfection efficiency and biological activity of the polyplexes.
Synthetic-based cationic polymers such as PLL, PLA, and PEI are the most 
studied polymers for in vitro and in vivo transport of siRNA. The size of the com-
plexes is one of the most important factors affecting cellular uptake. Due to their 
small size, the cationic polymers generally complex with the genetic material more 
effectively than lipids. In addition, owing to being mostly synthetic, they have some 
special feature such as customized size, branching, and composition, and these 
features can be easily changed [49].
These polymers used for siRNA delivery is well-studied, biodegradable, biocom-
patible, and capable of exhibiting nucleic acid sustained release in pharmaceutical 
applications for decades.
PEI was used to create cationic charges on the surface of PLGA particles, which 
allowed the complexation of nucleic acids on the surface of the particles [50].
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effectively than lipids. In addition, owing to being mostly synthetic, they have some 
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In a study done by Patil and Panyam [51], siRNA encapsulation studies were 
performed in PLGA nanoparticles. These nanoparticles were prepared by the sol-
vent evaporation method. In this method, a cationic polymer, PEI, was added to the 
PLGA matrix, and ultimately it has been reported that nanoparticles can penetrate 
into the cell at twice the rate.
Furthermore, cationic polymers with high charge densities have “proton sponge” 
properties that stimulate escape from endosomes and protect genetic materials 
from degradation. For example, PEI, by pulling and sustaining a significant amount 
of protons, induces osmotic swelling and rupture of endosomes, causing the genetic 
material to be released from the nanoparticles in the cytoplasm and thus preventing 
the transport to lysosomes and degradation of genetic material [52].
In another study, the hydrogel scaffold based on polyamidoamine (PAMAM) 
dendrimer cross-linked with dextran aldehyde was prepared to improve the stability 
of the nanoparticle. These nanoparticle systems were found to be effective for gene 
silencing [53].
3.2.2 Natural polymers
Many polysaccharides in natural Polymer structure are used for siRNA. 
Polysaccharides are generally biocompatible polymers. The main advantage is the 
presence of different functional groups (i.e., carboxyl, hydroxyl, amine) which 
enable functionalization to obtain structural heterogeneity and copolymers [54].
The most commonly used polysaccharides for siRNA administration include 
chitosan, which contains both biodegradable, biocompatible, low-cost, low cytotox-
icity hydroxyl and amines. The presence of primary amino groups (pKa ≈ 6) makes 
the chitosan a polycation that promotes the association with nucleic acids and also 
the formation of polyplex [55].
In order to increase the solubility of chitosan, various modifications have been 
done and water-soluble chitololigosaccharides have been obtained. These chitololi-
gosaccharides were used for delivery of the siRNA [35, 56].
Collagen is another biologically compatible and safe natural polymer and is a 
suitable carrier for drug delivery. In a study performed by Peng et al., localized and 
sustained release of siRNA-loaded collagen formulations were prepared for use 
in vivo gastric cancer, and positive results were obtained [57].
3.3 Lipid-polymer hybrid nanoparticles
Lipid-polymer hybrid nanoparticles (LPNs) were developed to eliminate the disad-
vantages of polymeric and lipid-based nanoparticles. The precious properties of LPNs 
containing polymer cores and lipid shells carry the complementary properties of both 
materials. In a study on the administration of LPNs in cancer treatment, the lipid/rPAA-
Chol polymer hybrid nanoparticles were modified with PEG and T7 peptide; tumor has 
been shown to be largely inhibited without activating the immune system [58].
In another study, LPNs were used for the antitumoral effect in the pancreatic 
tumor model in combination with hypoxia-inducible factor 1α (HIF1alpha)-
targeted siRNA and gemitabicin. This prepared LPN complex showed an excellent 
ability to inhibit tumor metastasis in an orthotopic tumor model [59].
4. Conclusion
In recent years, siRNA has been widely used as a promising therapeutic phenom-
enon to many pathological conditions. Progress has been made in researching target 
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genes and in the development of delivery systems for siRNA. However, challenges 
remain for successful clinical application of RNAi-based therapeutics. Safety 
concerns are the main reason for the withdrawal of clinical trials of some RNAi 
therapies.
Since its discovery, siRNA therapeutics have been actively used because of their 
high specificity, easy modifications, and unlimited therapeutic targets. However, 
the instability in the bloodstream and the problems with the accumulation in 
the target region necessitated the application of these therapeutics in a transport 
system.
The lipidic and polymeric nanoparticle systems described in this chapter are one 
step ahead the systems than other nanoparticle systems and have been proven to be 
of importance in these delivery processes in recent years. New modified systems are 
being developed to ensure safe and targeted distribution of siRNA. According to the 
results obtained from studies, new formulations are expected to reach clinical trials 
very soon such as patisiran.
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Therapeutic Implication of 
miRNA in Human Disease
Andrew Walayat, Meizi Yang and DaLiao Xiao
Abstract
MicroRNAs (miRNAs) are a class of short non-coding RNA molecules 
that are involved in development and diseases. Early studies are focusing on 
the miRNA profile as a biomarker in disease. As discovery of human miRNAs 
increased in the setting of disease, the research focus was gradually shifted 
towards miRNA therapeutic strategy for diagnostic and treatment of disease. 
Increasing evidences suggest that miRNAs are the next important class of anti-
sense therapeutic molecules, which have significant advantage over antisense 
such as siRNAs because miRNAs are naturally occurring endogenous molecules. 
Aberrant alteration of the endogenous miRNAs has been linked to the develop-
ment of certain diseases. Correcting these altered miRNAs by their mimics or 
inhibitors has been developed as potential therapeutic approaches. Some of 
the miRNA-based therapeutics are processed in preclinical and clinical trial 
for treatment hepatitis C, liver cancer, and other diseases. Currently, the major 
focus in the development of miRNA-based therapeutics is how to increase the 
miRNA stability and optimize delivery systems for specific disease with mini-
mal off-target effect. This chapter will first overview the miRNA biogenesis, 
patho- and physiologic function, and regulation of miRNA molecules. Then, we 
discuss the miRNA-based potential therapeutic approaches and implication in 
disease.
Keywords: miRNA, function, disease biomarker, therapeutics
1. Introduction
MicroRNAs (miRNAs) belong to a family of small non-protein-coding RNAs 
with a single strand of 18–25 nucleotides that regulate multiple target genes at the 
post-transcriptional level. Functionally, miRNAs bind to 6–8 bp seed sequences 
in the 3’ Untranslated Region (3’ UTR) of targets mRNA and induce mRNA 
degradation or repression of protein translation. The term “non-coding RNA” is 
commonly defined a group of RNA that does not encode a protein. With a rapid 
advancement of molecular technology, many new classes of noncoding RNA have 
been founded. Among those noncoding RNAs, miRNA has attracted consider-
able attention because its endogenous origin and its role in the regulation of gene 
makes it more likely target for drug discovery and potential biomarker for specific 
disease.
miRNA research is a relatively new topic, with research ranging back for 
the past 25 years; it has its beginnings in its detection in C. elegans in 1993 and 
its detection in humans in 2000 [1]. Their use in transgenic mice in 2005 to 
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1. Introduction
MicroRNAs (miRNAs) belong to a family of small non-protein-coding RNAs 
with a single strand of 18–25 nucleotides that regulate multiple target genes at the 
post-transcriptional level. Functionally, miRNAs bind to 6–8 bp seed sequences 
in the 3’ Untranslated Region (3’ UTR) of targets mRNA and induce mRNA 
degradation or repression of protein translation. The term “non-coding RNA” is 
commonly defined a group of RNA that does not encode a protein. With a rapid 
advancement of molecular technology, many new classes of noncoding RNA have 
been founded. Among those noncoding RNAs, miRNA has attracted consider-
able attention because its endogenous origin and its role in the regulation of gene 
makes it more likely target for drug discovery and potential biomarker for specific 
disease.
miRNA research is a relatively new topic, with research ranging back for 
the past 25 years; it has its beginnings in its detection in C. elegans in 1993 and 
its detection in humans in 2000 [1]. Their use in transgenic mice in 2005 to 
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eventually efficacy studies of modified inhibitors of miRNAs in primates in 
2010 illustrates the explosion of research surrounding miRNAs in just 5 years. 
There are now over 2000 miRNAs that have been discovered in humans and it 
is believed that they collectively regulate one third of the genes in the genome 
[2]. miRNAs have been linked to many human diseases and are being pursued as 
clinical diagnostics and as therapeutic targets, showing promise in many fields, 
ranging from cancer therapy to cardiac disease, to even suggestions as a poten-
tial biomarker for numerous diseases and treatment responses. This chapter 
will briefly discuss the miRNAs biogenesis, their function, regulation, and 
implication in disease, then discuss the miRNA-based therapeutic strategies, 
their therapeutic implication in diseases, and some of the current clinical trials 
involving miRNAs.
2. miRNA biochemical synthesis
miRNAs are encoded in the genomes (inter or intragenic) and are transcribed 
from genes located in nuclear DNA; however, such genes are not eventually trans-
lated into protein [3]. These transcribed genes are typically longer than the eventual 
gene product miRNA and undergo much post-transcriptional modification between 
initial transcription and the functional miRNA end-product. After initial transcrip-
tion of the DNA sequence, the miRNA sequence contains a reverse-complement 
base pair segment that forms a double stranded RNA hairpin loop. The entire DNA 
transcript, including the double stranded RNA loop, constitute the primary miRNA 
structure (called pri-miRNA). Pri-miRNA is usually several kilobases long and has 
local stem loop structures. The primary transcripts undergo further processing in 
the nucleus. The ribonucleases Drosha and DiGeorge syndrome critical region gene 
8 (DGCR8) complex are mainly involved in the pri-miRNA processing, which is 
cleaved at the stem of the hairpin structure and generates a hairpin intermediate of 
about 70–100 nucleotides, called pre-miRNA.
The pre-miRNA is then transported out of the nucleus to the cytoplasm for 
further processing to become mature miRNA. There are nuclear pore complexes in 
the nuclear membrane where the pre-miRNA can be transported out of the nucleus 
by means of the RanGTP-dependent nuclear transport receptor exportin 5. In the 
cytoplasm, the pre-miRNA is processed by another ribonuclease, Dicer to create 
a mature miRNA. The mature miRNA is a double-stranded miRNA of variable 
length (~18–25 nucleotides). After the generation of mature miRNA duplex by 
Dicer, the miRNA duplex is incorporated into an Ago family protein complex, 
which generates an effector complex. Then one strand of the miRNA is degraded, 
whereas the other strand remains bound to Ago as mature miRNA (guide strand). 
After strand separation, the guide strand or mature miRNA is incorporated into an 
RNA-induced silencing complex (RISC). After loading, the miRNA promotes the 
RISC to its target mRNA and induces mRNA degradation or translational repres-
sion (see Figure 1).
3. Functions of miRNAs
The general function of miRNA is oriented towards gene silencing [3, 4]. miRNAs 
specifically recognize mRNA and downregulate gene expression by one of the two post-
transcriptional mechanisms: (1) translational repression and (2) mRNA cleavage. The 
determinant of the regulatory mechanism process is mainly dependent on the degree of 
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miRNA–mRNA complementarity. If there is a high degree of complementarity between 
the miRNA and mRNA, it will enable the Ago-catalyzed degradation of target mRNA 
sequences through the mRNA cleavage mechanism process. However, if there is a low 
degree of degree of miRNA–mRNA complementarity, a central mismatch will omit 
degradation and promotes the translational repression mechanism.
The exact mechanism for translational repression by miRNA is still not fully 
understood. However, recent studies suggest that, as the miRNA is incorporated 
into a RISC [3, 4], the associated protein silencing complex can either repress 
translational mechanisms typically associated with ribosomal translation, or induce 
deadenylation of the 3′ poly-A protective posttranscriptional mRNA modification, 
thought to be involved in repression via the mRNA 5′ terminal cap. The mechanism 
for mRNA degradation is mainly involved in endonucleolytic cleavage, which is 
facilitated by Argonaute cleavage proteins. It has been shown that when miRNAs 
have a high degree of sequence complementarity, then target mRNA degradation 
processes are facilitated through Ago protein slicer activity [2, 3]. miRNA typically 
binds to the 3′ untranslated region (3’ UTR) in mRNA that follows the translation 
termination codon. The mechanism of miRNA translation inhibition requires par-
tial sequence match, whereas the mechanism of miRNA-mediated mRNA degrada-
tion requires a near-perfect complementary match (see Figure 1).
Figure 1. 
miRNA biogenesis, function, and strategies for miRNA-based therapies. miRNA is transcribed from miRNA gene 
via RNA polymerase II as pri-miRNA and cleaved by Drosha complex in the nucleus. The resulting precursor 
miRNA (pre-miRNA) is exported to the cytoplasm via exportin 5 complex. In the cytoplasm, Dicer complex 
cleaves pre-miRNA to form mature miRNA duplex. The strand is separated and the functional strand is loaded 
into the RISC complex. The function of miRNA is depending on the complementarity of the seed region of mature 
miRNA to the 3’UTR of the target mRNA gene, either undergoing mRNA cleavage or translational repression. 
Strategies for miRNA-based therapies: improving miRNA in disease can be achieved by the following approaches: 
(a) Small molecule miRNA inhibitors can regulate miRNA expression at the transcriptional level. (b) Antisense 
oligonucleotides can bind to the target miRNA and induce degradation effect. (c) The miR-mask oligonucleotides 
are synthetic oligonucleotides complementary to the 3’ UTR target mRNA that compete with endogenous miRNA 
for its target. (d) The miRNA sponges are oligonucleotide constructs with multiple complementary miRNA 
binding sites to the target miRNA. (e) The miRNA mimics are synthetic miRNAs which can restored the 
downregulated miRNA expression. (f) The AAV miRNA vectors are a group of adenovirus-associated vectors that 
have been inserted genes coding for miRNAs and they are used for restoring downregulated miRNA expression.
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4. Regulation of miRNAs
There are multiple levels of regulation of miRNA expression [5]. Those regula-
tory mechanisms mainly include transcriptional and post-transcriptional mecha-
nisms, as well as effects of endogenous and exogenous compounds on the miRNA 
expression.
4.1 Transcriptional regulation
Similar to protein-coding genes, miRNA genes can also be regulated through 
transcription level. The promoters of miRNA genes are controlled by transcrip-
tion factors (TFs). Many TFs regulate miRNA gene expression through positive 
or negative mechanism in a tissue-specific or developmental-specific manner. For 
instance, MYC inhibits expression of tumor suppressor miRNA-15a, which pro-
mote MYC-mediated tumorigenesis [6]. On the other hands, MYC can stimulate 
expression of miR-9 in neuroblastoma cells, resulting in regulation of E-cadherin 
and cancer metastasis [7]. It has shown that p53 enhances the expression of miR-
34 and miR-107 families, which induce cell cycle arrest and apoptosis [8]. In addi-
tion to regulate by TFs, the expression of miRNA can be regulated by methylation 
of the promoter. Most of the miRNA promoter region has certain CpG islands. 
For example, promoter hypermethylation of genes such as miR-132, miR-34b/c, 
miR-218-1/2, and miR33b have been associated with or denote a poor prognosis 
of various cancers [9, 10]. In addition, the changes in DNMT1 and DNMT3b DNA 
methyltransferases lead to alter the miRNAs (miR-148a, miR-34b/c, miR-9 and 
let-7) gene promoter methylation status, resulting in regulation of their gene 
transcription levels [11]. Furthermore, it has reported that miR-210 is highly 
induced by hypoxia in various cancer cell lines [12], whose expression is not only 
regulated by the transcription factors hypoxia-inducible factor-1 (HIF-1), but 
also regulated by DNA demethylation mechanism in neural progenitor cells under 
both normoxia and hypoxia [12].
4.2 Post-transcriptional regulation
Post-transcriptional regulation has emerged as another important mechanism 
in define the miRNA expression pattern, which mainly involves the process-
ing of the miRNA after transcription. On the post-transcriptional level, the 
expression of microRNAs can be downregulated due to changes in the activity 
of key miRNA biogenesis enzymes, such as Dicer and Drosha. Dicer and Drosha 
generally operate in complexes with double-stranded RBP partner (such as TRBP 
and DGCR8). Both the levels and activity of all of these proteins are subject to 
regulate the accumulation of miRNAs. For example, a decrease in TRBP leads 
to Dicer destabilization and pre-miRNA processing defects [9, 13]. In addition, 
recent studies have also demonstrated that post-translational changes in the Ago 
family of protein could cause significant changes in miRNA expression profiles 
[9, 13].
Another important contributor to miRNA levels is the stability of miRNA, which 
depends on the stage of development or cell type involved. It has been discovered 
that some proteins can bind miRNAs and affect their half-life [9, 14]. For example, 
HuR, a member of the ElaV family of RNA-binding proteins has been shown to sup-
press the inhibitory effect of miRNAs [14]. On the other hands, it has been shown 
that overexpression of Argonaute proteins can decelerate miRNA degradation and 
increase miRNA stability [9, 15].
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4.3 Endogenous and xenobiotics regulation
The presence of physiological and pathological conditions have been demon-
strated to regulate miRNA expression. Previous studies have shown that steroid 
hormones can regulate miRNA expression [16, 17]. Treatment with estradiol or 
tamoxifen has been shown significant changes of different miRNAs expressions 
in patients with breast cancer and in various breast cancer cell lines [16, 17]. In 
addition, corticosterone also can directly regulate miRNAs expressions [18]. Rats 
given chronic corticosterone showed significant behavioral disorder associated with 
differential regulation of 26 miRNAs in the rat prefrontal cortex [18]. Off interest-
ing, those altered miRNAs that were modulated by corticosterone have binding sites 
for glucocorticoid receptor element (GRE), which were either simple, composite or 
tethering type within the 1-kb upstream of the transcription start site. These find-
ing suggests that binding with GRE is a common regulatory mechanism of miRNA 
regulation by corticosterone.
In addition to endogenous regulation, xenobiotics can affect miRNA expres-
sion. Increasing evidence from in vivo and in vitro experiments have showed that 
specific carcinogen could differentially alter certain miRNAs expressions [19]. 
Chronic treatment with benzene in mice had showed significant changes in certain 
miRNAs expressions [20]. Aflatoxin B1, a genotoxic carcinogen, has been reported 
that it can affect the profile of miRNA expression in different animal models 
and cell lines [21, 22]. Therefore, miRNAs can serve as biomarkers of toxicity of 
carcinogen agents and may be useful for early cancer diagnosis. Furthermore, 
harmful life styles such as alcohol consumption and tobacco smoking can impair 
miRNAs expressions [23, 24]. Cigarette smoking can change microRNA profile in 
many human organs and induces the change of plasma miRNA expression profiles 
in healthy subjects [25, 26]. It has been reported that 24 miRNAs were up-regulated 
and 11 miRNAs were down-regulated in plasma from smokers [26]. In addition, 
the serum miRNA profiles in nonsmokers, smokers, and lung-cancer patients were 
significantly different [24].
5. Clinical implication of miRNAs
MicroRNAs are becoming well recognized as their expression levels are changed 
in different diseases such as cancer, liver disease, coronary heart ischemic disease, 
and metabolic disease. Some miRNAs are increased, whereas others are decreased 
in a specific disease, creating a signature miRNA pattern that could serve as a 
biomarker or molecular therapeutic target for a particular disease. For example, 
in the case of cancers, the overexpressed miRNAs are commonly considered as 
oncogenes. On the other hand, some of the miRNAs are expressed very low levels 
in certain cancerous cells and usually prevent tumor development. These groups 
of miRNAs are called as tumor suppressor miRNAs. Let-7 is one of these tumor 
suppressor miRNAs [27]. The miRNAs have remarkable potential in the clini-
cal arena because they can be detected in the blood, serum, tissues (fresh and 
formalin-fixed paraffin- embedded), and fine-needle aspirate specimens. Recently, 
novel in situ hybridization techniques have been described to detect miRNAs in 
tissues, which enables direct miRNA and histomorphologic correlation [28]. The 
clinical implications of miRNA use in medicine are present in both diagnostic and 
therapeutic approaches. In miRNA-based diagnostics, miRNA expression profiling 
has been evaluated as a reliable diagnostic biomarker for differentiating between 
normal and tumor specimens [29, 30]. Ali et al. have reported that the expression of 
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let-7c, let-7f, and miR-200c were significantly decreased in pancreas cancer patients 
whereas miR-486-5p and miR-451 were significantly increased in those patients 
compared with the normal people, which suggests that these miRNAs can be served 
as signature biomarkers for pancreas cancer [30]. Additionally, circulating miRNAs 
can be employed in diagnostic strategies to detect for alterations associated with 
either disorder affliction or treatment response. In the miRNA-based therapeutics, 
the miRNA expression is altered in different diseases and it is now feasible to cor-
rect miRNA expression by injecting miRNAs similar to the use of antisense mRNAs 
and RNAi. For example, because the activation of onco-miRNA genes could cause 
development of cancer, artificial antisense miRNAs could be synthesized and used 
to inhibit their targeted miRNAs to treat or prevent the cancer.
6. miRNA therapeutics: strategies
There are at least two main strategies to target miRNA expression for prevention 
and potential treatment of disease. The first strategies is the use of oligonucleotides 
or virus-based constructs to either directly block the expression of a disease-
associated signature miRNA or to directly substitute for the loss of expression of the 
miRNA. The second strategies is indirectly employing drugs to alter miRNA expres-
sion by targeting their transcription and processing. Blocking miRNA expression 
can be achieved by the use of antisense oligonucleotides, miRNA sponges, miRNA-
mask and small RNA inhibitors. Restoring downregulated miRNA expression 
can be achieved by using synthetic miRNA (miRNA mimic) or by inserting genes 
coding for miRNA into viral constructs. At the transcriptional level, small-molecule 
miRNA inhibitors can be employed to prevent the transitions from DNA transcript 
to pri-miRNA and pre-miRNA. Antisense oligonucleotides can be employed at 
the mature miRNA level to induce degradation or revert the mature miRNA into 
a duplex form with the antisense oligonucleotide. At the functional level, miRNA 
masks can bind complementarily to the 3’ UTR region of target mRNA, compet-
ing for bindings with endogenous miRNAs for the specific target. miRNA sponges 
can be employed to bind target miRNA via complementary mRNA binding sites, 
decreasing expression levels of target miRNAs (see Figure 1).
6.1 Antisense oligonucleotides (AMO)
Antisense inhibition of miRNA function has been an important tool for uncov-
ering miRNA biology and potential therapeutics [31]. Synthetic oligonucleotides 
can be used therapeutically when miRNA dysregulation contributes to pathophysi-
ology. These oligonucleotides are known as anti-miRNA oligonucleotides (miRNA 
inhibitors). To improve functional potency and to provide protection against 
nuclease degradation, they are often chemically modified [31, 32]. An ideal modifi-
cation should increase binding affinity to the extent that specificity is compromised 
and should be non-toxic. There are four most common oligonucleotide modifica-
tions: (1) 2’-O-methyl groups, (2) phosphorothioate, (3) locked nucleic acid (LNA) 
anti-miRNA constructs, and (4) N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-
phenylamine (ZEN).
2’-O-methyl groups are the first generation of AMOs. 2’-O-methyl modi-
fications can help AMOs to increase nuclease resistance and facilitate binding 
affinities to miRNA by the addition of an O-methyl group to the 2’-C atom. 
Phosphorothioate, compared to the 2’-O-methyl analogs, bonds at both the 3′ 
and 5′ ends to prevent nuclease degradation, and a 3′ cholesterol tail to help with 
cell uptake [33]. These modifications help the AMO to penetrate into tissues and 
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organs and significantly increase their half-lives in the target tissues. However, 
the first generation of AMOs have relative low potencies to be effective in animal 
model [34]. Second generation AMOs contain other modifications at the 2′ sugar 
position. Locked nucleic acid (LNA) modifications which are bicyclic nucleic acids 
that tether the 2’O to the 4’C via methylene bridge locking sugar into a 3′ endo 
conformation have been shown to have the best binding affinity and nuclease 
resistance. This group of AMO has been widely used in experimental animals 
[35–37]. Currently, the most advanced miRNA targeting therapy is SPC3649 
(miravirsen), which is a locked nucleic acid-modified oligonucleotide antagoniz-
ing miR-122. This is the first miRNA-targeted drug to enter human clinical trials 
[38]. Despite LNA modifications have higher binding affinity, these modifications 
can lead to off-target effects which may cause toxicity in vivo [35]. Recently, a 
new compound called N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine 
(ZEN), when is included at each end of the AMO, led to increased binding affinity 
to the miRNA and inhibited exonuclease degradation. Recent studies have shown 
that this group of AMOs (ZEN-AMOs) have higher potency and less toxicity than 
LNA-AMOs [39].
6.2 miRNA sponges
miRNA sponges are transcripts that contain multiple (typically 4–10 sepa-
rated by a few nucleotides) tandem-binding sites to a miRNA of interest and are 
transcribed from mammalian expression vectors. The use of miRNA sponges in 
mammalian cells was introduced by Ebert and colleagues [40]. miRNA sponges 
have been found to occur naturally as long non-coding RNA in plants and animals. 
Synthetic miRNA sponges are usually plasmid or viral vectors which contain 
tandemly arrayed miRNA binding sites, separated with a small nucleotide spacer 
and inserted into a 3’UTR of the reporter gene driven by an RNA polymerase II 
promoter [40, 41]. miRNA sponges have the ability to inhibit an entire family of 
miRNA by using the common seed sequence, and can therefore inhibit multiple 
miRNAs at once. Some of the endogenous circular RNAs have been founded to 
function as nature miRNA sponges. For example, circRNA7 has been shown to be 
functions as a miRNA sponge for miRNA-7 in the mouse tissues [42]. The authors 
have further demonstrated that the testis-specific circRNA, sex-determining region 
Y (Sry), serves as a miR-138 sponge [42]. These finding suggest that circRNA 
functioning as a miRNA sponge to regulate miRNA expression may be a common 
phenomenon in human and animals.
6.3 miRNA masking
MicroRNA-masking antisense oligonucleotide technology (miR-mask) is 
another strategy for miRNA-based therapeutics. In contrast to miRNA sponges, 
miR-masks consist of single-stranded 2’-O-methyl modified antisense oligonucle-
otides that are fully complementary to the expected miRNA binding site in the 
3’-UTR of target mRNA [43]. A miR-mask does not directly interact with its target 
miRNA but binds to the binding site of that miRNA in the 3’ UTR of the target 
mRNA by fully complementary mechanism. Therefore, the miR-mask blocks the 
access of its target miRNA to the binding site so as to rescue its target mRNA via 
blocking the action of its target miRNA. miR mask is designed to be fully comple-
mentary to the target mRNA sequence of a miRNA, which suggests that the anti-
miRNA action of a miR-mask is gene-specific. The strategy of miRNA masking 
has been used to disrupt miRNA function and involves masking the target site on 
target mRNA using a modified single-stranded RNA complementary to the target 
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organs and significantly increase their half-lives in the target tissues. However, 
the first generation of AMOs have relative low potencies to be effective in animal 
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ing miR-122. This is the first miRNA-targeted drug to enter human clinical trials 
[38]. Despite LNA modifications have higher binding affinity, these modifications 
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promoter [40, 41]. miRNA sponges have the ability to inhibit an entire family of 
miRNA by using the common seed sequence, and can therefore inhibit multiple 
miRNAs at once. Some of the endogenous circular RNAs have been founded to 
function as nature miRNA sponges. For example, circRNA7 has been shown to be 
functions as a miRNA sponge for miRNA-7 in the mouse tissues [42]. The authors 
have further demonstrated that the testis-specific circRNA, sex-determining region 
Y (Sry), serves as a miR-138 sponge [42]. These finding suggest that circRNA 
functioning as a miRNA sponge to regulate miRNA expression may be a common 
phenomenon in human and animals.
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otides that are fully complementary to the expected miRNA binding site in the 
3’-UTR of target mRNA [43]. A miR-mask does not directly interact with its target 
miRNA but binds to the binding site of that miRNA in the 3’ UTR of the target 
mRNA by fully complementary mechanism. Therefore, the miR-mask blocks the 
access of its target miRNA to the binding site so as to rescue its target mRNA via 
blocking the action of its target miRNA. miR mask is designed to be fully comple-
mentary to the target mRNA sequence of a miRNA, which suggests that the anti-
miRNA action of a miR-mask is gene-specific. The strategy of miRNA masking 
has been used to disrupt miRNA function and involves masking the target site on 
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sequence [44, 45]. The miRNA-masking method, in which only specific mRNA is 
masked, may lead to more specific and safer therapeutic strategies.
6.4 Small molecule inhibitors
Several drugs may possess the ability to modulate miRNA expression, targeting 
signaling pathways in miRNA biogenesis, ultimate converging on the activation 
of transcription factors involved in the regulation of miRNA encoding genes. 
The first specific molecule founded to be effective for inhibition of miRNA is an 
azobenzene [46]. The authors have demonstrated that the azobenzene can inhibit 
miRNA-21 by inhibiting miRNA-21 precursor in live cells [46]. MicroRNA-21 is 
significantly overexpressed in many types of human cancers, thus miR-21 is a 
potential therapeutic target. Recently, Naro et al. [47] have reported that, using a 
luciferase-based reporter assay, a high-throughput screen of >300,000 compounds 
led to the discovery of a new aryl amide class of small-molecule miR-21 inhibitors. 
Their studies further found that four aryl amide derivatives were very potent and 
selective miR-21 inhibitors [47]. The small molecule miRNA inhibitors are currently 
limited by their relatively low potencies and issues with specificity to a particular 
miRNA, however, they are much easier to deliver and have the promise for develop-
ment of therapeutics.
6.5 miRNA mimics
In addition to miRNA inhibition as a major miRNA therapeutic approach, 
miRNA replacement treatment with miRNA mimics should be another miRNA 
therapeutic approach in disease associated with decreased miRNAs expressions. 
Synthetic miRNA mimics can assume the regulatory role of natural miRNAs. In dis-
eases such as cancer, some tumor suppression-related miRNAs are downregulated. 
Therefore, artificial double-stranded miRNA (miRNA mimic) has been introduced 
to inhibit cancer [48]. Recent studies have reported that miRNA-34 is a master 
regulator of tumor suppression and a well-defined miRNA tumor suppressor [49]. 
It acts on several cancer relevant cellular pathways, including the p53 and wnt/β-
catenin pathways. Down-regulation of miR-34 expression has been found in many 
tumor types, including lung, liver, breast, and colon carcinoma, and treatment with 
miR-34 mimic has been shown to inhibit tumor growth and progression [49, 50]. 
Consequently, miR-34 mimic, the first miRNA replacement therapy, is headed to 
the clinic for treatment of cancer [49, 50]. Replacement of oncosuppressor miRNAs 
with their mimics provides an effective strategy against cancer.
6.6 Viral vectors
Viral vector administration and encoding of miRNAs have been used for various 
therapeutic purposes [51]. A range of viruses can be employed for these purposes, 
including lentiviruses, adenoviruses, and adenoassociated viruses (AAVs). Since 
these vectors do not integrate into the genome, they can be eliminated efficiently with 
minimal toxicity, yet show remarkable efficiency in transferring RNA-encoding vectors 
into the nucleus of mammalian cells, ensuring high expression of miRNA [51]. Previous 
studies have shown that systemic lentivirus delivery of miR-15a/16 reduces lympho-
cytic leukemia progression in a mouse model [52]. In a murine model of muscular 
dystrophy-associated chronic dilated cardiomyopathy [53], intraventricular delivery 
of AAV vectors containing miR-669a induces long-term miR-669a overexpression and 
significantly decreases hypertrophic remodeling, fibrosis, and cardiomyocyte apop-
tosis. Furthermore, it significantly reduces adverse remodeling and enhances systolic 
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fractional shortening of the left ventricle in treated dystrophic mice, without significant 
detrimental consequences on skeletal muscle wastage [53]. Viral vector therapies have 
shown the highest efficacy for delivering miRNA into cells and organs in vitro and 
in vivo. However, their safety and toxicity remains a controversial issue.
7. miRNA therapeutics in disease
miRNAs are abundant in many mammalian cell types and appear to target about 
60% of the genes of humans and other mammals [54]. Many miRNAs are evolu-
tionarily conserved, which implies that they have important biological functions. 
However, growing evidence suggests that alteration of miRNAs expressions plays 
a key role in the development of disease. The signature miRNAs associated with 
disease and their potential therapeutics in the most common diseases are discussed 
in the following sections.
7.1 Therapeutic potential of microRNAs in cancer
Rapidly growing evidence supports that miRNAs play key roles in the pathogen-
esis of cancer and many miRNAs can function either as oncogenes or tumor sup-
pressors [55]. MiRNAs can influence the development, progression, and metastasis 
of cancers [29, 30]. Their functional effect may differ depending on their expres-
sion levels. They have either an oncogenic potential or tumor-suppressor effect 
depending on their downstream impact on target genes and thereby controlling the 
biologic manifestations of cancers. The activity of a lost or down-regulated tumor 
suppressor miRNA can be restored by using miRNA mimics [56]. To date, there are 
some miRNA-based trials for treatment of cancers. For examples, miR-34 is one of 
the tumor suppressor miRNAs and it is significantly downregulated in many kinds 
of cancer [57]. Therefore, a cancer therapy synthetic miR-34 (MRX34) has been 
developed and has entered phase I clinical trial for liver cancer and metastasis from 
other cancers (NCT01829971) [57]. In lung cancer, miR-27a has been reported to 
be a potential targeted therapy for lung cancer [58]. MicroRNA-loaded minicells 
(miR-16-based mimic miRNA) are designed to counteract the loss of the miR-15 
and miR-16 family and are used in clinic trials for small-cell lung cancer and meso-
thelioma [59]. The miR-205BP/S3 is a possible promising therapeutic modality for 
melanoma [60]. Let-7 is well recognized as one of the important tumor suppres-
sors. So re-expression of the tumor-suppressor let-7 is another proposed miRNA 
therapeutic strategy to upregulate tumor-suppressor miRNA by exogenously trans-
fecting with pre-let-7 that led to the inhibition of growth [27]. In addition to tumor 
suppressor miRNAs, some of the miRNAs can be served as oncogenes and used as 
therapeutic targets for cancer. For example, miR-21 is significantly overexpressed 
in many types of human cancers, thus miR-21 is a potential therapeutic target for a 
certain cancer [47].
7.2 Therapeutic potential of microRNAs in liver disease
Numerous studies have demonstrated that alterations in intracellular miRNAs 
correlated with various liver diseases [28, 38, 61]. In the liver, MiR-122 is one of the 
highly abundant miRNAs that affects various genes involved in hepatic cholesterol 
and lipid metabolism, thereby playing a central role in maintaining liver homeostasis 
[61]. Intriguingly, miR-122 is essential to the stability and propagation of hepatitis C 
virus (HCV) [61]. The finding of the role of miR-122 in the HCV replication process 
is one of the best examples of the potential targeted miRNA-based therapeutic 
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the clinic for treatment of cancer [49, 50]. Replacement of oncosuppressor miRNAs 
with their mimics provides an effective strategy against cancer.
6.6 Viral vectors
Viral vector administration and encoding of miRNAs have been used for various 
therapeutic purposes [51]. A range of viruses can be employed for these purposes, 
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these vectors do not integrate into the genome, they can be eliminated efficiently with 
minimal toxicity, yet show remarkable efficiency in transferring RNA-encoding vectors 
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studies have shown that systemic lentivirus delivery of miR-15a/16 reduces lympho-
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fractional shortening of the left ventricle in treated dystrophic mice, without significant 
detrimental consequences on skeletal muscle wastage [53]. Viral vector therapies have 
shown the highest efficacy for delivering miRNA into cells and organs in vitro and 
in vivo. However, their safety and toxicity remains a controversial issue.
7. miRNA therapeutics in disease
miRNAs are abundant in many mammalian cell types and appear to target about 
60% of the genes of humans and other mammals [54]. Many miRNAs are evolu-
tionarily conserved, which implies that they have important biological functions. 
However, growing evidence suggests that alteration of miRNAs expressions plays 
a key role in the development of disease. The signature miRNAs associated with 
disease and their potential therapeutics in the most common diseases are discussed 
in the following sections.
7.1 Therapeutic potential of microRNAs in cancer
Rapidly growing evidence supports that miRNAs play key roles in the pathogen-
esis of cancer and many miRNAs can function either as oncogenes or tumor sup-
pressors [55]. MiRNAs can influence the development, progression, and metastasis 
of cancers [29, 30]. Their functional effect may differ depending on their expres-
sion levels. They have either an oncogenic potential or tumor-suppressor effect 
depending on their downstream impact on target genes and thereby controlling the 
biologic manifestations of cancers. The activity of a lost or down-regulated tumor 
suppressor miRNA can be restored by using miRNA mimics [56]. To date, there are 
some miRNA-based trials for treatment of cancers. For examples, miR-34 is one of 
the tumor suppressor miRNAs and it is significantly downregulated in many kinds 
of cancer [57]. Therefore, a cancer therapy synthetic miR-34 (MRX34) has been 
developed and has entered phase I clinical trial for liver cancer and metastasis from 
other cancers (NCT01829971) [57]. In lung cancer, miR-27a has been reported to 
be a potential targeted therapy for lung cancer [58]. MicroRNA-loaded minicells 
(miR-16-based mimic miRNA) are designed to counteract the loss of the miR-15 
and miR-16 family and are used in clinic trials for small-cell lung cancer and meso-
thelioma [59]. The miR-205BP/S3 is a possible promising therapeutic modality for 
melanoma [60]. Let-7 is well recognized as one of the important tumor suppres-
sors. So re-expression of the tumor-suppressor let-7 is another proposed miRNA 
therapeutic strategy to upregulate tumor-suppressor miRNA by exogenously trans-
fecting with pre-let-7 that led to the inhibition of growth [27]. In addition to tumor 
suppressor miRNAs, some of the miRNAs can be served as oncogenes and used as 
therapeutic targets for cancer. For example, miR-21 is significantly overexpressed 
in many types of human cancers, thus miR-21 is a potential therapeutic target for a 
certain cancer [47].
7.2 Therapeutic potential of microRNAs in liver disease
Numerous studies have demonstrated that alterations in intracellular miRNAs 
correlated with various liver diseases [28, 38, 61]. In the liver, MiR-122 is one of the 
highly abundant miRNAs that affects various genes involved in hepatic cholesterol 
and lipid metabolism, thereby playing a central role in maintaining liver homeostasis 
[61]. Intriguingly, miR-122 is essential to the stability and propagation of hepatitis C 
virus (HCV) [61]. The finding of the role of miR-122 in the HCV replication process 
is one of the best examples of the potential targeted miRNA-based therapeutic 
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approaches. Blocking miR-122 using antisense approaches has reduced HCV replica-
tion in animal model [61]. MiR-122 binds to two closely spaced target sites (S1 and 
S2) in the highly conserved 5′ untranslated region of the HCV genome, thereby 
forming an oligomeric miR-122–HCV complex that protects the HCV genome from 
nucleolytic degradation or from host innate immune responses. Recently, a LNA-
miR-122, known as Miravirsen, has been introduced and demonstrated that it can 
decrease HCV in nonhuman primates with no side effects [62]. Furthermore, in 
clinical trials of Miravirsen (NCT01200420), it has shown that the use of miravirsen 
in patients with chronic HCV genotype 1 infection can induce dose-dependent 
reductions in HCV RNA levels without evidence of viral resistance [61]. This miRNA-
based therapeutics might deliver promising outcomes in the setting of liver disease.
7.3 Therapeutic potential of microRNAs in heart disease
Growing evidence shows miRNAs could be a promise molecular therapeutic 
strategy for cardiovascular disease [63, 64]. Previous studies have demonstrated 
that miRNA-21 level is upregulated in activated fibroblasts of the failing heart [65]. 
The investigators further demonstrated in an in vivo study of a mouse model of 
pressure-overload-induced heart disease that administration of a miRNA-21 anti-
sense construct reduces the extent of heart fibrosis and overall heart function [65]. 
Their findings validate miR-21 as a disease target in heart failure and establish the 
therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular dis-
ease setting. The miR-15 family is also found to be significantly increased in cardiac 
diseases [66]. Knockdown of the miR-15 family with LNA-modified anti-miRNAs 
resulted in reduced infarct size after ischaemia-reperfusion injury [66], suggesting 
it could serve as a therapeutic target for the manipulation of cardiac remodeling and 
function in the setting of myocardial infarction.
Diastolic dysfunction is a major clinical syndrome. Gain- and loss-of-function 
studies in animal model have shown that genetic deletion of the cardiac-specific 
miR-208a prevents pathological cardiac remodeling. Furthermore, therapeutic 
inhibition of miR-208a by subcutaneous delivery of miR-208a antisense during 
hypertension-induced heart failure in rats can prevent pathological myosin switch-
ing and cardiac remodeling and improve cardiac function [67, 68]. These studies 
suggest that miR-208 can serve as a potent therapeutic target for the modulation 
of cardiac function and remodeling during heart disease progression. In addition, 
miRNAs also play an important role in regulation of cardiovascular angiogenesis. 
AntimiR-92a (MRG-110) is currently used as a Phase I clinical trial for Miragen and 
it could offer a potential therapeutic to accelerate the healing process and revascu-
larization in chronic ischemic disease. MRG-110 is being developed under a license 
and collaboration agreement with Servier for the treatment of heart failure and 
other ischemic disease [www.miragen.com]. To date, there is another therapeutics 
miRNA (MGN-5804 which targeting miR-378) in the development phase for the 
treatment of cardiovascular disease.
7.4 Therapeutic potential of microRNAs in renal disease
MicroRNAs can serve as mediators and therapeutic targets in many chronic renal 
diseases [69].
A variety of miRNAs are specifically enriched in the renal tissue as compared 
with other tissues, including miR-192, miR-194, miR-204, miR-215, and miR-216 
[69]. miR-192 is one of the key miRNAs which is involved in diabetic nephropathy 
[70]. The authors reported that, in individual biopsies, tubulointerstitial fibrosis 
and low estimated GFR are associated with a decrease in miR-192 expression [70].
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miR-192 targets E-cadherin, resulting in fibrosis of tubular cells and develop-
ment of diabetic nephropathy. These findings suggests that miR-192 mimics should 
potentially be used as therapeutics of diabetic nephropathy. A global expres-
sion profiling study have shown that miR-21 is one of the most highly regulated 
miRNAs in kidneys of mice with diabetic nephropathy [71]. It has been reported 
that miR-21 antagonism in vitro and in vivo in streptozotocin-induced diabetic 
mice decreased mesangial expansion, interstitial fibrosis, macrophage infiltra-
tion, podocyte loss, albuminuria, and fibrotic- and inflammatory gene expres-
sion, which suggests that therapeutic miR-21 silencing could ameliorate diabetic 
kidney disease. Indeed, in a mouse model of chronic kidney disease, treatment 
with antagomir against miR-21 reverses both glomerular and tubular cell damage, 
resulting in a decrease in renal fibrosis and prolonging the life span of the chronic 
kidney disease-affected mice [72].
7.5 Therapeutic potential of microRNAs in neurological disease
Some of the miRNAs are highly abundant in the nervous system, where they 
play key roles in developmental neurobiology. Numerous studies have shown a 
dysregulation of miRNAs in neurological disease [73, 74]. These alterations in 
miRNAs expression prior to the onset of or during the course of disease pathology 
raises the possibility that expressing or inhibiting specific miRNAs might amelio-
rate the disease process and provide an effective therapeutic strategy. For example, 
Alzheimer’s disease (AD) is being tested for potential miRNA-based therapy 
[75]. It has reported that a member of the miR-15/107 superfamily, miR-16 can 
specifically inhibits the expression of AD biomarkers Aβ and Tau, as well as brain 
inflammation and oxidative stress. MicroR-16 mimics delivered into the brain of 
mice resulted in a reduction of AD-related genes expression in a region-dependent 
manner, thus supporting the potential of miR-16 as an excellent therapeutic 
candidate for treatment of Alzheimer’s disease. Similar to the changes of miRNAs 
in Alzheimer’s disease, numerous miRNAs in human and animal models are also 
reported to be dysregulated in Parkinson’s disease [76]. Some of these dysregulated 
miRNAs have been suggested to be potential therapeutic targets for Parkinson’s 
disease. For example, Cho et al. had suggested that overexpression of miR-205 
by miR-205 mimic could provide a potential therapeutic strategy to suppress the 
abnormal upregulation of LRRK2 protein in Parkinson’s disease [77]. In addi-
tion, it has been reported that early downregulation of miR-34b/c in Parkinson’s 
disease triggers downstream transcriptome alterations underlying mitochondrial 
dysfunction and oxidative stress, which ultimately compromise cell viability [78]. 
Therefore, upregulation of miR-34b/c may be an applicable therapeutic strategy for 
Parkinson’s disease.
8. Future prospects
As the miRNA field dramatically grows, a better understanding of miRNA bio-
genesis and path-physiologic function will help to develop miRNA-based therapies. 
In addition, it is well known that a specific miRNA could target multiple genes and 
affect different organs in the same time. Therefore, research efforts should try to 
maximize the benefit of target diversity and prevent off-target effects. To achieve 
this goal, improvement of the chemical design of miRNA antisense and mimics and 
developing novel delivery systems are very important to ensure that the desired 
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potentially be used as therapeutics of diabetic nephropathy. A global expres-
sion profiling study have shown that miR-21 is one of the most highly regulated 
miRNAs in kidneys of mice with diabetic nephropathy [71]. It has been reported 
that miR-21 antagonism in vitro and in vivo in streptozotocin-induced diabetic 
mice decreased mesangial expansion, interstitial fibrosis, macrophage infiltra-
tion, podocyte loss, albuminuria, and fibrotic- and inflammatory gene expres-
sion, which suggests that therapeutic miR-21 silencing could ameliorate diabetic 
kidney disease. Indeed, in a mouse model of chronic kidney disease, treatment 
with antagomir against miR-21 reverses both glomerular and tubular cell damage, 
resulting in a decrease in renal fibrosis and prolonging the life span of the chronic 
kidney disease-affected mice [72].
7.5 Therapeutic potential of microRNAs in neurological disease
Some of the miRNAs are highly abundant in the nervous system, where they 
play key roles in developmental neurobiology. Numerous studies have shown a 
dysregulation of miRNAs in neurological disease [73, 74]. These alterations in 
miRNAs expression prior to the onset of or during the course of disease pathology 
raises the possibility that expressing or inhibiting specific miRNAs might amelio-
rate the disease process and provide an effective therapeutic strategy. For example, 
Alzheimer’s disease (AD) is being tested for potential miRNA-based therapy 
[75]. It has reported that a member of the miR-15/107 superfamily, miR-16 can 
specifically inhibits the expression of AD biomarkers Aβ and Tau, as well as brain 
inflammation and oxidative stress. MicroR-16 mimics delivered into the brain of 
mice resulted in a reduction of AD-related genes expression in a region-dependent 
manner, thus supporting the potential of miR-16 as an excellent therapeutic 
candidate for treatment of Alzheimer’s disease. Similar to the changes of miRNAs 
in Alzheimer’s disease, numerous miRNAs in human and animal models are also 
reported to be dysregulated in Parkinson’s disease [76]. Some of these dysregulated 
miRNAs have been suggested to be potential therapeutic targets for Parkinson’s 
disease. For example, Cho et al. had suggested that overexpression of miR-205 
by miR-205 mimic could provide a potential therapeutic strategy to suppress the 
abnormal upregulation of LRRK2 protein in Parkinson’s disease [77]. In addi-
tion, it has been reported that early downregulation of miR-34b/c in Parkinson’s 
disease triggers downstream transcriptome alterations underlying mitochondrial 
dysfunction and oxidative stress, which ultimately compromise cell viability [78]. 
Therefore, upregulation of miR-34b/c may be an applicable therapeutic strategy for 
Parkinson’s disease.
8. Future prospects
As the miRNA field dramatically grows, a better understanding of miRNA bio-
genesis and path-physiologic function will help to develop miRNA-based therapies. 
In addition, it is well known that a specific miRNA could target multiple genes and 
affect different organs in the same time. Therefore, research efforts should try to 
maximize the benefit of target diversity and prevent off-target effects. To achieve 
this goal, improvement of the chemical design of miRNA antisense and mimics and 
developing novel delivery systems are very important to ensure that the desired 




The use of synthetic miRNAs holds great promise as a new class of potential thera-
peutic agents by silencing the gene(s) of interest. Applicable to a wide variety of human 
diseases such as cancer, viral infections, genetic disorders, and cardiovascular disease, 
the attractiveness of miRNA therapeutics is their ability to target specific genes of inter-
est, not always possible with small molecules or protein-based drugs. When designing 
drugs for therapeutic use, RNA sequence must be carefully designed to avoid undesired 
effects and immune responses in the body. The care into making a safe and relevant 
delivery system for miRNA-based therapies must also balance considerations of target 
tissue and cell delivery, cellular uptake, and nuclease degradation of the molecule.
Although a considerable number of clinical trials involving miRNA therapeutics 
have been conducted over the years, not all of those miRNA therapeutics have so far 
moved into clinical implication. The big challenges for miRNA-based therapeutics 
is to identify the best miRNA candidates or miRNA targets for each type of disease. 
The other challenges include the optimizing the miRNA delivery vehicles that can 
have higher targeting specificity and stability, as well as having lower toxicities and 
off-target effects. Although there are still hurdles to the use of mRNA-targeting 
approaches for clinical applications, with the rapid expansion occurring in this 
field, the prospects of miRNA-based therapeutics remain promising.
9. Conclusions
Growing evidences have shown that miRNAs play a key role in biological 
function and cell homeostasis. If the miRNAs are dysregulated, they lead to the 
 development of many disease phenotypes. The miRNAs have immense potential 
in the clinical arena because they can be detected in the blood, serum, tissues, and 
fine-needle aspirate specimens. In addition, the discovery of miRNAs and their 
expression profile in a wide variety of diseases has led investigators to understand 
the key role of miRNAs as biomarkers during disease progression. Furthermore, 
because the miRNAs are relatively small size and they can regulate the network 
of target genes, they are promising targets for therapeutics. The most attractive 
feature of miRNA-based therapy is that a single miRNA could be useful for target-
ing multiple genes that are deregulated in disease, which can be further investigated 
through systems biology and network analysis that allows designing disease-specific 
personalized therapy. In summary, miRNAs are poised to provide diagnostic, prog-
nostic, and therapeutic targets for several diseases. As the field continues to grow, 
miRNA-based therapeutics may develop a novel class of drugs for different diseases.
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